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Summary
G-proteins are guanine-nucleotide-binding regulatory proteins 
which couple receptors to effector mechanisms; G-protein 
associated 'second messengers' include cAMP and the phospho- 
inositides, while other G-proteins are coupled to calcium and 
potassium channels. The expanding G-protein family (all of 
which share a common trimeric structure) currently includes at
Ieast12 distinct G-proteins some of which can be identified in
plasma membranes using specific antibodies (Western immuno- 
blotting): antibodies are available against several a subunits 
(Gsa, Gia1, Gia2, Gia3 and Goa)(which possess receptor and 
effector binding sites) as well as against B subunits. Function 
has not yet been ascribed to all G-proteins, but Gsa and Gia2 are 
concerned with the dual regulation (respectively stimulating and 
inhibiting) of adenylyl cyclase (AC) catalytic unit activity (A).
G-protein abnormalities have been implicated in the patho­
genesis of several human and experimental disease processes. 
Resistance to hormone action (specifically to hormones coupling 
to Gsa) is a feature of the human disease pseudohypopara­
thyroidism, and is attributable to abnormal Gsa. Tissue specific 
alterations of G-proteins have also previously been demons­
trated in the STZ model of IDDM where reduced expression,
levels and function of hepatocyte Gi may be related to the
insulin resistance seen in STZ-DM hepatocytes. Similar changes 
of Gi function have also been reported in hepatocytes from the 
Zucker rat model of obesity which also features insulin
21
resistance: this raises the possibility that abnormalities of G- 
proteins may be implicated in diseases characterised by insulin 
resistance.
Insulin resistance and hyperinsulinaemia are features of certain 
human diseases including NIDDM (chapter 3) and essential 
hypertension (EH) (chapter 4) and studies were performed in 
platelets from human NIDDM and EH to ascertain whether 
common G-protein abnormalities might be present in these 
conditions which might lend support to the concept of a common 
underlying pathophysiology. Platelets represent a homogeneous 
tissue from which purified plasma membranes can be readily 
prepared, are implicated in morbidity accompanying NIDDM and 
EH and exhibit abnormalities of function (assessed in vitro). G- 
protein levels were measured by semiquantitative immuno- 
blotting techniques (against subunits cited previously), while 
assessment of G-protein function was restricted to Gsa and 
Gia2, and was inferred from studies of ACA.
Platelets from 11 (6M) newly presenting NIDDM and 17 (12M) 
controls were studied in chapter 3. Platelets from NIDDM 
exhibited lower stimulation of ACA in response to forskolin and 
PGE1 (approx. 40% and 50% less stimulation, p=0.006 and 
p=0.001 respectively) while Gia2 (a2 receptor-activated and 
receptor-independent,via GppNHp) mediated inhibition of AC 
catalyitc unit was unaltered. Although altered catalytic unit 
activity may have contributed, it is probable that altered levels 
of G-protein subunits may also be relevant: reductions in the 
levels of Gja2(p=0.003), Gsa (p=0.02) and Gja3 (NS) were
22
demonstrated. It is possible that relative changes in Gja2 and 
Gsa may have greater implications for functional change than 
alterations in either alone. The observation of reduced Gjoc2 was 
similar to previous findings in hepatocyte membranes from the 
STZ-IDDM although contrasts with those in adipocytes where Gi3 
has previously been shown to be increased. The observed 
reduction of G-protein levels in human platelets from NIDDM and 
hepatocytes from STZ-DM are consistent with the possibility 
that G-proteins may be implicated in diseases manifesting 
insulin resistance.
The study of human EH described in chapter 4, is based on the 
strong epidemiological and clinical links between NIDDM and EH, 
and the increasing evidence of shared pathophysiology on the 
basis of insulin resistance. Platelets from 14 EH with matched 
controls were studied. No changes in levels of G-proteins (Gsa, 
G ia2 and (3 subunits) were seen. However, in contrast to the 
observations in NIDDM, studies of AC function identified greater 
PGE1 stimulated AC activites in hypertensive platelet 
membranes than controls (88.8% v 72% stimulation, p=0.018). 
Although unexplained by altered G-protein levels, this is 
consistent with the findings of previous workers and may have 
its physiological basis in protection of cells against Ca2+ 
overload (Resink et al. 1986).
Weak correlation was noted between plasma cholesterol 
concentration and relative amounts of Gia2 (z=-2.084, n=29, 
p=0.04) when considering all EH and control subjects together.
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(Correlations were also noted when considering NIDDM with 
control subjects, between plasma cholesterol concentration and 
extent of forskolin and PGE1 stimulation of adenylyl cyclase 
actvity). the explanation for this novel observation remains 
unclear, but does raise the possibility that abnormalities of G- 
protein levels could be related to abnormal lipids, providing an 
alternative explanation for changes in NIDDM and EH.
However, the data argue against alteration of G-proteins in 
hypertension by virtue of insulin resistance, but further studies 
would be desirable in metabolically active tissues and in 
arteriolar peripheral resistance vessels.
In chapter 5, G-protein levels and function were studied in 
vascular tissue (myocardium) from the spontaneously 
hypertensive rat (SHR). The SHR is a widely used model of 
genetic hypertension with many features in common with human 
EH including glucose intolerance/ insulin resistance. SHR 
myocardium is known to exhibit abnormalities of AC activation; 
reduced B adrenergic activation of adenylyl cyclase has been 
reported.
Myocardial plasma membrane homogenates prepared from 
11 week SHR (weighing 255g) and (two control species) WKY and 
Wistar rats were studied (chapter 5). Differences in AC activity 
were seen in SHR when compared to WKY myocardium: WKY ACA 
was greater than SHR (up to 100% greater) under basal 
conditions and in the presence of fluoride, forskolin and a
24
number of ligands which couple to AC catalytic unit via Gs, 
including PGE1, glucagon and isoproterenol. However, SHR 
myocardial ACA was similar to activities in the other control 
group, Wistar rats (with exception of forskolin stimulated 
activity, where SHR was greater than Wistar).(A similar trend 
was observed when the data were expressed as 'percentage 
change' over 'basal' in the presence of Mn2+). Studies of Gi 
function failed to effect major inhibition of ACA. However, it 
seems likely that the differences in ACA may be attributable to 
species differences in amount of AC catalytic unit, rather than 
altered G-proten function. Immunoblotting studies excluded a 
contribution to these changes in ACA from altered levels of G- 
protein subunits; Gsa, Gia2 (and Goa) levels were similar in all 
three species..
Studies of renal cortical plasma membrane preps, failed to 
identify any differences in ACA (expressed as 'percentage 
change' over basal in presence of Mn2+), nor in Gsa, Gia1, Gia2, 
Goa and 13 subunit levels.
These studies, however, emphasise the problems inherent in 
studies of the SHR. The absence of an isogenetic control species 
raises the distinct possibility that the differences observed in 
our studies may relate to the inherent genetic heterogeneity 
among the species studied: this problem cannot be circumvented. 
The inclusion in this study of the second control species 
(Wistar) highlights the dangers of the customary comparison 
between SHR and WKY species.
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The studies in hypertension were extended to include 
assessment of G-proteins in the poorly understood entity of 
glucocorticoid hypertension (chapters 6 & 7). As humoral 
regulation of G-protein expression and function by gluco­
corticoids has apparently been demonstrated in experimental 
animals and cell culture it seemed possible that G-protein 
changes could be implicated in this pathological state. Previous 
studies of glucocorticoid effect on the differential regulation of 
G-protein subunits are in general, based on administration of 
massive doses of glucocorticoid to adrenalectomised rats. In the 
study reported here, a model of glucocorticoid hypertension 
based on administration of rather more physiological 
concentrations (likely to still be in the 'pharmacological range') 
of the glucocorticoid, dexamethasone, was used. 5pg/d DEX 
infusion (s.c.)(to 180g Sprague Dawley rats) resulted in 
elevation of tail-cuff BP increased by 30mmHg (representing an 
increase of around 25%) without causing major restriction of 
weight gain. Immunoblotting studies for G-protein subunits 
failed to identify any relevant changes in brain, myocardium, 
renal cortex, liver and mesenteric vasculature. Our studies of 
ACA also failed to reveal any differences in ACA responses in 
renal cortical, myocardial and mesenteric plasma membranes. 
This contrasts with the in vitro work of chapter 7, and suggests 
that neither changes in G-protein function nor AC catalytic unit 
are implicated in the pathogenesis of glucocorticoid hyper­
tension. Review of these results in the context of previous 
studies suggests that if glucocorticoids do have a role in 
regulating G-protein levels, then this may merely be a
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permissive role, enabling other agents, possibly humoral, to 
exert their influence.
However, dexamethasone administration in vitro has been 
previously shown to increase ACA in vascular smooth muscle 
cells (from renal arteries)and in non-vascular cell lines. To 
ascertain whether G-proteins were implicated, cultured VSMC 
were studied: VSMC were obtained from (Sprague Dawley) rat 
mesenteric vascular tree and half the flasks were exposed to 
10nM DEX for 24h (and 48h)(chapter 7). Basal ACA was increased 
about 50% in the presence of DEX. The differences persist and are 
independent of ligand mediated stimulation of catalytic unit via 
Gs (by isoproterenol and PGE1) and of direct, Gi mediated 
inhibition of catalytic unit by GppNHp (0.1 nM), suggesting that 
AC catalytic unit, rather than the G-proteins which modulate its 
activity, is altered.
The results are compatible with possible alteration of AC 
catalytic unit; absence of alteration of the levels of Gsa, Gi2a, 
G i3a and 6 subunits in the membranes essentially excludes a 
role for DEX mediated alteration of levels or function of G- 
protein subunits in the observed changes in ACA.
• The studies of platelet membranes from NIDDM and EH thus 
exclude common pathophysiology based on alterations of G- 
proteins, although both conditions do feature abnormalities of 
ACA which may contribute to the altered platelet function 
observed in these diseases. Platelets from NIDDM (but not EH) do 
exhibit reduced levels of G-protein subunits which may
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contribute to altered ACA, but these changes may be related to 
altered plasma membrane composition in diabetes mellitus.
• Species differences exist in ACA in myocardial plasma 
membrane preparations (comparing SHR, WKY and Wistar 
species). The validity of the customary comparison between SHR 
and WKY is challenged. Differences in ACA are not explained 
through altered G-protein levels, but may be due to differences 
in AC catalytic unit.
• Despite evidence implicating glucocorticoids in G-protein 
regulation, no changes in G-protein levels were seen in 
myocardium, brain, kidney and mesenteric artery in a well 
validated model of glucocorticoid hypertension. Glucocortiocoid 
exposure did enhance ACA in cultured VSMC but probably by 
altering AC catalytic unit, and not through changes in levels of 
G-protein subunits.
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Chapter 1
Introduction
G-proteins are guanine nucleotide binding regulatory 
proteins which function as transmembrane signal 
transducers .
1.1. Historical background
The appreciation of the role of G-proteins in transmembrane 
signalling has its origins in three disparate observations made 
in the the early 1970s. Following the demonstration that GTP is 
a prerequisite for hormonal activation of adenylyl cyclase (AC) 
(Rodbell, Birnbaumer, Pohl & Krans 1971) it was subsequently 
shown that guanine nucleotides are able to alter ligand-receptor 
binding affinity in a manner which is agonist-specific (Maguire, 
Van Arsdale, & Gilman 1976). The third fundamental observation 
was the demonstration of catecholamine stimulated GTPase 
activity (in turkey erythrocyte membranes)(Cassel & Selinger 
1976). These findings form the essentials of our current under­
standing of G-protein function (section 1.3. and figure 2). How­
ever, it was as recently as1980 that a 'transducing protein1 was 
first isolated (Northup, Sternweis, Smigel et al. 1980) (using the 
e y e  reconstitution system-see section 2.8.) and was shown to 
be a guanine-nucleotide-binding protein. This was definitive 
evidence in support of the hypothesis originally proposed by 
Rodbell and colleagues a decade previously (Birnbaumer, Pohl, 
Michiel, Krans & Rodbell 1970) that a regulatory protein couples 
receptors to AC. As will be described more fully, these findings
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form the basis of our current understanding of G-proteins as 
receptor-effector coupling proteins. Although the bulk of the 
early work in this field was on the dual regulation of AC, the G- 
protein family has evolved over the last decade and it is clear 
that a number of other effector mechanisms are modulated by G- 
proteins; these include the inositol phosphate (IP) pathway 
(Cockcroft & Gomperts 1985) and calcium (Hescheler, Rosenthal, 
Trautwein & Schultz 1987)and potassium channels (Yatani, 
Codina, Brown & Birnbaumer 1986). Despite the current diversity 
of G-proteins-several properties are common to most G- 
proteins, and a detailed description of these facilitates an 
understanding of the initial definition and of the role and 
mechanisms of action of these "transmembrane signal trans­
ducers".
1.2. The properties and mechanisms of action of G 
p ro te ins
G-proteins are heterotrimeric proteins (see section 1.2.3.), 
comprising a, 6 and y subunits; each of these is encoded by a 
separate gene. Functional specificity is determined by the a 
subunit (section 1.2.3., table 2); for example, it is the a subun it 
of Gs which effects stimulation of AC catalytic unit (see 
section 1.3, figure 2). However, identical 13 are shared by all 
members of the G-protein family (section 1.2.3.). Thus despite 
functional heterogeneity (by virtue of the a subunit), s im ilar­
ities do exist among G-proteins; these are summarised in 
table 1.
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Table 1: Properties shared bv G proteins:
1. They are receptor-effector coupling proteins.
2 . They are associated with the cytoplasmic
surface of the plasma membrane.
3. They share a common subunit structure and 
function .
4. They possess GTPase enzyme activity.
5. They act as substrates for ADP ribosylation by
bacterial toxins.
1.2.1. G-proteins are receptor-effector coupling 
pro te ins .
Over 80 different G-protein mediated receptor-effector 
relationships have been described: ligands which bind to G- 
protein coupled receptors include biogenic amines, proteins and 
polypeptides, autocoids and neurotransmitters. Early studies of 
G-proteins concentrated on G-protein mediated modulation of 
AC-with cAMP as the second messenger system (effector); AC is 
under dual regulation by Gs and Gj-which respectively represent 
G-proteins which effect stimulation and inhibition of AC by a 
number of different ligands (see figure 1). The aim of this thesis 
is to examine the possible role of dysfunction of these G- 
proteins in non-insulin dependent diabetes mellitus and various 
types of hypertension; G-protein function has been studied by 
manipulation of AC activity using a number of agents which 
function via Gs and Gj.
ADRENERGIC 1)1,2, 
DOPAMINE D1, 
ADENOSINE A2, 
SEROTONIN S2, 
VASOPRESSIN V 2 , 
ACTH, LH, FSH, 
TSH, CRF, GRF, 
GLUCAGON, V IP , 
HISTAMINE H2
ADRENERGIC
alpha 2, 
DOPAMINE D2, 
ADENOSINE A 1, 
SEROTONIN S2, 
THROMBIN, 
BRADYKININ, 
PG E1/2, ACETYL 
CHOLINE M l.
ADRENERGIC alpha 1, 
ACETYL CHOLINE M l,  
TRH, GnRH, 
CHOLECYSTOKININ, 
VASPORESSIN V I ,  
THROMBIN, 
BRADYKININ.
? STIM.
STinULATION;:::::::::: :::::::::::: INHIBITION
ADENYLYL
CYCLASE
PHOSPHO- 
LIPRSE C k
CAMP
NK:
:PROTEiN:-::;-;Ca
Adapted fro m  T a y lo r & M e rr it t  1986
Fig. 1. Examples of ligands which are coupled to the adenylyl 
cyclase and the phospholnosltlde pathways via G-proteins (Gs, 
Gi and ‘Gp’). Ligands bind to receptors (R 1-3 ) causing release 
of alpha subunits from the hetero trim eric  G-proteins. Alpha 
subunits In teract w ith e ffec to r & generate second messengers.
Other effector mechansims known to be regulated by G-proteins 
include the IP3 system, calcium and potassium channels and 
cGMP phosphodiesterase (see table 2). The G-protein regulation 
of the inositol triphosphate (1P3) system has been extensively 
studied but remains to be fully elucidated (figure 1); phos- 
phatidylinositol 4,5-biphosphate (IP2) is catalysed to IP3 and 
diacylglycerol (DAG) by phosphoinositol phosphodiesterase (PPI- 
PDE) both of which act as second messengers. There is 
increasing evidence that IP3 and IP4 (a product of IP3 hydroly­
sis) are both required to mobilise intracellular calcium-which is 
how IP3 is thought to mediate its effects. Evidence that a G- 
protein couples PPI-PDE to receptors was provided by Cockcroft 
& Gomperts (1985)-but despite substantial evidence in support 
of the role of a G-protein (the G-protein has been termed 'Gp'), 
the DNA encoding this G-protein has hitherto has not been 
id en tified .
1.2.2. G-proteins-evolution and distribution.
G-proteins are ubiquitous in the animal kingdom. Teleogical 
studies have demonstrated the presence of similar G-protein 
subunits (see section 1.2.3.) for example Goa, in vertebrates 
(including mammals (rat), avians (pigeon), amphibians (frog), 
fish (trout), and reptiles (turtle)) and in invertebrates (such as 
molluscs (snail) and insects (locust)). In contrast, it has only 
been possibe to demonstrate By complexes immunologically in 
vertebrates (Homburger, Brabet, Audigier et al.1987). (It is 
unclear whether homologous, but immunologically distinct By 
complexes exist in these species.)
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G-proteins are also ubiquitous within tissues (human and 
animal) although the relative preponderance of the various G- 
proteins may vary from tissue to tissue. They are in general, 
found within the plasma membranes of cells (in most membrane 
preparations several G-proteins are likely to be present) and are 
located at the cytoplasmic surface of the membrane where they 
are anchored by their amino terminus. Two recent reports have 
suggested, however, that G-proteins may also be associated with 
intracellular organelles-the Golgi stack (Melancon, Glick, 
Malhotra et al. 1987) and hepatic microsomes (Codina, Kimura & 
Kraus-Friedmann 1988). The functions of these G-proteins 
remain to be determined although it has been suggested at least 
in the Golgi stack that the G-proteins may subserve a role in 
transport through the complex.
1.2.3. G-proteins share common subunit structure and 
fu nc tio n
The G-proteins associated with transmembrane signal trans­
duction are not the only proteins which have been identified 
which can bind and hydrolyse GTP; others include cytosolic 
initiation and elongation factors- two proteins involved in 
protein synthesis-and ras gene products. Furthermore coupling of 
receptors to effectors is not a function unique to G-proteins as 
the ras gene products (Barbacid 1987) (although this is contro­
versial) are thought to share this function. However, the hetero- 
trimeric structure of the G-proteins of transmembrane signal 
transduction sets them apart from all the other GTP-binding 
proteins. This heterotrimeric structure consists of a, p and y
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subunits (in order of decreasing molecular weight): the a subunit 
confers immunological and functional identity on the G-protein. 
Currently at least 9 distinct a subunits have been identified 
(each a unique gene product). cDNA studies have identified 4 Gj a 
subunits (numbered 1-4), and at least 4 different mRNA encoding 
Gsa subunits] (see table 2).
Table 2: G -prote in  subun its .
SUBUNIT M r  (kDa) TOXIN EFFECTOR
G s a 52 CT A C -s tim u la tion
G s a 44.5 CT A C -s tim u la tion
G j 1 ot 40.4 PT A C -inh ib ition
G j2 a 40.5 PT A C -inh ib ition
G j3 a PT K+ channels
G j4 a PT ?A C -in h ib itio n
G o a 39 PT Ca2+ channels
G t1 a 40 PT cGMP PDE
G t2  a 40.4 PT ?cGMP PDE
CT
Gz - ?
G ( t ) p x  2 37.4
G ( t ) y 8.4
(After Casey & Gilman 1988)
a s u b u n i t s :
The G-protein a subunits have molecular weights ranging from 
39kDa-52kDa. Amongst the recognised a subunits there is 
substantial, if variable, amino acid sequence homology; 95% 
homology has been reported for G ila  and Gj2a . However, lesser 
degrees of homology exist between Goa and Gja (68%), Gja and 
Gsa (about 50%) and G0aand Gsa (50%)(Gilman 1987). In addition
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to the heterogeneity which defines the major G-protein classes, 
there are multiple subunit polypeptides within each class. While 
the different Gi subclasses represent distinct gene products the 
different forms of Gsa are due to alternative splicing of 
precursosr mRNA (Robishaw, Smigel & Gilman 1986).
Enzymatic cleavage of a subunits with trypsin and carboxy- 
peptidase A has enabled function to be ascribed to certain amino 
acid sequences e.g. tryptic cleavage of the Goa subunits in the 
presence of guanosine 5f-(thio)triphosphate removes a 2 kDa 
peptide from the amino terminus which prevents the association 
of a subunits with the 6 and y units, but does not affect GTPase 
activity nor the Km for GTP (Neer, Pulsifer & Wolf 1988). ADP 
ribosylation by pertussis toxin (which is known to require the 
a.p.y trimer) is however compromised. Digestion of the carboxyl 
terminus of a39 with carboxypeptidase A (Neer et al. 1988) 
similarly prevents ADP ribosylation by pertussis toxin, but has 
no effect on a.p.y trimer formation. The receptor-contact site 
involved in receptor-G protein coupling has been identified in the 
e y e  S49 lymphoma cell line which possesses a Gs which cannot 
be activated by hormone receptors and thus cannot transduce 
hormone signals: comparison of the cDNA and amino acid 
sequences of the Gs.a subunits from the eye- and the 'wild' cell 
lines has identified a point mutation near the carboxyl terminus 
of the a s  polypeptide (proline for arginine) (Rail & Harris 1987). 
ADP ribosylation of Gj and Gt at a cysteine residue four from the 
carboxy-terminus prevents G-protein-receptor interaction (Van 
Dop, Yamanaka, & Steinberg et al.1984).
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ft and y subun its :
13 subunits prepared from Gs, Gt and Gj have identical amino acid 
composition and they are functionally interchangeable (Katada, 
Bokoch, Northup, Ui & Gilman 1984). However, there appear to be 
two genes encoding 13 subunits (Gilman 1987): it is unclear 
whether these two genes account for a doublet which can be 
resolved on SDS-PAGE from the 35kDa beta subunits of Gs, Go 
and Gj.
cDNA for G ty  has been cloned and sequenced (Hurley, Fong, 
Teplow, Dreyer & Simon 1984). However, it is likely that 
different forms of y subunit exist and these differences may 
contribute to the functional heterogeneity of different G- 
proteins: differences in the efficacies of the p-y complexes of 
bovine brain Gj and bovine retinal (?Gt) subunits in inhibiting 
ACA in reconstituted phospholipid vesicles may be attributable 
to variability in the y units as the p subunits appear to be 
immunologically identical (Cerione, Gierschik, Staniszewski et 
al. 1987).
It is artificial to consider (3 and y subunits as separate entities 
as they form a single functional unit. They remain closely 
associated and can only be separated by denaturation. As will be 
discussed (section 1.3.) the prime role of the By complex may be 
to 'mop up' free Gsa. However, it has been also been suggested 
that this complex may directly increase phospholipase A2 
activity (Jelsema & Axelrod 1987).
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1.2.4. G -pro te ins share fea tures o f an in tr in s ic  GTPase 
c y c le .
GTPase is an enzyme which cleaves the terminal phosphate from 
GTP. This enzyme, which is common to all a subunits, is an 
intergral component of the amino acid sequence of the a subunit, 
and is essential for G-protein function (see figure 2). Hydrolysis 
of GTP effects term-ination of the a subunit function, and 
permits reassociation of a with p-y subunits and restores the G- 
protein to the dormant heterotrimeric form associated with GDP 
(vide infra).
1.2.5. G -pro te ins act as substra tes  fo r ADP rib o sy la tio n  
by bacte ria l to x in s .
The pathophysiology of both whooping cough and cholera can be 
explained on the basis of systemic effects of secreted toxins 
which are known to function by altering G-protein activity. 
Pertussis toxin is the only known asparagine specific ADP 
ribosyl transferase and the con-sequent ADP ribosylation of Gj 
leads to subunit dissociation and loss of Gj function by impairing 
the ability of Gj to interact with receptor. The diarrhoea which 
characterises the effect of cholera toxin is due to ADP ribosyl­
ation of Gsa - which results in activation (irreversible) of Gs. 
The susceptibilities of a subunits to ADP ribosylation by these 
two toxins are summarised in table 2.
1.3. How do G prote ins work? (Figure 2)
In the inactive state GDP is bound to the a.p.y trimer. The cycle 
of activation is initiated by the binding of a ligand to a receptor
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(examples of ligands associated with G-proteins are given in 
figure 1) which results in association with the G-protein (a.p.y 
trimer). GTP then binds to the a subunit, displacing GDP. The a 
subunit (binding GTP) is then probably cleaved from the parent 
trimer, dissociating it from the p.y fraction (the subunit 
dissociation model for activation of G-proteins-see review 
Casey & Gilman 1988); this dissociation results in reduced 
affinity of the receptor for its bound ligand while the "free" a 
subunit-GTP can interact with the effector mechanism, for 
example, the cat-alytic subunit of AC. Hydrolysis of GTP to GDP 
allows a.p.y reassociation. As will be seen later non-hydrolys- 
able GTP analogues such as GppNHp prevent reassociation of the 
subunits.
The mechanisms whereby dissociated a(-GTP) subunits effect 
activation of second messenger systems are becoming clearer; 
G sa directly stimulates activity of the AC catalytic subunit. Gja 
may effect inhibition of AC catalytic unit either by a direct 
action of Gja or by liberating p.y subunits which "mop up" free 
G sa subunits- relieving tonic stimulation of AC (the 'subunit 
exchange model') (Gilman 1984). Support for this theory is 
provided by the observation that addition of p.y subunits (from 
either bovine brain Gj or from retinal transducin) can effect 90% 
inhibition of guanine nucleotide stimulated cyclase in recons­
tituted phospholipid vesicles which otherwise essentially 
contain only human erythrocyte Gs and bovine AC catalytic 
subunit (Cerione, Staniszewski, Gierschik et al. 1986; Cerione et 
al.1987). p.y subunits have been demonstrated to inhibit forskolin
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Fig. 2. How G-proteins function  
(fo r  explanation-see  
section 1.3.)
RECEPTOR + AGONIST
N
ACTIVATED RECEPTOR-AGONIST 
COMPLEX
SECOND
MESSENGER
SYSTEM
ATP CAMP [MILLIGAN 1988]
40
stimulated catalytic unit (without a requirement for guanine 
nucleotides)(Enomoto & Asakawa 1986) in addition to inhibition 
of Gs stimulated AC catalytic unit. Further evidence that p.y 
complexes may exert a direct inhibitory role on the catalytic 
subunit was provided by Katada and colleagues (Katada, Oinuma & 
Ui 1986) who showed additivity of cyclase inhibition between p.y 
complexes and GTPyS-bound-a 41 (raising the possibility there­
fore also of direct inhibition by a subunits).
How specificity of action is achieved within the current models 
of G-protein function remains to be fully elucidated. Although it 
is not impossible that there is strict coupling between a 
receptor and a number of G-protein molecules the consensus 
favours the existence of a mobile plasma membrane pool of G- 
proteins ( the 'free dissociation model'); this model envisages 
that hormone receptors, a.p.y trimers, dissociated subunits and 
effector molecules all float freely in the plasma membrane and 
that any subunit can theoretically bind any receptor or any 
effector provided it is of the appropriate structural specificity. 
Gilman (1987) proposes that coordinate regulation of trans­
membrane signalling pathways is possible against the back­
ground of the subunit dissociation model and with a p.y com plex 
that is shared among different a subunits. The basic premise is 
that receptor mediated activation of a sufficient pool of G- 
protein will increase the concentration of p.y to a point where it 
will inhibit some pathways while release of aGTP can initiate 
other processes.
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1.4. Receptor-G-protein/ G-protein-effector  
asso c ia tio n s
Studies have been performed to assess the specificity of 
receptor-G-protein and of G-protein-effector interactions: There 
does appear to be more specificity of the latter processes than 
the former. Although activated receptors appear to exhibit a 
functional preference for a particular G-protein subtype-for 
example, a2 adrenergic receptors and Gj, a surprising degree of 
cross reactivity between receptors and G-proteins can be 
demonstrated experimentally such that a2 adrenergic receptors 
can also associate with Go more readily than Gt (transducin), but 
both to lesser degrees than Gj. This presumably reflects the 
previously described homology which exists amongst G-proteins 
and which extends to their receptor binding domains. Greater 
specificity does, however, exist in the G-protein-effector 
relationship as, for example, only cGMP PDE can be activated by 
transducin. However, although Gsa can stimulate AC it can also 
activate dihydropyridine-sensitive Ca2+ channels; furthermore 
it seems likely that all splice variants of Gsa share these 
porperties (Mattera, Graziano, Yatani et al. 1989).
1.5. Regulation of G-proteins
Although the mechanisms controlling G-protein expression and 
function remain to be fully resolved, several regulatory 
processes have already been described: these include covalent 
modification, humoral regulation and downregulation associated 
with receptor desensitisation.
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The known abilities of PT and CT to ADP ribosylate a subunits 
and modify their function raises the possibility that covalent 
modification of a subunits might be a mechansim by which G- 
protein function can be regulated. There is, however, only 
circumstantial evidence to support this concept. It has, for 
example, been demonstrated in vitro, that covalent modification 
of Gs can reduce AC activation (Perfilyeva, Skurat, Yurkova et 
al.1985). Two possible mechanisms of such regulation have been 
proposed-phosphorylation and ADP ribosylation. The existence of 
an enzyme system capable of effecting ADP ribosyl-ation in vivo 
has been demonstrated in human erythrocytes and adds credance 
to the concept: Tanuma and colleagues (1988) have shown that 
human erythrocytes contain an ADP ribosyltransferase which 
could catalyse ADP-ribosylation of a cysteine residue in Gja. 
Furthermore free Gja subunits (but not Gj heterotrimer) have 
been demonstrated to be suitable substrates for phosphorylation 
by protein kinase C (Katada, Gilman, Watanabe, Bauer & 
Jakobs1985). Thus mechanisms capable of effecting covalent 
modification have been demonstrated.
G-protein levels and/ or function appear to be under hormonal 
control. Glucocorticoids (see chapters 6 & 7)(Rodan & Rodan 
1986; Chang & Bourne 1987; Ros, Watkins, Rapiejko & Malbon 
1989; Saito, Guitart, Hayward et al.1989) and thyroid hormones 
(Milligan, Spiegel, Unson & Saggerson 1987) have been shown in 
experimental animals and cell culture to regulate differentially 
G-protein subunits. The effects of glucocorticoids will be 
studied in detail later, but it remains unclear whether the role
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of glucocorticoids is primary or merely permissive of the 
effects of other regulatory factors. Thyroid hormone deficiency 
(at least in rat adipose tissue) is associated with increased 
levels of Gja, Goa and IB subunits; all these changes are 
reversible with thyroid hormone administration (Milligan 1987). 
Furthermore, insulin may have a role in regulating Gi function 
and levels. Loss of tonic Gi-mediated inhibition and attenuation 
of receptor mediated inhibition of ACA accompany induction of 
experimental IDDM (streptozotocin and alloxan diabetes in the 
rat) (Gawler, Milligan, Spiegel, Unson & Houslay 1987; Bushfield, 
Griffiths, Strassheim et al. 1990)(see section 1.6.2.): insulin 
administration restores these changes to normal. Clearly many 
metabolic changes accompany IDDM and it would be premature to 
ascribe G-protein changes specifically to changes in insulin 
concentration (although this possibility remains).
In addition to the regulatory roles of hormones on G-protein 
expression and /or levels (which may be mediated directly or 
possibly in association with receptor changes) G-protein levels 
are modulated by ligand-receptor binding and thus have key roles 
in receptor down-regulation / desensitisation. Heterologous 
desensitisation (that is when prolonged exposure to a ligand 
results in downregulation of a number of receptor types) has 
been shown to be related to alteration of G-protein subunits; 
exposure of rat adipocytes in vivo to PGE1 or phenylisopropyl 
adenosine (PIA)(an A1 adenosine receptor agonist) effects 
reduced responses to both hormones with concurrent 90% 
reduction of G ail and Gai3 in addition to 50% reduction of Gai2
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and 13 subunits and without alteration of Gsa. By contrast, the 
homologous desensitisation induced by chronic exposure to 
nicotinic acid, is not associated with altered G-protein levels. 
Thus heterologous desensitisation is related to, and may be 
explained on the basis of, G-protein changes (Green, Milligan & 
Belt 1990).
Go regulation has been studied in cultured neuroblastoma cells: 
chronic membrane depolarisation not only results in increase in 
muscarinic ACh receptor number but also increases Go cx subunit, 
without affecting Gja or B subunit quantities (Leutje & 
Nathanson 1988) adding further weight to the evidence that G- 
protein levels are intimately related to and partly determined by 
receptor function.
1.6. G-proteins in human and experimental models of 
disease
1.6.1. G-protein abnormalities in human disease
G-protein abnormalities have been demonstrated in the 
metabolic disease, pseudohypoparathyroidism and in a number of 
tumours-including some GH secreting adenomas causing acro­
megaly.
Albright's hereditary osteodystrophy (AHO)
AHO is an autosomal dominant condition which includes pseudo­
hypoparathyroidism (PHP)(type 1a). The classical phenotype of 
AHO also includes a number of skeletal abnormalities including 
short stature, stocky build, round facies, brachydactyly and
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subcutaneous ossification. A number of endocrine and metabolic 
abnormalities characterised by resistance of target organs to 
hormone action have been reported; these include pseudohypo­
parathyroidism, primary hypothyroidism and hypogonadism 
(Levine, Downs, Moses et al. 1983). The multi-organ hormone 
resistance has been attributed to a generalised deficiency of Gsa 
(both expression and function are reduced). The G-protein 
abnormality in PHP type 1a consists of a deficiency of Gs with­
out change in Gj. Determined using reconstitution assays 
(reconstitution of Gs activity in eye- membranes), Gs activities 
of 43% (Levine, Jap, Mauseth, Downs & Spiegel 1986)-79% (Saito, 
Akita, Fujita et al. 1986) normal have been reported in 
erythrocytes; similar findings have been reported in a number of 
other tissues including platelets (Farfel and Bourne 1980), 
erythrocyes (Levine, Downs, Singer et al. 1980), renal tissue 
(Downs, Levine, Drezner, Burch & Spiegel 1983) and cultured 
fibroblasts derived from affected subjects (Bourne, Kaslow, 
Brickman & Farfel 1981). Further evidence confirming the 
association of PHP type la  with reduced Gs is the finding of 50% 
reduction of mRNA for Gs in affected members of 6/8 pedigrees 
with the condition (Levine, Ahn, Klupt et al. 1988). The 
deficiency of Gsa appears to be due to single base substitution 
in the Gsa gene (Patten, Johns, Valle et al. 1990).
The pathogenesis of PHP may however be more complex: some 
kindreds with AHO include individuals who feature Gsa 
deficiency, and yet who have apparently normal hormone 
responsiveness (pseudopseudohypoparathyroidism)(Levine et
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al.1986). A possible explanation for this perplexing paradox has 
been propsed by Spiegel (1990), who suggested that the 
variabij^iy in clinical expression may depend on modifying genes. 
He proposes the possibility that two different non-allelic genes 
may determine the expression of the disease; when inherited 
separately the disease is not manifest, but when inherited 
together the two genes may then cause hormone resistance.
Acromegaly:
Abnormal Gsa also characterises the abnormality underlying 
acromegaly, at least in some patients’ GH secreting adenomas 
(Vallar, Spada & Giannattasio 1987; Landis, Masters, Spada et 
al.1989). cAMP functions as a second messenger for several 
trophic hormones (Rozengurt 1986) including GHRH (Billestrup, 
Swanson & Vale 1986). Vallar and colleagues have shown that 
some GH secreting adenomas charaterised by high secretory 
activity and high intracellular cAMP levels exhibit constitutive 
activation of Gsa (Vallar et al. 1987): the constitutive activation 
of Gsa is due to a mutation in the peptide sequence encoding 
GTPase activty such that GTPase is inhibited (Landis et al.
1989). Loss of this enzyme activity results in loss of the 
intrinsic switch mechanism which terminates G-protein 
function with consequent activation of Gsa.
Cardiovascular disease:
G-protein abnormalities have been reported in plasma mem­
branes from human myocardium (Feldman, Cates, Veazey et al. 
1988; Neuman, Schmitz, Scholz et al. 1988; Bohm, Gierschik,
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Schnabel & Erdmann 1990) and from peripheral blood lympho- 
cytes( Horn, Corwin & Steinberg et al. 1988). Although the use of 
lymphocytes has been justified on the basis of some correlation 
between levels of Gsa in lymphocyte and myocardial membranes 
(Horn et al. 1988), contrasting changes in G-protein subunits 
have been reported in studies using lymphocytes: cholera toxin 
substrate (i.e. Gsa) has been reported to be reduced by 80% in 
lymphocyte membranes from patients with heart failure due to 
dilated cardiomyopathy (Horn et al. 1988), while in other studies 
substrates for both cholera toxin (Gsa) and pertussis toxins 
(including Gia (table 2)) were reported to be unaltered in cardiac 
failure (Maisel, Michel & Insel 1990) irrespective of whether it 
was due to cardiomyopathy or coronary artery disease (Michel, 
Maisel & Brodde 1990). Studies of G-protein function inferred 
from studies of ACA were similarly inconclusive.
However, G-protein studies in plasma membrane preparations 
derived from myocardium taken from patients with dilated 
cardiomyopathy (with donor heart controls) have proved more 
conclusive: Gia has been reported to be increased (around 36%) on 
the basis of ADP ribosylation studies with pertussis toxin 
(Feldman et al. 1988; Neuman et al. 1988; Bohm et al. 1990) and 
immunoblotting (Bohm et al. 1990). Gsa levels are not altered 
(Feldman et al. 1988). However, altered Gia was not confirmed in 
a study of myocardium from cardiac failure due to ischaemic 
heart disease (Bohm, Gierschik & Jakobs et al. 1990) raising the 
intruiging possibility that G-protein changes are more likely to 
be determined by the underlying pathology than the resulting
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cardiac failure. Furthermore, it remains unclear currently 
whether the observed G-protein changes contribute to the 
reduced 6 receptor-mediated inotropic responses which 
accompany chronic heart failure (Bristow, Hershberger, Port & 
Rasmussen 1989).
1.6.2. G-protein abnormalities in experimental models 
of disease 
Hypothyroidism
Human and experimental hypothyroidism is associated with 
weight gain which is largely attributable to metabolic changes 
which include blunted responses to agents that stimulate cAMP 
accumulation and lipolysis (B adrenergic agonists (Wahrenberg, 
Engfeldt, Arner, Wennlund & Ostman 1986), glucagon). In 
addition, responses to ligands which inhibit lipolysis and cAMP 
accumulation have generally been reported to be increased 
(adenosine, PGE1, nicotinic acid (Ohisalo & Stouffer 1979; 
Saggerson 1986). In the absence of major alterations in receptor 
number (a2 / B in humans (Wahrenberg et al.1986; Ros, Northup & 
Malbon 1988) or AC activity (Armstrong, Stouffer, Van Inwegen, 
Thompson & Robison 1974) to account for the metabolic 
changes-the possible contribution from G-proteins has been 
studied. Using plasma membranes derived from adipocytes, 
hypothyroid rats have been shown to exhibit increased Gja (based 
on ADP ribosylation studies (Malbon, Rapiejko & Mangano 1985) 
and on Western blots using specific antisera (Milligan et al. 
1987)); increased Gja in conjunction with elevated B subunit 
levels (Milligan et al. 1987) could account for the observed
functional changes noted in experimental and human hypo­
thyroidism. However, confirmation of similar alterations in G- 
proteins in human hypothyroidism (in contrast to the exp­
erimental model described above) is lacking. Studies based on 
plasma membranes from adipocytes taken from hypothyroid 
human subjects (post thyroidectomy for papillary carcinoma, but 
without thyroxine replacement for 4 weeks) failed to show any 
changes in G-protein levels: specifically Gi and Gs were 
unchanged (Ohisalo & Milligan 1989).
Obesity:
Obesity is associated with metabolic changes which contrast 
with those of hypothyroidism, viz. the sensitivity of adipocytes 
to inhibitory agents is reduced whereas sensitivity to ligands 
which promote lipolysis is increased (Ohisalo, Ranta & 
Huhtaniemi1986; Richelson 1988). The role of G-proteins has 
been studied in two experimental models-the ob/ob strain of 
obese mouse and the obese Zucker rat. In the former model 
Begin-Heick (1985) reported deficiency of functional Gj al though 
a subsequent study by Greenberg and colleagues (Greenberg,
Tatlor & Londos1987) failed to confirm this. Western blots for 
G ja in  hepatocyte plasma membranes from Zucker rats failed to 
show any change in Gja levels although functional deficiency of 
G jawas inferred from studies of GppNHp inhibition of AC 
(Houslay, Gawler, Milligan & Wilson 1989).
Ohisalo & Milligan (1989) performed similar studies in 
membranes derived from obese human subjects and although the
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absolute levels of Gsa and Gjoc were reduced the relative amounts 
of both were unaltered.
Thus controversy exists regarding the role of Gja in obesity. 
There is agreement that Gja levels in membranes from Zucker 
rats and obese human are not altered, but the possibility of 
deficiency of Gja function remains and would be compatible with 
the biochemical changes discussed above.
Diabetes mellitus:
Houslay's group have shown that chemically induced insulin 
dependent diabetes mellitus in the rat is associated with altered 
G-protein expression and function (table 3) (Gawler et al. 1987; 
Bushfield et al. 1990; Bushfield, Griffiths, Murphy et al.1990; 
Srassheim, Milligan & Houslay 1990). These changes are common 
to both STZ and alloxan induced DM. The alterations are tissue 
specific, do not invariably reflect altered expression and are 
selective for particular G-protein a subunits.
STZ and alloxan diabetes are associated with a number of 
biochemical changes which include a marked reduction in plasma 
insulin concentrations with a consequent rise in blood glucose. 
However, both are also associated with development of apparent 
insulin resistance in hepatocytes and enhanced ability of 
glucagon to stimulate AC (Gawler et al. 1987; Bushfield et al.
1990). Changes in G-protein subunits are accompanied by altered 
G-protein function in hepatocytes and adipocytes; tonic 
inhibition of AC by Gi is lost while receptor mediated inhibition 
(via Gi) is attenuated in both tissues (Gawler et al.1987;
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Bushfield et al. 1990). These changes are reversed by insulin 
adm in is tra tion .
Correlation of altered function with changes in G-protein 
subunits is currently only possible with the AC system (Gsa 
Table 3: G-protein changes in experimental diabetes 
m e ll i tu s .
T ISSUE G j1 a Gj2oc G j3oc G s a  fi
m 1,2 1,2 1,2♦  ♦  ♦
1 , 2  1,2 1,2 2
♦ t 4 4
2 2 2
♦  4  ♦
KEY: 1= change in amount of G-protein assessed by western blotting 
2= changes in mRNA encoding G-protein subunit
Data are dervied from the following references:
Gawler et al. (1987) Bushfield et al. (1990a)
Bushfield et al. (1990b) Srassheim et al.(1990)
effects stimulation while Gja effects inhibition of AC catalytic 
unit). Loss of Gi function correlates with reduced amount of Gj2a
cand reduced Gj2a mRNA. However, this plausible series of
associated observations does not hold true for adipocytes where 
Gj2a levels and mRNA are unaltered. Post transcriptional 
modification of the G-protein subunits, for example by phospho­
HEPATOCYTES
ADIPOCYTES +  t
2
KIDNEY ^
HEART
SKELETAL
MUSCLE
BRAIN
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rylation, could account for these observations. Whether this is 
effected by insulin (the insulin receptor tyrosyl kinase can 
phosphorylate the a subunit of Gi (Katada, Gilman, Watanabe, 
Bauer & Jakobs 1985) or by other hormones such as glucagon 
(Bushfield et al. 1990) remains unclear.
1.7. Aims of this thesis:
The aim of this thesis is to examine whether human non-insulin 
dependent diabetes mellitus and various types of hypertension 
(human and experimental) are associated with alterations of G- 
protein function or levels.
In chapter 3, human non-insulin dependent diabetics (who exhibit 
insulin resistance and hyperinsulinaemia) were studied to 
assess whether NIDDM is associated with G-protein abnormal­
ities as seen in experimental STZ-IDDM. Platelets were used as a 
source of plasma membrane for study, partly because of their 
availability and because platelets from diabetics exhibit 
functional abnormalities for which the underlying mechanism 
remains to be elucidated.
Study of experimental models of obesity (Zucker rat)(Houslay et 
al. 1989) and of STZ/alloxan IDDM has raised the possibility that 
these two states which are characterised by insulin resistance 
(see above) may share a common G-protein abnormality viz., 
altered function (± levels) of Gi2 - Several human disease states
also exhibit insulin resistance including obesity, NIDDM and 
essential hypertension (Ferrannini, Buzzigoli, Bonadonna et al.
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1987): indeed there is growing evidence that insulin resistance 
and hyperinsulinaemia may be implicated in the pathogenesis of 
essential hypertension. In addition, strong clinical and 
epidemiological associations link diabetes mellitus (in 
particular NIDDM) and essential hypertension (for example, the 
prevalence of hypertension is increased in diabetes: 40-53% of 
patients presenting with NIDDM (age 25-65yrs) are hypertensive 
(BP>160/95) (United Kingdom Prospective Diabetes Study.1985) 
and after age adjustments, the prevalence of hypertension may 
actually be higher in IDDM(National Diabetes Data Group. 1985)). 
Thus, in chapter 4, G-protein levels and function in human 
essential hypertension (again using platelets) were assessed in 
order to study the possibility that EH might share similar 
abnormalities of function (or levels) of G-proteins (in particular 
Gi2) with experimental models of obesity and diabetes mellitus 
(by virtue of shared insulin resistance).
In chapter 5, studies of the spontaneously hypertensive rat 
(SHR), a commonly used model of genetic hypertension, are 
described. This model is particularly useful as it has many 
features in common with human EH including glucose 
intolerance/ insulin resistance. This experimental model of 
hypertension was used in order to study G-protein changes in 
myocardium (tissue which is not available from human subjects!) 
as there is substantial evidence of abnormalities of AC 
activation; reduced B adrenergic activation of adenylyl cyclase 
has been widely reported (vide infra Amer, Gomoll, Perhach, 
Ferguson & McKinney 1974; Bhalla & Ashley 1978; Bhalla,
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Sharma & Ramanathan 1980; Blumenthal, McConnaughey & lams 
1982; Sharma, Kemp, Gupta & Bhalla 1982; Kumano, Upsher & 
Khairallah 1983; Anand-Srivastava 1988). Thus, in addition to 
the possibility of G-protein changes in association with insulin 
resistance, the role of G-proteins in the observed changes in 
cyclase activities requires clarification.
In chapters 6 & 7 potential changes in G-proteins in 
glucocorticoid hypertension were studied. There is increasing 
evidence that glucocorticoids may directly differentially 
regulate G-protein subunits, at least in suprapharmacological 
doses (Rodan & Rodan 1986; Chang & Bourne 1987; Ros et 
al.1989; Saito et al.1989), and it is appropriate to examine 
whether these changes are relevant to glucocorticoid hyper­
tension
Using an established animal model (Tonolo, Fraser, Connell & 
Kenyon 1988) of glucocorticoid hypertension the effect of 
glucocorticoid (dexamethasone (DEX)) administration for 14d (in 
vivo ) on the function and levels of G-proteins in several organs 
with key roles in the regulation of blood pressure (chapter 6) 
was studied.
In chapter 7, the effects of in vitro DEX on G-protein function 
and levels in membranes derived from cultured VSMC were 
studied. The aim was to assess whether the increase in ACA seen 
in cultured VSMC (Yasunari, Kohno, Balmforth et al. 1989) in
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response to DEX can be ascribed to alterations in G-protein 
subunits.
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Chapter 2
Materials & Methods
& Prelim inaries
2.1. Materials
All chemicals were supplied by Sigma (UK) Ltd. with the 
exception of guanosine-5'-triphosphate (GTP), guanylylimido- 
diphosphate (GppNHp), creatine kinase and creatine phosphate 
which were supplied by Boehringer Mannheim (West Germany).
Radioisotopes including a-32P ATP , 5',8-3H cAMP and y 32P GTP 
were supplied by Amersham International pic (UK).
Antibodies to G-protein a subunits were prepared and kindly 
donated by Dr G. Milligan, Dept, of Biochemistry, University of 
Glasgow. Table 4 lists the antibodies used in these studies, the 
peptide sequences against which the antibodies were generated 
and the specificities of the resulting antibodies. The principle of 
antibody production is described for antisera CS1 and SG1, but 
similar methods were used to generate all the antibodies.
Briefly, antiserum CS1 was produced in the New Zealand White 
rabbit, using a conjugate (conditions for coupling and use as 
described by Goldsmith, Gierschik, Milligan et al.1987) of 
keyhole limpet haemocyanin and a synthetic peptide 
(RMHLRQYELL) which corresponds to the C-terminal decapeptide 
of Gsa. Antiserum SG1 was raised in a similar fashion except 
that the synthetic peptide used (KENLKDCGLF) corresponds to the 
C-terminal decapeptide of rod transducin. This sequence differs 
from the equivalent region of Gi in only one substitution, and as 
for other antisera generated against this conjugate (Goldsmith
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et al. 1987; Milligan et al. 1987), this antiserum identifies 
forms of Gi. As the distribution of transducin is limited to 
tissues that contain photoreceptors, this antiserum can be used 
to identify Gi in all other tissues. The antibodies bound to G- 
proteins (for example on a Western blot) were subsequently 
identified using one of two 'second antibodies' - horse radish 
peroxidase (HRP) labelled anti-rabbit-lg (which was kindly 
supplied by the Scottish Antibody Production Unit, Law Hospital) 
and | -labelled donkey antirabbit IgG which was obtained 
from Amersham International pic (UK).
Table 4: Antibodies used to identify G-proteins: peptide 
sequence identified and antibody specificity.
CODE PEPTIDE SEQUENCE NATIVE PEPTIDE Ab SPECIFICITY
SG KENLKDCGLF TD 341-350 TD1 ,TD2,G i1 ,G i2
I1C LDRIAQPNYI Gil 159-168 G il
LE3 CERYAQSDY Gi2 160-169 Gi2
I3B KNNLKECGLY Gi3 345-354 Gi3
cs RMHLRQYELL Gs 385-394 Gs
ON GCTLSAEERAALERSK Go 1- 16 Go
BN MSELDQLRQE 131 1-10 61 ,132
Peptide sequence based on single letter coding for amino acids. 
TD = TRANSDUCIN
REFERENCES: Mitchell, Griffiths, Saggerson et al. 1989
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2.2. Experimental animals
A number of genetic models of hypertension exist (reviewed by 
Yamori 1983). Although none exactly mirrors human EH, the 
spontaneously hypertensive rat (SHR) (developed in Japan, by 
Okamoto & Aoki (Okamoto & Aoki, 1963)) shares many features 
in common with EH, and is consequently widely used. The hyper­
tension of human EH and of the SHR can be regarded as multi­
factorial in aetiology with a polygenic hereditary basis (the SHR, 
if anything has a stronger genetic basis than EH). As in EH, the 
hypertension of the SHR is not associated with volume overload, 
but develops and is maintained in association with increased 
peripheral vascular resistance. The factor initiating hyper­
tension in the SHR may be neurogenic (promoting vasocon­
striction) while (as in EH) later stages are characterised by 
structural and functional vascular changes: a number of 
membrane transport abnormalitites are shared by EH and SHR 
(reviewed by Yamori 1983). Both SHR (Mondon & Reaven 1988) 
and EH (Ferraninni et al. 1987) share the abnormalities of insulin 
resistance and hyperinsulinaemia which will be discussed later 
in greater detail (chapter 4). A further attraction of the SHR 
model is that it mimics the natural history of the human 
disease-in that both share a tendency to end organ damage (for 
example, myocardial hypertrophy) and to cardiovascular 
com plications.
One potential weakness exists in the use of this particular 
model; there is controversy as to the most appropriate normo- 
tensive control. This problem stems from the original breeding 
programme. After the SHR species had been developed the
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investigators (Okamoto & Aoki) subsequently appreciated the 
need for an appropriate control and returned to the original 
Wistar (outbred) species and selected and subsequently bred 
normotensive controls (WKY). The majority of the studies 
involving SHR cited in this thesis have used WKY control species. 
However, genetic heterogeneity has recently been shown not only 
between animal suppliers but also among WKY rats from a 
particular supplier, highlighting that the rats are not fully 
inbred (Kurtz et al. 1989). It has recently become apparent, 
however, that the outbred Wistar strain may at be least as 
appropriate a control as WKY, and for this reason, in this work 
both WKY and Wistar rats were used as control species for the 
studies involving SHR.
Animals were obtained from Charles River laboratories. In this 
thesis tissues were obtained from 10-11 week old SHR, Wistar 
and WKY rats in the study of rat myocardium. Sprague Dawley 
rats were used as donors of tissue and of cells for culture in the 
studies of the effects of dexamethasone (chapters 6 & 7) on G- 
protein expression.
The animals were housed in the local animal house under 
standard conditions of light and temperature. They were fed 
standard chow and free access to water was allowed. Further 
details of animal procedures are given in the appropriate 
methods sections; sacrifice was by cervical dislocation.
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2.3. Membrane preparations
2.3.1. Human platelet plasma membrane preparation.
Platelets were prepared as described by MacIntyre and Pollock 
(1983). Blood was collected in 3.8% w/v trisodium citrate and 
centrifuged atlOOOg for 5 min. at room temperature to obtain a 
supernatant of platelet rich plasma. Following aspiration and 
further centrifugation at 30,000g for 15 min at 4°C  the 
resulting pellet was resuspended in ice cold lysing buffer (10 
mM-Tris/HCI buffer containing 1 mM EDTA, pH 7.4). Membranes 
were subsequently prepared from this pellet as described by 
Jakobs and colleagues (Jakobs, Lasch, Minuth, Aktories & Schultz 
1982). The pellet was homogenised in lysing buffer with ten 
strokes of a motorised Teflon pestle/glass homogeniser and was 
then subjected to further centrifugation at 30,000g for 15 min. 
Following washing in lysing buffer and another centrifugation 
the final pellet was resuspended in 10 mM Tris/HCI buffer, pH 
7.4 and frozen at -80°C.
2 .3 .2  Plasma membrane preparations derived from 
animal tissues: liver cell plasma membrane 
prep ara tio n .
Although liver is relatively homogeneous with hepatocytes 
accounting for more than 90% of adult liver mass, 40-50% of the 
actual cell population consists of other cells including erythro­
cytes, reticuloendothelial cells, Kupffer cells etc. Furthermore 
hepatocyte 'plasma membrane1 comprises three distinct 
functional zones- the blood sinusoidal, the lateral and the bile 
canalicular regions. Membranes have been prepared in two ways- 
'crude' membrane preparations prepared essentially by
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differential centrifugation and 'purified' membrane preparations 
based on centrifugation through density gradients (Neville 1960; 
Neville 1967; Touster, Aronson, Dulaney & Hendrickson 1970). 
Several protocols representing variations on the latter theme 
are available and these are broadly designed to isolate lateral & 
bile canalicular membrane (Song, Rubin, Rifkind & Kappas 1969) 
or alternatively blood sinusoidal membrane (Touster et al. 
1970)-but difficulties have arisen with low yield of membrane 
(Ray 1969) and with reproducibility between investigators 
(Touster et al. 1970). Glucagon-activated AC is primarily located 
in the blood sinusoidal membrane fraction while G-protein 
immunoreactivity appears to be greatest in the bile canalicular 
fraction. The hepatocyte preparation used here (llliano and 
Cuatrecasas 1972) represents a compromise- being relatively 
simple to perform while offering a final membrane preparation 
which is enriched with plasma membrane; the essence of the 
method is differential centrifugation.
In brief,whole livers were excised from control and hyper- 
trensive rats and minced with a scalpel blade. The 'mince' was 
homogenised in ice cold 0.25M sucrose using a Polytron at 
21,000 rpm (setting '6') for 90sec. After centrifugation for 10 
min. at 600g, the supernatant was centrifuged at 12,000g for 30 
min. This supernatant was adjusted with NaCI (0.1 M) and MgS04 
(0.2mM) and centrifuged at 40,000g for 40 min. The pellet was 
then suspended in 10 mM TRIS (tris(hydroxymethyl)amino- 
methane-HCI) buffer pH 7.4, homogenised and centrifuged at 
40,000g for 40 min. This step was repeated twice. The final
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pellet was resuspended in TRIS buffer and stored in aliquots at - 
80°C.
2.3 .3 . Rat myocardial plasma membrane preparation:
Myocardial plasma membranes were prepared as described by 
Sharma and colleagues (Sharma, Kemp, Gupta & Bhalla (1982)). 
Hearts were removed as soon as possible after sacrifice of the 
rats. They were cleaned of loose connective tissue, fat and 
residual blood and were minced with a scalpel blade. The mince 
was washed twice with cold homogenising buffer [20mm Tris- 
HCI, pH 7.4, containing 0.25M sucrose, 1 mM EDTA, 1 mM MgCI2 
and 1 mM DTT] and was then homogenised in 7-10 volumes of ice 
cold buffer using a 'Polytron' at setting '5' for 3 x 10 sec. with 1 
minute interval between bursts. The homogenate was filtered 
through two layers of cheesecloth and centrifuged at 9000g for 
10 min. The pellet was rehomogenised and centrifuged again. The 
two supernatants were combined and centrifuged at 37,000g for 
30min. to yield membranes. The membrane fractions were 
washed once with 0.6M KCI in homogenising buffer followed by 
two washes with homogenising buffer to remove intrinsic 
guanine nucleotides and contractile proteins. The pellet was 
finally resuspended in a buffer containing 10mM Tris-HCI, 
ImMDTT and 1mM MgCI2, pH7.4 and stored at -80°C.
2.3.4. Rat brain piasma membrane preparation:
Whole rat brains were excised and, after weighing, were 
homogenised in 10mM Tris/1mM EDTA pH 7.5 buffer with 20 
strokes of a Potter-Elvejhem teflon-glass tissue homogeniser. 
This crude homogenate was centrifuged for 10 min. at 2,600 rpm
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to remove nuclear and other dense material, and the supernatant 
containing the plasma membranes was recovered. The super­
natant was then centrifuged at 40,000g for 20 min. to produce a 
membrane pellet which was resuspended and washed in 
Tris/EDTA buffer. After a further centrifugation (40,000rpm for 
20 min.) the final pellet was suspended in buffer and stored in 
aliquots at -80°C .
2.3.5. Rat renal cortical plasma membrane preparation:
Rat renal cortical plasma membranes were produced according to 
a modification of Snavely and Insel's protocol (1982); the 
modification was drawn from the liver plasma membrane 
preparation of llliano and Cuatrecasas (1972) and was incorp­
orated to increase the purity of the final plasma membrane 
preparation. Whole kidneys were excised and the perinephric 
membrane and adjacent fat were removed. The kidneys were 
bisected longitudinally and the cortex was dissected from the 
renal pelvis and medulla. After weighing, the cortical tissue was 
homo-genised in 10 volumes of buffer [20mm Tris-HCI, pH 7.4, 
containing 0.25M sucrose, 1 mM EDTA, and 1 mM DTT with 10 
strokes of a Potter-Elvejhem teflon-glass tissue homogeniser. 
The homogenate was centrifuged at 500g for 5 min. and the 
resulting supernatant was recovered; this was then centrfiuged 
at 12,000g for 30 min. and plasma membranes were recovered 
from the supernatant by centrifugation at 37,000g for 30 min. 
After a wash in homogenising buffer followed by further 
centrifugation at 37,000g for 30 min. the resulting plasma 
membrane pellet was suspended in 10mM Tris-HCI, ImMDTT and 
1 mM MgCI2, pH7.4 and stored in aliquots at -80°C.
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2.3.6. Rat mesenteric & VSMC plasma membrane 
p rep aratio n :
The mesenteric vascular beds and aortas were dissected free of 
fat into ice cold homogenising buffer [10mM Tris/1mM EDTA]. 
They were homogenised using a 'Polytron' at setting'10' for 15 
sec. The homogenate was then centrfiuged at 1000rpm for 
10min. to remove the bulk of residual fat, and after a further 10 
min. at 1500rpm the supernatant was recovered. Plasma 
membranes were recovered from this fraction by centrifugation 
at 37,000g for 30 min. The final pellet was suspended in 10 mM 
Tris and stored in aliquots at -80°C.
2.4. Western Blotting
2.4.1. Preparation of Western Blots
The presence and amount of particular G-protein subunits was 
determined by Western blotting, using the antibodies described 
in (section 2.1.) Gel electrophoresis was performed according to 
the method of Laemmli (1970). Gels containing 10% acrylamide 
were prepared from a stock solution of 30% by weight of 
acrylamide and 0.8% N,N'-bis-methylene acrylamide. The final 
concentrations in the separation gel were as follows: 0.38M 
Tris-HCI (pH 8.8), 0.1% SDS and 3.3% glycerol. The gels were 
chemically polymerised by the addition 0.03% (by volume) of 
tetramethylethylenediamine (TEMED) and ammonium persulphate. 
100 x 150 x 1.5 mm gels were prepared between glass plates. 
Stacking gels of 3% acrylamide, containing 0.12 M Tris-HCI (pH 
6.8) and 0.1% SDS, polymerised by TEMED and ammonium 
persulphate were layered on top of the separation gel. The
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electrode buffer contained 0.025M Tris, 0.19M glycine and 0.1% 
SDS.
In general, 10Ojag aliquots of plasma membrane protein were 
used unless otherwise stated. The protein was solubilised and 
precipitated by the addition of 2% deoxycholate and 24% TCA. 
Following resuspension of the protein in buffer containing 0.5M 
Tris, 2.4% SDS (w/v), 2.8% DTT,14.28% urea and Bromophenol 
blue dye, the samples were immersed in boiling water for 2 min. 
to ensure complete dissociation of the protein fractions (Maizel 
1969). BRL (Bethesda Research Labs., USA) high MW protein 
standards were run in parallel with the samples under study. In 
addition, a 'standard' plasma membrane preparation was included 
on all blots to facilitate comparison of data from different 
blots.
The electrophoresis was run vertically in a BRL electrophoresis 
tank with a current of 15mA and voltage of 35 V until the 
Bromophenol blue dye front had reached the bottom of the gel 
(generally about 16 hr). The proteins were electrophoretically 
transferred to nitrocellulose paper (100V for 120 min) 
essentially as described by Towbin (Towbin, Staehelin & 
Gordon1979). After blocking with 5% "Marvel" (Cadbury Ltd, UK) 
in Tris-buffered saline (TBS) for 2h at 3 7 °C, the blot was 
incubated with the first antibody in 1% gelatin in PBS overnight. 
The bound antibody was visualised either with horse radish 
peroxidase-labelled donkey, anti-rabbit IgG (developed using O- 
dianisidine)(as previously described by Milligan et al.1987) or 
with 125| labelled anti-rabbit IgG which was suspended in PBS
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containing1% gelatin with 0.2% Nonidet P40 (nonionic detergent). 
The radiolabelled 'second antibody' was visualised by 
autoradiography by exposure to Kodak XOMAT AR Film (Kodak 
Eastman Ltd) which was processed automatically in a Kodak 
XOMAT processor. The bands were subsequently cut out and 
counted on a NE1612 gamma counter (Nuclear Enterprises, EMI, 
UK).
The gels were retained and residual protein (which had not been 
transferred electrophoretically) was visualised by staining with 
Coomassie Blue (0.25% in 45% methanol/10% glacial acetic acid) 
with subsequent destaining in 45% methanol/10% glacial acetic 
acid.
O ther m ethods are ava ilab le  fo r  id e n tifica tio n  and 
quan tita tio n  o f G -prote in subun its . Covalent m odification 
of G-proteins by ADP ribosylation has proved to be a useful 
means of identifying G-proteins. Cholera toxin and pertussis 
toxin (see section 1.2.5.) are essentially ADP-ribosyltrans- 
ferases which catalyse the transfer of the ADP-ribose moiety 
from NAD+ to the recipient a subunit. Cholera toxin mediated 
ADP ribosylation is a process specific for Gsa. In contrast, 
pertussis toxin mediated ADP ribosylation is limited due to 
multiple substrates within membrane preparations- including 
Gi(1,2,3)(Suki et al.1987) and Go (Itoh et al. 1986). Used 
extensively in the past to identify the presence of G-proteins, 
the problem of multiple substrates coupled with the availability 
of antibodies specific for particular a subunits has rendered 
Western blotting the prime means of identifying G-proteins.
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Furthermore difficulties have arisen in achieving ADP-ribosyl- 
ation in some systems-notably the human platelet. The problem 
may be partly circumvented by using detergent-(saponin) treated 
whole platelets- which allow entry of pertussis toxin through 
the membrane. In light of these difficulties use of specific 
antibodies, rather than ADP ribosylation studies, was the 
preferred method for identifying G-proteins within our 
membrane preparations.
2.4.2. G-proteins identified in plasma membrane 
p rep ara tio ns:
Figure 3 is a typical blot showing Gsa expression in a number of 
membrane preparations. The data obtained from all such 
exploratory blots are summarised in table 5.
It should be noted that none of the membrane preparations 
comprised highly purified plasma membrane-but rather they all 
represent plasma membrane enriched preparations. It would thus 
be invalid to draw conclusions form the apparent differences in 
the relative abundance of G-proteins in different tissues. 
However, comparisons can be made between similar plasma 
membrane types from different species as invariably the study 
preparations were prepared concurrently and according to the 
same protocol.
In order to make useful comparisons of G-protein levels in study 
and control membrane preparations, it was necessary first to 
identify which G-proteins were present in the membrane prep-
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Fig. 3. Dem onstration o f G sasubun its  in a range of 
p lasm a mem brane p repa ra tions .
(100jig p ro te in  loaded).
A. nephroblastoma cell line E. adipocyte
B. brain F. renal cortex (A)
C. liver G. renal cortex (B)
D. m yocardium H. m esenteric artery
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Table 5: G-proteins expressed in membrane preparations 
MEMBRANE PREP. G sa G i l  G i 2 a  G i 3 a  G o a  B
PLATELET * • • •
MYOCARDIUM • • • •
RENAL CORTEX • • • •
LIVER •
BRAIN • • • •
VSMC/MESENTERY • • • •
All membrane preparations studied were derived from rat species except platelet*- 
from humans.
Note: in all preparations Gsa was represented as 2 bands of around 40kDa and 
42kDa (splice variants), although the relative abundance of these varied.
aration. For comparisons to be valid, identical amounts of 
membrane preparation were loaded (study and control prep- 
arations)(this was confirmed by determining protein conc­
entration of the actual samples which would be loaded onto gels 
later in the day). It is assumed that the amount of antibody 
present is in excess of the available binding sites (G-protein, 
within preparation under study). Furthermore, to ensure that this 
was genuinely the case 'dose response' curves were constructed 
for each membrane preparation/ antibody used and the amount of 
protein to be loaded was determined from the linear portion of 
the curve (plot of CPM v pg protein loaded). A typical 'dose 
response' curve is shown-figure 4. (The amounts of plasma 
membrane protein derived from these studies and loaded on 
Western blots are cited in appropriate chapters.)
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2.5. Cell Culture - VSMC.
VSMC culture (for subsequent G-protein studies by the author) 
was performed by Dr F. Lyall and Miss S. Tawil, MRC Blood 
Pressure Unit as described by Balmforth and colleagues 
(Balmforth, Lyall, Morton & Ball 1988). Briefly cells were 
isolated from the mesenteric vascular bed of 6-8 x 300-350g 
Sprague Dawley rats. Fat was removed by blunt dissection and 
the vascular tree was transferred to an enzyme dissociation 
mixture (10ml) of collagenase (1.25mg/ml), elastase (0.05 
mg/ml) and soya bean trypsin inhibitor (0.1%) in Hank's balanced 
salt solution (HBSS). After incubation at 37°C for 10-15 min. the 
arteries were transferred to fresh HBSS and any remaining fat, 
adventitia and endothelial cells were removed by careful 
dissection. The cleaned arteries were cut into small pieces and 
transferred to fresh enzyme dissociation mixture and incubated 
at 37°C with periodic trituration until a single cell suspension 
was obtained. The cell suspension was centrifuged (5°C, 200g 
for 5 min.) and the pellet resuspended in Dulbecco's modified 
Eagle medium containing 10% foetal calf serum, 2mM L-glut- 
amine, 100U/ml penicillin and 100pg/ml streptomycin. The 
dispersed cells were plated in a 25cm2 culture flask and 
maintained in a humidified atmosphere of 5% CO2 , 95% air at 
37°C. Cells were subcultured as required up to 7th passage and 
were used for experiments when confluent.
Verification that the cultured cells were indeed VSMC was based 
on a number of investigations. These included electron micro­
scopic morphology, absence of light microscopic staining for
72
endothelial cells, and the demonstration of cell contractility to 
angiotensin II (only feasible within the first 48h of culture).
Cell culture conditions and additions to culture medium are 
specified in chapter 7.
2.6. Measurement of protein concentration
Protein concentrations in the membrane preparations were 
measured colorimetrically using Peterson's modification 
(Peterson 1977) of the Lowry protocol (Lowry 1951) based on 
bovine serum albumin as standard.
2.7. 5' Nucleotidase Activity
The enzyme 5f-Nucleotidase (5ND) (EC 3.1.3.5) was used as a 
plasma membrane marker to trace recoveries and losses of 
membrane during the membrane preparative procedures. Although 
essentially an ectoenzyme, 5ND has been identified on intra­
cellular membranes including endoplasmic reticular membranes 
(Widnell 1972) and Golgi membranes (Farquhar et al.1974). The 
enzyme hydrolyses 5' ribo-nucleotides to ribonucleosides and 
orthophosphate. 5ND activity was measured as described by 
Dixon & Purdom (1954); the phosphorus liberated during the 5'- 
nucleotidase hydrolysis of adenosine 5'-monophosphate is 
measured as an index of the enzyme's activity (the method 
allows correction for the hydrolysis of adenosine 5'-mono- 
phosphate by non-specific phosphatases by incorporating the 
determination of phosphorus released from glycerophosphate 
substrate). The phosphorus liberated is measured color­
imetrically by the Fiske and Subbarow (1925) method.
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2.8. Functional assessment of G -proteins
Several methods are available to assess G-protein function. The 
most convenient of these is to measure changes in second 
messenger activity induced by ligands which either act directly 
on associated G-proteins (for example GTP and GppNHp) or which 
act on receptors which are coupled via G-proteins to the effector 
mechanism. The experiments described here are based on assess­
ment of G-protein modulation of adenylyl cyclase activity- 
measured as cAMP production by the Salomon assay (see 2.8.1.).
Other methods are available and include the functiona l 
reconstitution of Gs activity using membrane extracts from 
cells under study in conjunction with eye- S49 lymphoma 
membranes which lack an intrinsic Gs activity (genetic mutation 
prevents binding of Gs to AC catalytic unit). Alternatively, ADP 
ribosylation by cholera and pertussis toxins can be adapted to 
study G-protein function: pertussis toxin mediated ADP-ribosyl- 
ation of Gi effects inhibition of Gi (i.e. net activation of 
effector) while cholera toxin mediated ADP ribosylation of Gs 
effects activation of Gs (i.e. net further activation of effector). 
This approach is clearly limited by the potential problems cited 
in the previous section. GTPase is an intrinsic component of the 
a subunit and its activity can be directly measured; as will be 
discussed later, this method also has its limitations (2.9.).
2.8.1. Measurement of adenylyl cyclase activity
Adenylyl cyclase activity was assessed according to the 
protocol of Salomon (1974) by measurement of the cAMP 
synthesised in the following reaction:
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LIGAND
I
a 3 2 p _ / \ T P — adenylyl cyclase oc3 2 P -cA M P  + P-P
catalytic unit
I
Mg2+, GTP
The method consists essentially of two phases. The reaction 
phase (detailed below) followed by the separation of the 
reaction products by sequential column chromatography on 
Dowex 50G and neutral alumina. Thus 32P CAMP can be separated 
from 32P ATP. The 32P counts were corrected for column 
recovery (70-80%) using 3H cAMP.
Two different reaction mixtures were used for incubations. 
Plasma membranes from (rat) myocardium, renal cortex, liver 
and mesenteric arteries were incubated in Mix A while 
membranes from platelets and VSMC were incubated in Mix B.
Mix A: Rat myocardium/ renal cortex /liver/mesenteric arterv: 
The reaction mix was essentially as de^|rbield by Sharma et al. 
(1982) and included a phosphate regenerating system consisting 
of creatine phosphate (sodium salt) 20mM, 60U/ml creatine 
kinase and myokinase 40U/ml in addition to 25mM tris- 
acetate,pH 7.6, 5 mM MgCI2, 0.5mM ATP, 0.05 mM cAMP, 1mM 
DTT, 1mM EDTA and 0.5mM 3-isobutyl-1-methyl xanthine (a 
phosphodiesterase inhibitor). Guanine nucleotides were included 
at the specified concentrations, but unless otherwise stated the 
reaction mix included 10“5M GTP. a32P ATP was added to give 2
x  1 0 6  CPM/assay. Final assay volume was 50jlxI. All assays were 
performed in quadruplicate.
The reactions were started by the addition of membrane 
(generally 8pg membrane protein) suspended in 10mM tris pH7.4. 
Tubes were incubated at 30°C for 10 min.- a time shown to be in 
the linear portion of the time course of the reaction (figure 5).
The reactions were stopped by replacing in an ice bath and by the 
addition of 100pl of 'stopping solution' containing 2% SDS, 45mM 
ATP and 1.3mM cAMP. 50pl of ^H-cAMP were added and the tubes 
were then placed in a 95°C water bath for 3 min. to solubilise 
all membrane protein. The contents of the tubes were then 
subjected to column chromatography (see above) after addition 
of 1 ml of water to each tube or were frozen at -20°C (without 
demonstrable loss of cAMP) until chromatography was 
performed. The final 6 ml eluate were collected directly into 
scintillation vials containing 12 ml. Ecoscint scintillation fluid 
(National Diagnostics, U.K.) and were counted in a Beckman 
LS1800 using a dual channel programme.
Mix B: Platelets and VSMC:
The assay mix for platelet membrane experiments was as 
described by Salomon (1979) and was similar to the above 
protocol with the exclusion of IBMX and myokinase, but with the 
inclusion of BSA 0.1 mg/ml. Incubations were at 37°C for 15 min. 
which were again within the linear part of the time course of 
the reaction. The stopping solution and subsequent handling of 
the samples were exactly as shown for Mix A.
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Figure 5. Time course of adenylyl cyclase enzyme 
activity in rat myocardium-showing  
linear time course over 25min.
The interassay coefficient of variation for this assay was 
around 10%.
2.8.2. Ligands used to study adenylyl cyclase activity 
(table 6)
2.8.3. Forskolin
Forskolin has been used in all studies of ACA described in this
thesis; it has been used alone and in combination with ligands
which stimulate or inhibit ACA. Forskolin, a derivative of the
root of Coleus Forskolii, is a potent stimulant of adenylyl 
cyclase activity which serves to amplify basal or ligand 
stimulated AC. Since the discovery of this property in 1981
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(Seamon, Padgett & Daly 1981), forskolin has been elevated from 
the realms of Indian herbal medicine to a useful tool in 
elucidating the properties and actions of AC and G-proteins. 
However, its ability to stimulate AC indiscriminately renders 
forskolin toxic on systemic administration; the prime effects in 
experimental animals are "cardiotonic", that is analagous to B 
adrenergic effects (but not susceptible to B blockade)- eliciting 
positive chronotropic and inotropic effects (dogs) but also 
vasorelaxation- resulting in reduced mean arterial resistance, 
peripheral resistance and left atrial pressure-and thus 
hypotension (Lindner, Dohadwalla & Bhattacharya 1978).
Forskolin is lipophilic and exhibits limited water solubility. 
100pM forskolin has been widely used in studies of AC activity 
in platelet membranes (Insel, Stengel, Ferry & Hanoune1982; 
Awad, Johnson, Jakobs & Schultz 1983). It can activate AC in 
both membrane and intact cell preparations without activation 
or inhibition of other enzymes involved in cyclic nucleotide 
metabolism (including guanylate cyclase and cyclic nucleotide 
phosphodiesterases). Forskolin exhibits a rapid onset of 
activation of AC and the activation is reversible. The absolute 
magnitude of the activation ranges between 2-30 x basal levels
of activity (in presence of Mg2+). The EC50 for activation of AC
by forskolin is about 10pM. Stimulation of AC by forskolin 
increases Vmax of the enzyme and in some preparations 
(including platelets) increases the Km of adenylyl cyclase for 
MgATP (platelets-from 20-80pM)(Awad et al. 1983). Forskolin 
has also been shown to alter the affinity of the enzyme for
divalent cations and its substrate ATP.
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Uncertainty exists as to the precise details of how forkolin 
effects stimulation of AC; it is probable, however, that forskolin 
interacts directly with the catalytic unit of cyclase (Seamon and 
Daly 1981)and probably also with Gsa. However, the activation is 
not dependent upon Gs or the Gs binding site (Seamon and Daly 
1981) (demonstrated in eye- S49 lymphoma cells)(cf activation 
of AC by hormones, NaF, guanine nucleotides and cholera toxin- 
all of which require Gs) or Gi (confirmed after ADP ribosylating 
membranes with pertussis toxin). However, the efficacy of 
forskolin in stimulating AC is affected by ligands which function 
via Gs or Gi. Ligands which function via Gs act generally in 
synergy with forskolin in increasing ACA. The interaction is 
associated with increased efficacy and/or potency of the agonist 
(and is probably dependent on the presence of guanine nucleo­
tides). First seen in platelets, the EC50 for PGE1 stimulation of 
AC was not affected by 50jiM forskolin, but maximal stimulation 
by PGE1 was increased 2 x (Insel et ai.1982) (increased 
efficacy). In contrast in rat renal cortex basolateral membranes 
forskolin is associated with increased potency of PTH: the EC50 
is reduced (5x) and the maximal stimulation of AC is increased 
(Martin et al. 1984). Inhibitory ligands (working via Gi) continue 
to effect inhibition albeit of enhanced basal cyclase in the 
presence of forskolin. This inhibition is independent of Gs, but 
requires the presence both of functional Gi (Aktories et al. 1983) 
and of GTP (Insel et al. 1982).
2.8.4. Other agents used in studies of G-protein function
Many other agents have been used in the study of G-protein 
function. Table 6 lists the agents used in the studies described
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Table 6: Ligands used in studies of adenylyl cyclase and 
G-proteins: sites of action in the receptor (R)-
G-protein(Gs or G i)-catalytic unit (C) complex.
LIGAND CONC. R Gs Gi C REFERENCE
Mn2+ 20 mM • Ross & Gilman '82
STIMULATORY
FORSKOLIN 1 0 uM •  • see section2.8.3
NaF° 1 0 mM •  •  • Insel et al. '82
PGE1 1 0 ix M • Lester et al. '82
ISOPROTERENOL 1 00 nM • Birnbaumer et al'87
GLUCAGON 1 U M • Birnbaumer et al'87
GppNHp 1 0 u M • Houslav et al.'89
VASOPRESSIN 1 On M • Birnbaumer et al'87
INHIBITORY
ACETYL
CHOLINE#
1 OOfiM • Hazeki & Ui '81
ANGIOTENSIN II 1 uM • Coaan '90
ADRENALINE+ 1 00 11M • Birnbaumer et al'87
GppNHp 1 OnM • Houslav et al'89
NEURO­
PEPTIDE Y
1fiM • Kassis et al.'87
NOTES: NaF°: in practice it is AIF4 which effects stimulation-the Al4+ is present
in trace, but adequate amounts in NaF.
ACETYL CHOLINE#: used in conjunciton with the cholinesterase inhibitor 
PHYSOSTIGMINE (10jxM). In addition, the poorly hydrolysed 
analogue of acetyl choline, CARBACHOLAMINE(IOOpM) was also 
used.
ADRENALINE+: adrenaline was used in conjucntion with 10pM 
propranolol-the net effect is alpha2 receptor activation.
Prime sites of action are indicated. NB 'downstream' consequences of events 
are not shown-for example if a G-protein activates Gs, catalytic unit 
will be activated as a consequence.
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in this thesis, and indicates the probable site of action in the 
receptor-G-protein-catalytic unit complex. The methods 
sections in each chapter indicate which of the agents described 
have been used in any particular study.
2.8.5. GTPase activity.
GTPase activity is central to the function of G-proteins (figure 
2): hydrolysis of GTP permits re-association of a with p.y units 
and thus 'switches off' the activation cycle. GTPase activity can 
be measured as an adjunct to functional assessment of G- 
proteins.
The principle of the assay is measurement of 3 2 Pi liberated 
from [y32P] GTP as described by Cassel and Selinger (1976). The 
reaction mixture (final volume 10Opil) contained 0.5pM GTP pH
7.5, 1mM ATP, pH 7.5, 0.1 mM App(NH)p, 1mM Ouabain, 0.1 M NaCI, 
5mM MgCI2, 2mM DTT, 0.1 mM EDTA pH7.5, 20mM tris pH 7.5, 100 
U creatine kinase, 10mM creatine phoshate and 50,000CPM 
gamma32P-GTP per assay tube. The reaction was initiated by 
addition of the membranes (8pg) and was terminated after 20 
min incubation at 37°C by placing in an ice bath and adding 0.9ml 
of a 5% suspension of activated charcoal in 20mM phosphoric 
acid, the tubes were then centrifuged at 2,500 rpm and 500pil of 
the supernatant was removed and counted on a Beckman LS1800 
scintillation counter. Assays were performed in quadruplicate.
GTPase activities have previously been demonstrated 
satisfactorily and reproducibly in platelets (Houslay, Bojanic, 
Gawler, O'Hagan & Wilson 1986). In the preliminary studies for
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this thesis GTPase activities were assessed in (normal) 
platelets. Platelet membranes were incubated as described both 
in the absence of added ligands ('basal') and in the presence of 
vasopressin (10nM), PGE1 (10pM) or adrenaline (100pM) (with 
propranolol (10|iM)). The resulting GTPase activties are 
presented in figure 6.
This approach, however, has limitations; it has, for example, not 
been possible to demonstrate receptor stimulation of GTPase 
activity in all membrane preparations even where a G-protein 
coupled effector mechanism is known to exist. There are several 
possible explanations for this apparent paradox: 'basal' GTPase 
activity is a composite of all GTPase activities and the 
contribution to the total of a single ligand-coupled GTPase 
activity is likely to be very small depending on the relative 
preponderance of the G-proteins expressed in the membrane. 
Furthermore, the Km of G-protein related GTP hydrolysis is low. 
Thus ligand stimulated GTPase activity could be dwarfed by 
'background' enzyme activty. The technique offers no major 
advantages over indirect assessment of function based on 
changes in the effector mechanism: it does however, offer the 
potential to assess G-proteins which are coulped to effectors 
other than adenylyl cyclase, for example, the phosphoinositide 
pathway. Although vasopressin did not induce activation of 
GTPase activity, a number of other ligands, for example 
thrombin, are known to exert effects through G'p' and can 
reproducibly and predictably activate GTPase activity.
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LIGAND
VASOPRESSIN
PGE1
ADR/PROP
BASAL
0 2 0 0  4 0 0  6 0 0  8 0 0  1 0 0 0  1 2 0 0
GTPase ACTIVITY 
pmol GTP/mg/20min.
Figure 6. Ligand stimulated GTPase activities in 
human platelet (expressed as pmol/mg/ 
min.) (mean ± sem, n=12).
**p < 0.01 v basal.
Comment: a2 adrenergic mediated AC inhibition, and 
PGE1- mediated AC stimulation are effected via Gi 
and Gs respectively. Thus both will activate GTPase 
activity (activation is intrinsic to G-protein 
function). Vasopressin may couple to the PPI 
pathway in platelets via G'p' and thus might be 
expected to activate GTPase activity; however, 
activation was not seen (see text for possible 
explanations).
83
In the light of these limitations GTPase activities as a means of 
assessing G-protein function were not studied further.
2.9. Other analytes
Serum urea, electrolytes and 'liver function tests' were 
determined on a SMAC II multichannel analyser (Technicon 
Corporation, Basingstoke, U.K.). HbA1 was measured by electro- 
endosmosis in agar gel, and bands were read at 420nm; 
coefficient of variation (C.V.) of assay was < 3.6% (ref. range:
4.9-7.8%). Blood glucose concentrations were measured by 
glucose oxidase method on a Beckman II glucose analyser 
(Beckman, Yellow Springs, Ohio); C.V. was 2%. Cholesterol (Henry 
1974) and triglyceride (Bucolo & David 1973) were measured 
enzymatically using the Cobas Bio Centrifugal Analyser (Roche 
Diagnostica, Welwyn City,UK); C.Vs. of these assays were 
< 5%,reference ranges:3.1-6.5 and <2.1 mmol/I respectively.
2.10. S tatis tics
Statistical analyses were performed on an Apple Macintosh Plus 
microcomputer using the Statview 512+ statistical programme, 
Brainpower Inc., USA. Nonparametric data are compared using 
Mann Whitney U tests and Wilcoxon Signed Ranks tests, 
correlations were calculated using Spearman Rank Correlations. 
Parametric data are compared using Student's t tests.
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____________________ Chapter 3
G-proteins in NIDDM:
a study of platelet plasma membranes.
3.1. Insulin & G-proteins
Humoral regulation is one of several mechanisms controlling G- 
protein expression and function (section 1.5.) Glucocorticoids 
(see chapters 6 & 7)(Rodan & Rodan 1986; Chang & Bourne 1987; 
Ros et al.1989; Saito et al.1989) and thyroid hormones (Milligan 
et al. 1987) have been shown in experimental animals and cell 
culture to regulate G-protein subunits differentially. Further­
more, insulin may have a role in regulating Gi function and 
levels. Loss of tonic Gi-mediated inhibition and attenuation of 
receptor mediated inhibition of ACA accompany induction of 
experimental IDDM (streptozotocin and alloxan diabetes in the 
rat) (Gawler et al. 1987; Bushfield et al. 1990)(see section
1.6.2.); insulin administration restores these changes to normal. 
Thus insulin may have a direct role in regulating levels and/or 
function of certain G-protein subunits.
3.2. The role of G-proteins in insulin's action:
There is increasing evidence that G-protein(s) play a role in the 
action of insulin. Interaction of insulin with its receptors 
(which possess intrinsic tyrosyl kinase activity) results 
(directly or indirectly) in a number of changes in intracellular 
'second messengers' including DAG, Ca2+ (Denton et al. 1986), 
cGMP (Denton et al. 1986) and inositol glycans (Low & Saltiel
1988). The activated insulin receptor also exerts an inhibitory 
influence on glucagon- and catecholamine- mediated elevations
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in intracellular cAMP in hepatocytes (isolated membranes and 
intact hepatocytes) and adipocytes (Johnson, Das, Butcher & Fain 
1972; Pilkis, Claus, Johnson & Park1975; Blackmore, 
Assimacopoulos-Jeannet, Chan & Exton 1979; Heyworth, Wallace 
& Houslay 1983). Houslay et al. (1983) have shown that insulin 
inhibits glucagon (1nM) stimulated AC in a dose dependent 
manner (no effect at 1(H  2M increasing to maximum of 25% 
inhibition at 10"8M insulin): the inhibition was shown to be 
dependent upon the presence of high concentrations of GTP. It is 
probable that two different mechanisms account for the ability 
of insulin to reduce cAMP levels- insulin activation of specific 
membrane bound phosphodiesterases (Heyworth et al.,1983; 
Houslay et al. 1983) and insulin mediated inhibition of AC (Hepp 
& Renner 1972; llliano & Cuatrecasas 1972; Kiss 1978) (although 
support for this property is not universal (Pilkis et al. 1974; 
Bitensky, Gorman & Neufeld 1972). Houslay has demonstrated 
that insulin can activate liver plasma membrane cAMP PDE 
(Marchmont and Houslay 1980b, 1981; Houslay et al. 1983 a,b) 
and can also inhibit (hepatic) glucagon stimulated ACA; both 
effects appear to be mediated by G-proteins (Heyworth et al. 
1983; Heyworth & Houslay 1983).
Although the G-protein which has been implicated in these 
actions of insulin has not been identified, there is some evidence 
to support the suggestion that G protein(s) may be involved. As 
described previously, the inhibition of glucagon stimulated AC 
insulin is a GTP-dependent process (Houslay et al. 1983). Insulin 
has been shown to stimulate GTPase activity (Gawler & Houslay 
1987); Gawler & Houslay demonstrated a cholera toxin-sensitive
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GTPase in human platelets , the activity of which was indep­
endent of (actually additive to) the GTPase of Gs (activated by 
PGE1), and of Gi (activated by adrenaline (+propranolol)) and of 
the putative Gp (activated by vasopressin). This apparent 
independence from recognised GTPase activities led to the 
suggestion of involvement of a putative 'Gins'. Despite its role in 
inhibition of AC it thus appears that the G-protein is not Gi 
(Gawler, Milligan & Houslay 1988); although it seems probable 
that another G-protein is directly involved it is not impossible 
that the AC modifying properties could involve alteration of Gs 
(?phosphorylation).
3.3. G-proteins and experimental diabetes meilitus
The experimental evidence regarding the possible role of G- 
proteins in the pathogenesis of diabetes relates to both 
experimental models of IDDM and NIDDM. This evidence will be 
reviewed: in both types of diabetes the net intracellular defect 
is deficiency of functioning insulin.
3.3.1. Experimental models of insulin dependent 
diabetes m eilitus
IDDM can be induced chemically in rats by administration of 
streptozotocin (STZ) or alloxan. STZ-DM is the most extensively 
studied rat model of diabetes: STZ is a cytotoxic with specific­
ity for pancreatic B cells. At doses of 45-65 mg/kg i.p. STZ 
induces ketotic, insulin dependent diabetes within a few days; 
alloxan has similar effects. STZ and alloxan diabetes are 
associated with a number of biochemical changes which include 
(not surprisingly) marked fall in plasma insulin concentrations,
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with rise in blood glucose with ketosis. However, both in 
addition, are associated with development of apparent insulin 
resistance in hepatocytes and enhanced ability of glucagon to 
stimulate AC (Gawler et al. 1987; Bushfield et al. 1990).
L iv e r
Given its central role in glucose metabolism, the liver is likely 
to be the most relevant tissue for study of AC and G-proteins in 
diabetes meilitus. Houslay's group have shown that chemically 
induced IDDM in the rat is associated with altered G-protein 
expression and function in hepatocyte membranes (table 3) 
(Gawler et al. 1987; Bushfield et al. 1990a; Bushfield et al. 
1990b); reduced levels of Gj2a, Gj3a and Gsa and their corres­
ponding mRNAs have been reported. Changes in G-protein 
subunits are accompanied by altered G-protein function in 
hepatocytes; Gawler (Gawler et al.1987) reported loss of Gi 
function (inferred from AC studies on the basis of loss of 
GppNHp mediated inhibition (at low concentrations 10"8 to 
1 0 '10 M) and failure of pertussis toxin pretreatment (which 
inactivates Gi) to enhance glucagon stimulated ACA in diabetic 
hepatocyte membranes). Reduction of both basal and forskolin 
stimulated ACA were also reported. In essence, tonic inhibition 
of AC by Gi is lost while receptor mediated inhibition (via Gi) is 
attenuated in hepatocyte membranes (Gawler et al.1987) and 
these changes were consistent with the observed reduction of Gi 
immunoreactivity. The observed alterations of Gi function and 
levels could be reversed by insulin administration (Gawler et 
al.1987).
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By contrast, the study of Lynch (Lynch et al. 1989) reported 
increased AC responses to GTP, NaF and glucagon; these changes 
were compatible with their evidence of increased Gi levels (by 
cholera toxin, immunoblotting and reconstitution studies). Lynch 
found no differences in Gi (ADP ribosylation by pertussis toxin 
and immunoblotting).
The conflicting results from studies of experimental IDDM 
demand explanation, and until such time no firm conclusions can 
be drawn on perturbations of G-protein function. It is of 
interest, however, that hepatocytes from the obese Zucker rat) 
which share hepatic insulin resistance with the STZ-DM model 
have also been shown by Houslay's group to exhibit functional 
deficiency of Gi (Houslay et al. 1989) raising the distinct 
possibility that insulin resistance may be related to altered 
function of Gi.
Adipose tissue
Houslay's group have also shown that chemically induced IDDM in 
the rat is also associated with altered G-protein function in 
adipocyte membranes (table 3) (Strassheim et al. 1990); loss of 
the tonic GTP-dependent inhibitory function of Gi (but not the 
receptor dependent inhibitory function) was observed in the 
absence of corresponding changes in the levels (nor of the 
mRNAs encoding) Gj1 a, Gj2a, Gj3a (Gj3a actually increased), Gsoc 
and B subunits.
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Vascular tissues- myocardium
The effect of experimental diabetes of between 5 days' and 4 
months' duration has been studied. There appears to be a 
consensus in studies of greater than 8 weeks' duration that basal 
(Nishio, Kashiwagi, Kida et al.1988; Smith, Pierce & Dhalla 1974; 
Michel, Cros, McNeill & Serrano 1985) and forskolin (Nishio et al. 
1988; Smith et al. 1984), NaF (Smith et al. 1984; Gizsche 1983; 
Chatelain, Gillat & Waelbroeck 1983), GppNHp (Smith et al. 1984; 
Gizsche 1983; Chatelain et al.1983), GTP (Srivastava & Anand- 
Srivastava 1985; Gizsche 1983; Chatelain et al. 1983) stimul­
ated AC is unaltered. In contrast, diabetes of 5 days' duration 
has been reported to be associated with enhanced basal, but 
reduced forskolin and NaF stimulated AC suggesting that 
duration of diabetes may play an important role in determining 
responsiveness of AC (Srivastava & Anand-Srivastava 1985). The 
most notable change however, is reduced B adrenergic stimul­
ated AC (isoproterenol, epinephrine)(reduced by 10-56%) (Nishio 
et al. 1988; Smith et al. 1984; Srivastava & Anand-Srivastava 
1985; Atkins, Dowell & Love 1985; Gizsche 1983; Sundaresan, 
Sharma, Gingold & Banerjee1984) although support has not been 
universal (Chatelain et al.1983; Atkins et al. 1985). Most 
studies which have included assessment of B receptor number 
(Nishio et al. 1988; Smith et al. 1984; Sundaresan et al.1984) 
report substantial reduction of B receptors (although again 
support has not been universal (Gizsche 1983).
In summary, these studies in myocardium in the STZ-diabetes 
model can be summarised as showing no effect on AC catalytic 
unit nor on G-protein function. B adrenergic agonist stimulated
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AC is reduced and this appears to be attributable either wholly 
(Nishio et al. 1988; Smith et al. 1984; Michel et al. 1985) or in 
part to reduced B receptor number. Functional uncoupling of B 
receptor from catalytic unit may also contribute (Gizsche 1983). 
There is thus little evidence to support a major change in 
myocardial G-proteins in established STZ-DM. In contrast, the 
wide range of abnormalities demonstrated early (after just 5 
days' diabetes)(that is reduction of AC responses mediated by 
both receptor -dependent and receptor-independent mechanisms) 
could be consistent with alterations of AC catalytic unit (but do 
not exclude the possibility of at least short lived alterations of 
G-protein levels or function). Only one study thus far has 
assessed levels of G-proteins in myocardium in STZ-DM; G- 
protein transcripts (rather than amounts of protein) were 
quantified-and no differences were found for Gj1 a, Gj2a, G j3a & 
Gsa (Bushfield et al. 1990b).
Other tissues
Gjloc, Gj2a, Gj3a & Gsa transcripts have also been measured in 
skeletal muscle, kidney and brain from STZ-DM and were found to 
be unchanged compared to non-diabetc controls.
Sum m ary
From the various studies cited it is clear that the reported 
observations in experimental IDDM occur irrespective of the 
chemical agent used to induce DM (STZ or alloxan), are tissue 
specific, and when alterations of G-protein levels have been 
found (for example, in hepatocyte membranes) these do not 
invariably reflect altered expression and tend to be selective for
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particular G-protein a subunits. Correlation between changes in 
G-protein function and levels is seen in hepatocyte mem/branes 
(Gawler et al. 1987) but is not invariable (c.f. adipocyte mem- 
branes-where Gj2oc levels and mRNA are unaltered)(Strassheim 
et al. 1990) raising the possibility that other regulatory 
processes such as post transcriptional modification of the G- 
protein subunits, for example by phosphorylation may be 
operating. (Whether this is effected by insulin (the insulin 
receptor tyrosyl kinase can phosphorylate the a subunit of Gi 
(Katada, Gilman, Watanabe, Bauer & Jakobs 1985) or by other 
hormones such as glucagon (Bushfield et al. 1990) remains 
unclear).
3.3.2. Experimental & Human NIDDM
Some work has also been done in experimental and human NIDDM. 
In contrast to IDDM, experimental and human NIDDM are 
associated with increased insulin levels but resistance to the 
actions of insulin. Major changes have been reported in ACA in 
rat liver plasma membranes after 7-9 months of experimental 
NIDDM. Basal, NaF and glucagon-stimulated ACA is reduced (in 
the absence of insulin or glucagon receptor changes (Portha et al. 
1983). This is consistent with reduced catalytic unit and may be 
independent of of G-protein change. Identical results have been 
found in a controlled study of ACA in liver from human (n=7) 
NIDDM (Arner et al. 1987).
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3.4. Study of G-protein function and levels in platelets 
of NIDDM
3.4.1 .In tro d u c tio n
As tissues which are central to carbohydrate metabolism 
(including liver) are not readily available from human subjects, 
platelet plasma membranes were studied in this experiment. 
Platelets are a homogeneous tissue from which purified plasma 
membranes can be readily prepared (section 2.3.1.). The 
justification for use of platelets from diabetics for study is 
based on two premises: platelets from diabetics exhibit 
abnormal function (in vitro assessments) and secondly (and not 
necessarily unrelated to the first) platelets may be implicated 
in the development of vascular disease. Platelets and endo­
thelium exhibit a functional interaction (for example, platelets 
release growth factors for endothelium)(Vanhoutte et al.1984) 
which may be implicated in the micro- and macro-vascular 
disease which frequently complicate diabetes meilitus. The 
prime functional change observed in diabetes meilitus is 
increased sensitivity to agonist induced aggregation, a change 
which may precede the appearance of clinically evident vascular 
disease.
The molecular basis of the altered platelet function in diabetes 
remains to be ascertained. Many possible candidate mechanisms 
exist including altered membrane signalling systems coupled to 
adenylyl cyclase and the phosphoinositide pathway. Other 
possibilities include altered membrane fluidity: reduced 
membrane fluidity has been reported in platelets from NIDDM.
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The purpose of this study was to compare G-protein 
function (inferrred from adenylyl cyclase studies) and 
levels in platelets from NIDDM and non diabetic 
co n tro ls .
3.4.2. Subjects:
Subjects: 11 (6 male) untreated, newly presenting NIDDMs 
(table 7) were recruited from the Diabetic Outpatient clinics of 
Garnavel General Hospital, Glasgow and Glasgow Royal Infirmary. 
Diabetes meilitus was diagnosed on the basis of a standard 75g 
oral glucose tolerance test (OGTT) (fasting glucose O' NIDDM v 
CONTROL: 12.0 ± 0.857 v 5.4 ± 0.2 mmol/l; 120' glucose 19.9 ± 1.3 
v 5.5 ± 0.2 mmol/l). In addition,17 healthy controls (CON)(12 
male) were recruited from among laboratory staff and from 
spouses of patients. All were studied according to a protocol 
which had been approved by the Hospital Ethical Committee. 
Subjects were studied after overnight fast. Blood pressure was 
measured after 10 min. sitting, with a standard mercury 
sphygmomanometer: (table 7) BP was normal within both groups, 
and did not differ between NIDDM and CON. Therafter 80 ml 
citrated (3.8%) blood were withdrawn: in addition to an OGTT, 
urea, electrolytes (U & E), liver function tests (LFT), plasma 
cholesterol, triglyceride were measured: all subjects had normal 
renal and hepatic function. Platelets rich plasma was obtained 
from the residue (about 70ml)from which plasma membranes 
were prepared as described (section 2.3.1.). Membrane aliquots 
were stored at -80°C.
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Membrane protein concentrations were measured by the modified 
Lowry protocol (described in section 2.6.).
3.4.3. M ateria ls & M ethods:
A denyly l cyclase assays (ACA): ACA were performed 
according to the Salomon assay protocol as described (section
2.8.1.), but with modifications. Briefly, the reaction cocktail 
(final volume 100pl) contained creatine phosphate (sodium salt) 
5mM, 50U/ml creatine kinase, 50pM ATP, 2mM MgCl2, 0.1 M EGTA, 
1mM IBMX, 1mM DTT in 50mM triethanolamine HCI buffer pH7.4 
and a32p ATP was added to give 2 x 1 0 ® CPM/assay. The guanine 
nucleotides, GTP or GppNHp were included at final concentrat­
ions of 10_®M and 10-7M respectively. In addition to assessment 
of basal activities, ACA was measured in the presence of fors­
kolin (10"5M) and PGE1 (10_5M). Gi function was inferred from 
studies of inhibition of ACA by GppNHp (10_7M) and of inhibition 
of forskolin and PGE1 stimulated ACA by adrenaline (10_4M), 
which in the presence of propranolol(10’ ®M) effects inhibition 
via the Gi coupled a receptor. The concentrations of the ligands 
used had previously been shown to be saturating with respect to 
effect on AC activity. The reactions were started by the addition 
of membrane (5jug membrane protein) suspended in 10mM tris 
pH7.4. and tubes were incubated at 37°C for 15 min. Details of 
termination of enzyme activity and of the subsequent chromato­
graphic separation of reaction products are as previously 
described (section 2.8.1.). Each assay was run in quadruplicate.
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Immunoblotting studies for G-proteins: Immunoblots were 
performed under denaturing conditions on 10% gels (SDS-PAGE) 
(section 2.4.1.) as described with antibodies to Gsa, G ia2 and 
Gia3 subunits (respectively CS1, LE2 and I3B: details of 
preparation and specificity of these antibodies-see section 2.1.) 
Amounts of platelet membrane protein loaded to achieve optimal 
blots were derived from ’dose response' (that is CPM obtained 
against membrane protein loaded) curves to each of the anti­
bodies; the amounts of protein used (60-100p,g per lane) were 
determined from the linear portions of these curves. The anti­
body-labelled G-protein bands were visualised using 125|_ 
labelled second antibody; autoradiographs were prepared and 
were analysed by densitometric scanning using a Bio-Rad
video densitometer. In addition, in some instances the 125-| 
labelled bands were cut out and counted on a gamma counter, 
with appropriate background controls. Similar results were 
obtained using the two methods. To facilitate combined analysis 
of data obtained from different blots, a 'standard' platelet 
membrane preparation was included in all immunoblots and the 
counts from the G-protein bands were all expressed relative to 
standard, the 'standard' being ascribed the arbitary value of 
100%.
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Table 7: Characteristics of diabetic and control 
subjects. Data presented as mean ± sem.
CONTROL NIDDM P
n 17 (12M) 11 (6 M)
age (yr) 44.1 ± 2.8 51 ± 5
weight (kg) 71.1 ± 1.6 84.1 ± 4.2 p < 0.01
SBP (mmHg) 126 ± 3.6 134 ± 7.2
DBP 81 ± 2.9 87 ± 2.4
HbA1 (%) 6.0 ± 0.1 10.2 ± 0.53 p < 0.0001
3.4.4. Results
Results of adenylyl cyclase studies and immunoblots are listed 
in appendix A. Complete data are not available from all subjects 
because amount of plasma membrane preparation available was 
lim ited .
Adenylyl cyclase studies:
Wide interindividual variation (approx. 4-5 fold) in ACA was 
noted under 'basal' conditions and irrespective of added ligands 
within CON and NIDDM study groups. No differences were 
observed between groups when comparing absolute ACA; for 
example, 'basal' ACA CON v NIDDM (mean ± sem) 120.2 ±12.1 v
158.2 ± 20.9 pmol cAMP/mg/15min. Consequently, data were 
presented as 'fold stimulation' (PGE1 and forskolin) over 'basal'
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or in the case of inhibitory ligands as 'percentage inhibition'. 
PGE1 and forskolin data are presented in fig.7. Fig.8 shows 
adrenaline (+ propranolol)(i.e. a 2 adrenergic) mediated 
inhibition of ACA stimulated by PGE1 and forskolin. GppNHp data 
(expressed as % inhibition of forskolin stimulated ACA) are only 
available for 7 CON and 6 NIDDM and show no difference between 
groups (29.7 ± 4.6 v 21.5 ± 4.7%).
Immunoblotting studies:
Fig.9. shows typical blots for Gia2, Gia3 and Gsa. In addition, a 
section of Coomassie Blue stained gel is included.
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Fig.7. ACA in platelet membranes from CON and NIDDM. 
Results expressed as 'fold stimulation' of ACA by fors­
kolin and PGE1 over 'basal activity', (mean ± sem).
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Fig.8. Inhibition of forskolin- and PGE1- stimulated 
ACA by adrenaline/propranolol (a2 adrenergic receptor 
activation) in platelet membranes from CON and NIDDM. 
Results expressed as '% inhibition', (mean ± sem).
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Other data:
Table 8: Correlations (Spearman Rank Correlation) 
between measures of G-protein function or levels of G- 
protein subunit and fasting blood glucose concentration. 
n= total number of data points (CON + NIDDM), z value- 
statistic used to assess the degree of correlation, with 
corresponding 'p value'.
CORRELATE n z value P
'fold stim .' 
by forskolin 2 4 - 2 . 5 3 5 0.01
'fold stim .' 
by PGE1 2 3 - 2 . 4 6 1 0 . 0 1 4
Gs 1 7 - 2 . 6 7 1 0 . 0 0 8
Gi2 2 2 - 2 . 6 2 9 0 . 0 0 8
Gi3 1 9 - 2 . 2 9 9 0 . 0 0 3
Other correlations were observed between forskolin-stimulated 
ACA and plasma cholesterol concentration (n=24, z=-2.784, 
p=0.005), between PGE1 stimulated ACA and plasma cholesterol 
concentration (n=23, z=-2.752, p=0.006) and between levels of 
Gia2 and body weight (kg)(n=22, z=-2.22, p=0.028).
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Fig. 9. Immunoblotting studies in platelet membranes 
from NIDDM and controls showing typical blots 
(R panel) and relative abundance (graph-L panel) 
(derived from densitometric scanning of blots) 
of (A) Gsa, (B) Gia2 and (C) G ia3.
A panel of Coomassie Blue stained gel is 
included (D).
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3.4.5. Discussion
a subunits of Gi2, Gi3 and Gs were identified in our platelet 
plasma membranes. B subunits are also present (section 2.4.2. & 
Chapter 4) but were not assayed in this study. Lower levels of 
all three a subunits were identified in membranes from diabetic 
subjects compared to a group of controls of similar age; 
statistically significant reductions were observed in Gsa and 
Gia2 (p=0.02 and p=0.003 resp). This observation in human 
NIDDM, a condition characterised by insulin resistance (with 
associated hyperinsulinaemia) is similar to previous findings in 
hepatocyte membranes from the streptozotocin-induced diabetic 
rat model of insulin-dependent diabetes mellitus (Gawler et al. 
1987; Bushfieldet al. 1990): tissue specific alterations of G- 
protein expression and mRNA are seen in STZ-DM (Griffiths et al. 
1990; Bushfield et al. 1990). These findings, however, contrast 
with those in adipocytes where Gi3 has previously been shown to 
be increased (Strassheim et al.1990) and with a number of other 
vascular and non-vascular tissues where no changes in G-protein 
transcripts have been identified (see section 3.3.1). The observed 
reduction of G-protein levels in human platelets from NIDDM and 
hepatocytes from STZ-DM are consistent with the possibility 
that insulin may have a role in the regulation of G-proteins: 
despite elevated plasma levels of insulin in NIDDM, there will be 
a net intracellular deficiency of insulin, while STZ-DM is 
characterised by insulopenia due to pancreatic destruction. This 
hypothesis is supported indirectly by several correlations (table 
8). Levels of Gia2, Gia3 and Gsa have all been shown to correlate 
inversely with fasting blood glucose concentration.
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Functional characteristics of the various G-protein species 
remains to be fully elucidated. Gsa couples to and stimulates AC 
catalytic unit, but may also interact with dihydropyridine 
sensitive Ca^+ channels. There is increasing evidence that Gia2 
mediates inhibition of AC (Bushfield et al. 1990; McKenzie & 
Milligan 1990; Simonds, Goldsmith, Codina, Unson & Spiegel 
(1989) while it appears that Gia2, Gia3 and Gsa may all share a 
role in the regulation of K+ channel function (Birnbaumer, 
Abramowitz & Brown 1990). Current studies of G-protein 
function are restricted to indirect assessment of Gia2 and Gsa 
inferred from AC studies. No evidence of altered function of Gia2 
was observed on the basis of studies with GppNHp (which effect 
AC inhibition directly via Gi) and with adrenaline (in conjunction 
with propranolol)(which binds to the a2 receptors which are 
coupled to AC catalytic unit via Gi). The study of GppNHp was 
limited by the small numbers studied (n=6 CON, n=6 NIDDM). As 
also noted in the study of human essential hypertension (chapter 
4), marked interindividual variation in AC was observed under 
'basal' conditions (and even in the presence of inhibitory and 
stimulatory ligands) in both groups. When forskolin and PGE1 
responses were expressed as 'fold stimulation' over 'basal' 
cyclase, however, the NIDDM platelets exhibited significantly 
lower cyclase activities. Forskolin functions through catalytic 
unit and probably through Gsa while PGE1 receptors couple to AC 
catalytic unit via Gsa. Differences in activities assessed in the 
presence of these agents may reflect altered amounts of AG 
catalytic unit and/or reduction in net Gsa effect. Reduced Gsa 
effect could be due to reduction in Gsa levels or possibly 
alteration in Gia2: Gs ratio. Either possibility is consistent with
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the immunoblotting studies. It was of interest that the extent of 
elevation of the levels of ACA achieved with forskolin and PGE1 
correlated with fasting blood glucose concentration (table 8 ).
Although the findings of altered G-protein levels and function 
are consistent and could possibly be explained through altered 
intracellular insulin concentrations, other explanations exist. 
Artifactual contribution from erythrocyte membrane 
contamination in our platelet plasma membrane homogenate has 
largely been excluded by subjecting membrane preparations to 
analysis with a monoclonal antibody specific for (a 93 kDa 
species) Band 3 glycoprotein of human erythrocytes (kindly 
donated by Dr M.J. Tanner, Biochemistry, Bristol). Furthermore as 
interpretation of our AC assay results and G-protein immuno- 
blots are dependent upon correction for the amount of membrane 
protein loaded (identical amounts of study and control sample 
protein were used in all studies), intrinsic differences in 
membrane protein content could bias the results; however, it has 
previously been shown that diabetes is not associated with 
altered platelet membrane protein content (Winocour,
Bryszweska, Watala et al. 1990). Altered forskolin and PGE1 
stimulated ACA could result from altered membrane fluidity; 
membrane fluidity of diabetic platelets has previously been 
shown to be lower than normals (Winocour et al. 1990)and 
platelet ACA has previously been shown to be extremely 
sensitive to changes in membrane fluidity (Spence & Hously
1989). Furthermore the current studies do not preclude the 
possibilty that PGE1 receptor number could be altered in NIDDM 
and contribute to the observed lower levels of PGE1 stimulated
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ACA in the diabetic group. However, such changes could not 
explain all the findings.
The study groups were similar with respect to age and blood 
pressure, but as might be anticipated, the NIDDMs were heavier 
(84.1 ± 4.2 v 71.1 ± 1.6 kg, p<0.01) and had higher plasma 
concentrations of cholesterol (6.6 ± 0.5 v 5.3 ± 0.2 mmol/l, 
p<0.005) and triglyceride (1.6 ± 0.1 v 0.9 ± 0.1 mmol/l, 
p<0.0006). Previous studies of a possible role of G-protein 
dysfunction in obesity in experimental models (obese Zucker rat: 
(Houslay et al. 1989; and ob/ob mouse: Begin-Heick 1985; 
Greenberg et al.1987) and have produced conflicting evidence. 
However, Ohisalo & Milligan (1989) studied adipocyte membranes 
obtained from obese humans and showed concomitant reduction 
of Gsa and Gia; they concluded, however, that the relative 
amounts of both were unaltered. Thus changes associated with 
obesity per se may have contributed to the observed differences 
between NIDDMs and controls. Obesity, like NIDDM, is a state of 
insulin resistance and could possibly share G-protein perturb­
ations with diabetes mellitus and other conditions associated 
with insulin resistance. Thus if differences in weight contribute 
in some way to the differences in G-protein levels and ACA seen 
in the NIDDM (v CON) it may be inappropriate to regard obesity as 
an independent disease process. Some regard obesity and NIDDM 
(along with other entitites such as essential hypertension and 
hyperlipidaemia ) as manifestations of a syndrome whose 
component diseases are characterised by insulin resistance 
(Reaven 1988). Consistent with this theory are correlations 
(inverse) between level of Gia2 and body weight (n=22, z=-2.22,
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p=0.028), and between cholesterol and forskolin stimulated ACA 
(n=24,z=-2.784,p=0.005) and PGE1 stimulated ACA (n=23, z= 
-2.752, p=0.006).
In summary, platelets from subjects with NIDDM have been 
shown to have significantly reduced plasma membrane levels of 
GsocandGj2oc. PGE1 and forskolin stimulated ACAs were lower in 
diabetic platelets, while assessment of inhibitory G-protein 
function by GppNHp (limited interpretation due to small 
numbers) and via a2 receptor activation failed to show any 
differences. It is possible that reduced levels of AC catalytic 
unit may contribute to the differences in ACA although relative 
changes amongst the G-protein subunits are more likely to 
contribute to the reduced PGE1 and forskolin stimulated ACA 
seen in platelets from diabetics. A previous study of ACA in 
livers from NIDDM concluded that AC catalytic unit was reduced, 
and that this observation was likely to be independent of G- 
protein changes (Arner et al. 1987). We have shown unequivocally 
that levels of Gsa and Gj2a are reduced. These changes are rather 
similar to those reported in hepatocyte membranes from experi­
mental IDDM (Gawler et al. 1987; Bushfield et al. 1990a;
Bushfield et al. 1990a) but contrast with those in other tisses 
(table 3). The possibility exists that insulin resistance which is 
common to hepatocytes from STZ-DM (Bushfield et al. 199b) and 
to human NIDDM may contribute to the altered levels of G- 
proteins seen in this study.
The observed changes in ACA which may be due to altered G- 
protein levels (and/or altered levels of AC catalytic unit) are
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likely to have implications for platelet function in NIDDM: cAMP 
has previously been shown to exert an inhibitory influence over 
platelet function (Mills 1982). It is thus probable that reduced 
cAMP generation in response to stimulatory ligands will be 
associated with a greater tendency to platelet activation and 
possibly contribute to the vascular disease which accounts for 
substantial morbidity in the diabetic population.
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Chapter 4
G-proteins in Essential Hypertension:
a study of platelet plasma membranes.
4.1. Introduction to Chapters 4 & 5:
4 .1 .1 .Essential hypertension and diabetes meilitus.
Hypertension is not one distinct pathophysiologic entity, but may 
arise from a number of different aetiologies; these include 
essential hypertension (EH) (with diastolic and/or systolic 
hypertension), and hypertension which is secondary to a 
surgically treatable cause, for example, Cushing's syndrome or 
renal artery stenosis. However, EH is the most prevalent cause 
accounting for about 90% of hypertensives. Although its true 
pathophysiology remains uncertain, it is clear that there is a 
major genetic component.
Epidemiological studies have established strong links between 
EH and insulin resistance / hyperinsulinaemia. A relationship 
between insulin concentration and blood pressure has been 
demonstrated both in the obese (Christlieb, Krolewski, Warram & 
Soeldner1985; Rose, Yalow, Schweitzer & Schwartz 1986; 
Manicardi, Cameiilin, Bellodi et al.1986) and non-obese (Modan, 
Halkin, Almog et al. 1985). Hypertensive subjects are less 
glucose tolerant than normotensive controls (Voors, 
Radhakrishnamurthy, Srinavasas, Webber & Berenson 1981; 
Stamler, Rhomberg, Schoenberger et al. 1975; Florey, Uppal & 
Lowy 1976; Jarrett, Keen, Mccartney et al. 1978) and untreated 
hypertensives exhibit higher insulin levels than normotensives 
(Lucas, Estigarribia, Darga & Reaven 1985; Singer, Godicke,
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Voigt, Hajdu & Weiss 1985; Modan, Halkin, Almog et al. et al. 
1985; Manicardi, Camellini, Belloidi, Coscelli & Ferrannini
1986). Ferrannini and colleagues(Ferrannini, Buzzigoli, 
Bonadonna et al.1987) have provided the best evidence of an 
association between hyperinsulinaemia and hypertension with 
their demonstration that EH in the non-obese is an insulin 
resistant state: in their controlled study of non-obese essential 
hypertensive subjects with moderate to severe untreated 
hypertension, marked impairment of glucose uptake into the 
peripheral tissues was demonstrated - consistent with insulin 
resistance. Reduced glycolysis and glycogen synthesis were 
believed to account for the reduced tissue uptake of glucose. The 
insulin resistance in this group of EH appeared specifically to 
affect glucose metabolism and was thought to be located in the 
peripheral tissues-most likely in skeletal muscle. Although 
such observations do not establish a causal relationship between 
insulin resistance and hypertension, this possibility remains. 
Insulin resistance is likely to be a graded phenomenon-both 
quantitatively and qualitatively -although the pathophysiology at 
receptor or post receptor levels is not clear. Hyperinsulinaemia 
per se probably does not directly result in hypertension but may 
contribute indirectly through enhanced renal sodium reabs­
orption (Miller and Bogdonoff 1954), increased catecholamine 
secretion (Rowe, Young, Minaker et al. 1981), increased Na/K- 
ATPase activity (Ng and Hockaday 1986) or through its growth 
promoting action on smooth muscle (Lever 1986). Whether 
hyperinsulinaemia associated alteration of G-protein function 
can be added to this list will be assessed in chapters 4 & 5 of 
this thesis.
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Insulin resistance and hyperinsulinaemia are not unique to EH, 
but are also found in obesity (Olefsky, Kolterman & Scarlett 
1982) and NIDDM (DeFronzo & Ferrannini 1982). This has led to 
the concept of the existence of a syndrome ('syndrome X' (Reaven 
1988; Foster 1989)) which includes the triad-NIDDM, obesity and 
EH but which includes other abnormalities, for example of 
plasma lipids. As the studies in hypertension described in this 
thesis have arisen from studies in diabetes and attempt to cast 
further light on the possible links between hypertension and 
diabetes the clinical links between these will be described in 
some detail.
The prevalence of hypertension is increased in diabetes: 40% of 
males and 53% females presenting with NIDDM (age 25-65yrs) 
are hypertensive (BP>160/95) (United Kingdom Prospective 
Diabetes Study. 1985). The prevalence of hypertension in IDDM 
appears to be even higher after age adjustments (National 
Diabetes Data Group. 1985)). Hypertension causes vascular 
disease and is the major risk factor in IDDM (Christlieb et 
al.1981) contributing to both microvascular (nephropathy) and 
macrovascular disease (ischaemic heart disease and cerebro­
vascular disease) which account for the majority of deaths in 
IDDM (Feingold & Siperstein1985) and NIDDM (Dorman, Laporte, 
Kuller et al. 1984).
Possession of genetic markers for risk of developing EH (as 
inferred from parental blood pressure recordings (Viberti et al.
1987), family history of hypertension (Krolewski, Canessa, 
Warram et al.1988) and assessment of red blood cell (rbc)
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sodium-lithium countertransport activity (Na-Li C A) (Krolewski 
et al.1988; Mangili, Bending, Scott et al. 1988) has been shown 
to be associated with increased prevalence of diabetic nephro­
pathy (the relationships are stronger in subjects with poor 
glycaemic control(Krolewski et al.1988)) -a major cause of 
morbidity and mortality in diabetics although support for this 
association has not been universal. Family clustering of nephro­
pathy in diabetic siblings has recently been noted, and although 
consistent with involvement of genetic factors such as hyper­
tension, the role of common environmetal factors cannot be 
excluded (Seaquist, Goetz, Rich & Barbosa 1989). Whatever its 
role in the pathogenesis of nephropathy in the diabetic, 
hypertension is an invariable accompaniment of nephropathy 
(generally arising concurrently with the onset of micro­
albuminuria) and treatment of hypertension mav result in 
attenuation of the rate of decline of renal function. (Mogensen 
1982; Parving, Andersen, Smidt & Svendsen1983; review- 
McLellan & Connell 1988, 1989).
Diabetes mellitus may occur more frequently in EH than expected 
although this association has been complicated by possible 
diabetogenic effects of antihypertensive medication such as 
thiazide diuretics.
4.1.2. The role of adenylyl cyclase in blood pressure 
regulation
AC is a ubiquitous membrane-bound effector mechanism which 
has been studied extensively in hypertension. cAMP is one of
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several 'second messengers' which control the contraction and 
relaxation of vascular smooth muscle; others include cGMP, 
inositol phosphates and Ca2+. However, aside from their key 
roles in determining vascular tone (Bar 1974), cyclic nucleo­
tides are effectors in many other processes which govern blood 
pressure: they mediate inotropic and chronotropic effects in the 
myocardium (Katz, Tada & Kirchberger 1975; Keely, Lincoln & 
Corbin 1978), have key roles in the endocrine control of blood 
pressure (in particular by mediating the release and functioning 
of catecholamines (Ramanathan & Shibata 1974; Williams & 
Dluhy 1978) and renin secretion (Hauger-Klevene 1970; Winer, 
Chokshi & Kalkenhorst 1971). In vascular smooth muscle cAMP is 
not the only cyclic nucleotide with a major role in regulating 
vascular tone (Triner, Nahas, Vulliemoz et al. 1971); cGMP is 
also important (Goldberg, O'Dea & Haddox 1973; Amer 1974).
Both cAMP and cGMP probably effect these changes through 
alteration of intracellular calcium level. In practice, the 
relative balance of concentrations of cAMP and cGMP is likely to 
be more important in governing vasomotor tone than either 
ind iv idua lly .
Consideration of cAMP in isolation would be inappropriate 
without appreciation of the AC system consisting of receptor/G- 
protein/ catalytic unit which is responsible for synthesis of 
cAMP and of the mechanisms by which cAMP couples to 
processes effecting vasomotor relaxation : cAMP effects changes 
via cAMP-dependent protein kinases (Greengard 1978; Cohen 
1982) which phosphorylate target proteins. The effects of cAMP 
are in turn modulated at several steps in the chain of events;
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enzymes can dephosphorylate the phosphorylated proteins (Cohen
1982) while cAMP itself is hydrolysed by cAMP phosphodiester­
ase. The work described in this thesis is based on measurement 
of ACA and thus of cAMP generated (as a means of assessing the 
dual regulation of the enzyme by G-proteins (Gs and Gi)) 
however, the existing evidence regarding the role of cyclic 
nucleotides in hypertension has been reviewed as a basis for 
discussion of the potential role of G-proteins in the abnormal­
ities which have been reported.
4.2. G-proteins in human essential hypertension
Platelets are cell fragments which subserve the vital role of 
haemostasis through their abilities to aggregate (necessitating 
alteration of shape) and secrete ('degranulation'). Both processes 
require mutual interaction of cAMP and Ca^+; cAMP and Ca^+ act 
antagonistically in the process of alteration of platelet shape 
while they act synergistically in platelet secretion. At a 
(simplified) biochemical level cAMP promotes platelet micro­
somal uptake of calcium (see review Tomlinson et al. 1985), 
while calcium (directly or through calmodulin) has been shown 
capable of inhibiting AC (Rodan & Feinstein 1976) and of 
activating cAMP phosphodiesterase (Cheung et al. 1975); in 
addition a dependence on calcium has been reported for hormone 
activation of many AC systems (Bradham and Cheung 1980) and 
this may be true for PGE1 activation of platelet adenylyl cyclase
(Tremblay & Hamet 1984).
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The usefulness of the platelet for studies in hypertension may 
extend beyond the biochemistry and physiology of clotting: 
resort has been made to platelets as a readily available source 
of homogeneous plasma membranes to study the mechanisms and 
effects of hypertension because of the lack of availability of 
human vascular tissue. The validity of the use of platelets is 
debatable but has previously been justified (Erne, Resink, 
Burgisser & Buhler1985) on the basis of several functional 
similarities to smooth muscle (Resink, Burgisser & Buhler 
1986); platelets and smooth muscle share a number of receptors 
(including vasopressin and prostaglandin receptors), they share 
an adenylyl cyclase linked a2 adrenergic receptor system and, 
further-more, both exhibit hormonal regulation of AC by cAMP 
and calcium. Platelets show contractile properties on activation 
which are similar to the contraction of smooth muscle: in vivo 
there is a functional interaction between platelets and vascular 
smooth muscle as platelets are the source of a number of growth 
factors for smooth muscle (including PDGF ) and contribute to 
arteriolar spasm through the release of vasoactive substances 
on activation by damaged endothelium (Vanhoutte et al. 1984) 
(which is more likely in vessels subject to hypertension).
Altered platelet function in vitro has been reported in human 
essential hypertension (Lentini and Bologna 1974; Poplawski, 
Skorulska & Niewiarowski 1968; Hamet, Skuherska, Pang & 
Tremblay1985) and these changes may relate to reported 
alterations of ACA (Brodde, Stuka, Dernuth et al. 1985; Erne et 
al. 1985; Resink et al. 1986). Similar functional changes in
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platelets have been found in experimental hypertension (SHR) 
(Hamet, Fraysse & Franks 1978; Baudouin Legros, Dard & 
Guicheney 1986) where there is evidence to suggest that 
associated AC changes (Hamet et al 1978; Tremblay & Hamet 
1984; Dard, Baudouin-Legros & Meyer 1987) may be at least 
partly due to altered G-protein function (Coquil and Brunelle 
1989).
The purpose of this study was to examine whether 
platelets from untreated essential hypertensive 
subjects exhibit abnormal adenylyl cyclase activities  
and whether any such changes could be attributed to 
altered G-protein levels or function.
4.2.1.Subjects: 18 untreated EH subjects (table 9), recruited 
consecutively from the medical outpatient department and 21 
healthy controls recruited from among laboratory staff and from 
spouses of patients were studied according to a protocol which 
had been approved by the Hospital Ethical Committee. Subjects 
were studied after over-night fast; following blood pressure 
measurement (after 10min. sitting, with a standard mercury 
sphygmomanometer), 80 ml citrated (3.8%) blood were with­
drawn. Urea, electrolytes (U & E), liver function tests (LFT), 
plasma cholesterol, triglyceride were measured: all subjects had 
normal U&E and LFT. Platelets rich plasma was obtained from the 
residue (about 70ml)from which plasma membranes were 
prepared as described (section 2.3.1). Membrane aliquots were 
stored at -80°C.
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Membrane protein concentrations were measured by the modified 
Lowry protocol (described in section 2.5. ).
It was not possible to complete both ACA and immunoblotting 
studies in all subjects due to limited quantities of platelet 
plasma membrane.
4.2.2.A denyly l cyclase assays (ACA): Platelet membrane 
preparations from EH (n=14) and controls who had been matched 
as far as possible for age and sex were paired for assay. The 
characteristics of these subjects are summarised in table 9A. 
Control subjects were slightly but significantly younger than EH 
(40±3.1 v 47.1 ±4.1 y, p=0.04). ACA were performed according to 
the Salomon assay protocol as described (section 2.8.1.). Briefly, 
the reaction cocktail (final volume 50pl) contained creatine 
phosphate (sodium salt) 5mM, 50U/ml creatine kinase, 25mM 
tris-acetate,pH 7.6, 5 mM magnesium acetate, 0.5mM ATP, 0.05 
mM cAMP, 1mM DTT, BSA 0.1 mg/ml and a^2p ATP was added to 
give 2 x 106 CPM/assay. The guanine nucleotides,GTP or GppNHp 
were included at final concentrations of 10"^M and lO '^M  
respectively. Apart from basal activities all studies (inhibitory 
and stimulatory) were performed in the presence of 10"5M 
forskolin. Adrenaline, propranolol and PGE1 were used at final 
concentrations of 10“4m,1 0‘ 5m and 10~5m respectively, which 
had previously been shown to be saturating with respect to 
effect on AC activity. The reactions were started by the addition 
of membrane (5pg membrane protein) suspended in 10mM tris 
pH7.4. and tubes were incubated at 37°C for 15 min. Details of
118
termination of enzyme activity and of the subsequent chromato­
graphic separation of reaction products are as previously 
described (section 2.8.1.). Each assay was run in quadruplicate. 
The interassay coefficient of variation of this assay was about 
10%.
4.2.3. Immunoblotting studies for G-proteins:
Hypertensive (n=15)(table 9B) and control subjects were 
selected as before (although the control subjects were not only 
slightly younger (43.3±2.6 v 50.3± 3.7, p=0.01) but also slightly 
lighter (69.1 ±2.2 v 79.3±3.1kg,p=0.02). 10 pairs of subjects had 
both ACA and immunoblotting studies performed.
Immunoblots were performed under denaturing conditions on 10% 
gels (SDS-PAGE) (section 2.4.1.) as described with antibodies to 
Gsa, Gia2 and 6 subunit (respectively CS1, SG1 and BN1: details 
of preparation and basis of use of these antibodies-see section
2.1.). Amounts of platelet membrane protein loaded to achieve 
optimal blots were derived from 'dose response' (that is CPM 
obtained against membrane protein loaded) curves to each of the 
antibodies; the amounts of protein used were determined from 
the linear portions of these curves. 100jig,100pg and 20Q|ig 
membrane protein were loaded respectively for Gsa, Gia2 and B 
subunit studies. The antibody-labelled G-protein bands were 
visualised using 12 5 l-labelled second antibody; following 
autoradio-graphy the bands were carefully cut out and counted 
on a gamma counter, with appropriate background controls. To 
facilitate combined analysis of data obtained from different 
blots, a 'standard' platelet
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Table 9. Characteristics of essential hypertensive and 
control subjects.
CONTROL HYPERTENSIVE SIGNIFICANCE
STUDY A
n 1 4 1 4
SEX 12 M 10 M
AGE 40 ± 3.1 47.1 ± 4.1 P = 0.04
WEIGHT 69.3 ± 2.0 75.7 ± 2.8 N.S.
SBP 129.7 ±5.0 162.1 ± 5.6 P = 0.0007
DBP 80.3 ± 1.9 105.8 ± 3.1 P = 0 .0 0 0 1
+VE FH HBP 5 5
STUDY B
n 1 5 1 5
SEX 13 M 11 M
AGE 43.3 ± 2.6 50.3 ± 3.7 P = 0.01
WEIGHT 69.1 ± 2.2 79.3 ± 3.1 P = 0.02
SBP 129.5 ± 4.6 160.6 ± 4.8 P = 0.0001
DBP 80.9 ± 2.4 102.4 ± 2.4 P = 0 .0 0 0 1
+VE FH HBP 4 4
membrane preparation was included in all immunoblots and the 
counts from the G-protein bands were all expressed relative to 
standard, the 'standard' being ascribed the arbitary value of one
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4.3. Results:
Adenylyl cyclase assays:
Data are presented In appendix B. Overall no differences were 
seen in adenylyl cyclase activities on comparing essential 
hypertensive membranes with those from normotensive controls 
under basal conditions (fig. 10). Similarly no differences were 
seen in the response to forskolin even when subject to Gi 
mediated inhibition (via a2 receptor activation or independently 
of receptor using GppNHp) and further stimulation by Gs (PGE1). 
However, as wide interindividual variations in cyclase activities 
were seen basally (5 fold variation) and in the presence of 
forskolin alone (3-4 fold variation), the data obtained in the 
presence of forskolin were expressed as 'percentage change1 due 
to ligand from cyclase activity in the presence of forskolin alone 
(see fig. 11). Greater stimulation of adenylyl cyclase activity 
was observed in membranes from essential hypertensives (88.8 ± 
3.8%) than control membranes (72± 6.5%) (p=0.018).
Im m unoblots:
Data are presented in appendix C. The data obtained are shown in 
figs. 12,13 & 14 . No differences were seen in blots exposed to 
antisera againstGsa, Gia2 and 13 subunits. Even when the results 
were expressed as a ratio (Gia2: Gsa) no differences were seen 
(2.24 ± 0.44 v 1.75 ± 0.29). NB represented by iSkDa bsndCCblab)
(fig. 13). S a l db identified 3 bends (fig. 13)} (bondX) o f iOfeDs and a (? ) phcsphoryt- 
sfed variant op higher molecular weight (band v).lfiis bend remains *fo be- f t  fly characfenred.
When considering all subjects (hypertensives and controls) weak
inverse correlations were found between plasma cholesterol
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concentration and relative amounts of Gia2 (z=-2.084, n=29, 
p=0.04). When the 10 pairs of subjects who had both AC and 
immunoblotting studies were considered, the only significant 
correlation between relative abundance of G-proteins and AC 
function, was that between the amount of Gi2 (c.p.m. expressed 
relative to the standard membrane prep.) and ADR/PROP 
associated AC activity ; z=-2.071, n=20, p=0.04 ).
Hypertensive and controls with positive FH of hypertension were 
subsequently grouped together; thus study A then included 9 
controls and 19 subjects and study B included 11 controls and 19 
subjects respectively. The only difference identified in AC 
functional studies was in the derived ratio of % change from 
forskolin of PGE1: % change from forskolin of adrenaline/ 
propranolol; the ratio was higher in hypertensive subjects and 
those with positive FH than controls (p=0.036). No differences 
between groups were found in the immunoblotting studies.
4.4. Discussion:
The studies of ACA have shown that EH exhibit significantly 
greater PGE1 stimulated cyclase activity than controls 
(p=0.018). The absence of a correlation between either age or 
weight and the ACA obtained in these studies suggest that the 
age and weight differences observed between our hypertensive 
and control groups are unlikely to have influenced the results. 
Furthermore our observation is consistent with three previous 
studies which have shown similar enhancement of PGE1
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stimulation of AC (Brodde et al. 1985; Erne et al. 1985; Resink et 
al. 1986) in essential hypertension.
This alteration of AC activity may at least in part account for 
the altered function of platelets reported in EH where increased 
platelet adhesion (Poplawski et al 1968) and altered aggregation 
(increased (Lentini & Bologna 1974) or reduced (Hamet et al. 
1985)) have been found. (The divergent results from in vitro 
aggregation studies may reflect methodological differences
(Hamet et al. 1978) and it is unclear how such studies relate to 
function in vivo.) It is of interest that enhanced PGE1 
stimulation of AC activity has also been reported in platelets 
from experimental hypertension (SHR)(Hamet et al. 1978; 
Tremblay & Hamet 1984; Dard et al. 1978) although 
demonstration of this difference may require addition of 
extracellular calcium (Hamet et al. 1978). The biochemical 
explanation for the enhanced AC response to PGE1 may reside in 
altered number of PGE1 receptors, Gsa, Gia, amount of AC 
catalytic unit or in PGE1-Gsa, G sa-cata lytic unit coupling. In 
contrast to the study of Resink and colleagues (1986), no 
difference was observed in the ability of forskolin to stimulate 
AC activity; thus in the absence of changes in basal or forskolin 
stimulated cyclase activities it is unlikely that altered amount 
of AC catalytic unit could explain the findings.
Platelets from SHR may, in addition to altered PGE1 respons­
iveness, have abnormal Gi function suggested by reduced AC
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inhibition by GppNHp (0.01-0.3pM)(Coquil and Brunelle 1989) and 
greater reduction of cAMP content in resonse to thrombin 
(Aktories and Jakobs 1984). Current models of Gi function 
propose that Gi may function as a donor of By units which serve 
to 'mop up' Gsa subunits and thus reduce AC activation. The 
converse situation could contribute to enhanced AC activation by 
a stimulatory ligand. The present studies in contrast to those in 
SHR platelets, however, show no differences in either receptor- 
independent activation of Gi, by GppNHp, or receptor driven AC 
inhibition (adrenaline/ propranolol-a combination which 
exclusively activates a l  adrenoreceptors) via Gi). The absence of 
significant differences in a l  receptor inhibited AC activity is 
consistent with studies which have reported similar a l  receptor 
numbers in platelets from controls and EH (Motulsky et al. 1983; 
Boon et al. 1983; Hollister, Onrot, Lonce, Nadeau & Robertson
1983), but is in contrast to those studies suggesting that EH may 
be associated with increased a l  receptor number (Kafka et al. 
1979; Brodde et al. 1985). Resink et al. (1986), however, did 
report that EH showed greater sensitivty to adrenaline as an 
inhibitor of PGE1 stimulated AC activity.
To date no studies of PGE1 receptor number nor of the receptors' 
binding characteristics have been performed in EH and thus the 
explanation for the functional change in AC activty could reside 
either at PGE1 receptor number or G-protein coupling.
In spite of the observation of a weak inverse correlation Gi2a 
and adrenaline/propranolol associated AC activity
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(p=0.04)(considering hypertensive and control subjects together) 
which is supportive of the evidence that Gi2a is implicated in 
receptor mediated AC inhibition, the immunoblotting studies of 
G-protein subunits failed to demonstrate any alteration of Gsa, 
Gia2 and B subunits which could account for the functional 
differences observed between hypertensive and control groups.
Weak inverse correlation was also seen between plasma 
cholesterol and amount of Gia2 ,p=0.04); this raises the 
intruiging possibility that alterations of plasma membrane 
composition possibly associated with abnormal plasma lipid 
concentrations could govern the amount and type of G-proteins 
present and further studies are underway to examine whether 
abnormally elevated plasma lipid concentrations are assoc-iated 
with G-protein changes.
A positive family history (FH) of hypertension was obtained from 
5 control subjects in study A and from 4 in study B. As FH is a 
marker for genetic risk of developing hypertension which could 
be relevant to any possible G-protein alteration (if any such 
change is involved in the pathogenesis of hypertension), the data 
were reanalysed. Although regrouping resulted in loss of the 
significance of the difference of PGE1 stimulation of AC activity 
the derived ratio of % change from forskolin of PGE1: % change 
from forskolin of adrenaline/ propranolol did prove to be higher 
in hypertensive subjects and those with positive FH than 
controls (p=0.036). No differences between groups were found in 
the immunoblotting studies.
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The only other reported study of the role of G-proteins in EH was 
based on plasma membranes derived, not from platelets but from 
erythrocytes Farfel, laina, Eliahou & Cohen 1984). Human 
erythrocytes lack an inrinsic AC system but the membranes do 
express G-protein subunits; functional studies can, however, be 
performed by extracting G-proteins with detergent (Lubrol) and 
by reconstituting stimulable AC function in eye- cells which 
lack a functioning Gs-cyclase system due to a mutation in the 
Gsa peptide sequence. No differences in (reconstituted) 
isoprenaline and guanosine-5'-0-(3-thiotriphosphate) stimulated 
adenylate cyclase activity were seen in a comparison with 
normal subjects (15) with EH(18). This study could be criticised 
on the basis of the use of erythrocyte membranes which have a 
substantially lesser claim to relevance to vascular smooth 
muscle than platelets and also on the heterogeneity of the 
hypertensive group; of the 18 hypertensive subjects only 8 were 
untreated (and had been off treatment for as short a period as 2 
weeks) and 10 were receiving drug therapy at the time of study 
(2 propranolol, 4 propranolol/diuretic, 4 propranolol/diuretic/ 
vasodila tor).
The current studies have shown that platelets from EH exhibit 
similar enhancement of AC response to PGE1 to that 
demonstrated by others in SHR, but may differ in response to 
GppNHp. It is apparent that SHR platelet membranes do not 
exhibit the same perturbations of ACA which have been reported 
in myocardial and other vascular tissues in experimental 
hypertension suggesting that in SHR there is unlikely to be a
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ubiquitous abnormality of G-protein levels in plasma membranes 
in hypertension (see also chapter 5). There is no evidence of 
altered amounts of Gsa, Gia2 and IB in platelets from human EH. 
Any extrapolation of to human vascular tissue would be highly 
speculative, but it is probable that platelet membrane 
abnormalities are not representative of plasma membranes in 
general. The physiological relevance of altered platelet AC 
resonsiveness to PGE1 is probably based on the ability of cAMP 
to regulate intracellular Ca2+ (Zavoico & Feinstein 1984); as 
cytosolic free Ca2+ is significantly elevated in EH, it is 
suggested that enhanced PGE1 stimulation of adenylyl cyclase 
may serve as a negative feedback system to protect cells 
against Ca2+ overload (Resink et al. 1986). Further evidence 
supporting this hypothesis (le Quan Sang & Devynck 1986) is 
that 10“7M PGE1 effects lowering of platelet Ca2+ in EH 
(although no effect was seen in control subjects.)
Altered G-protein levels appear not to explain the changes in 
PGE1 stimulation of ACA seen in platelet membranes from EH; 
however, further studies are required to elucidate the relative 
roles of changes in PGE1 receptor number and of altered PGE1 
receptor-Gs coupling in this abnormality. The absence of major 
changes in G-protein levels in essential hypertension contrasts 
with the results obtained in the study of NIDDM (chapter 3). The 
data argue against alteration of G-proteins in hypertension by 
virtue of hyperinsulinaemia, but further study would be 
desirable in metabolically active tissues such as fat or liver and 
preferably in the arteriolar peripheral resistance vessels.
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Chapter 5
G-proteins in Experimental Hypertension
a study of SHR myocardial, renal cortical and 
hepatic plasma membranes.
5.1. Introduction
The existence of several animal experimental models of hyper­
tension (vide infra) permits study of possible causes and effects 
of hypertension; these models include the SHR, a model of 
genetically determined hypertension resembling human EH, and a 
number of renovascular hypertension models based on surgical 
induction of renal artery stenosis, for example the 2K,1C 
Goldblatt model. In addition, there are models of glucocorticoid 
hypertension (chapter 6), mineralocorticoid hypertension (the 
DOCA-salt model) and of hypertension attributable to central/ 
neural mechanisms-'stress hypertension' and 'neurogenic hyper­
tension'. As already implied, hypertension represents the 
common outcome of a number of pathological processes: irresp­
ective of aetiology, hypertension results in a number of well 
established functional and structural changes in affected organs 
which ultimately contribute to cardiovasular, cerebrovascular 
and renal morbidity and mortality. Experimental models express 
the same responses to hypertension, for example the develop­
ment of myocardial hypertrophy, and thus identification of 
differences between hypertensive and control species must be 
interpreted with caution as to whether a change reflects a cause 
or effect of hypertension.
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5.1.1. Experimental hypertension-cAMP and adenylyl 
cyclase .
Cyclic nucleotides and ACA have been studied in most models of 
experimental hypertension including the SHR (Amer 1973; Amer, 
Gomoll, Perhach, Ferguson & McKinney 1974; Triner, Valliemoz, 
Verosky & Manger 1975; Bhalla, Sharma & Ashley 1978; Bhalla & 
Ashley 1978, Bhalla, Sharma & Ramanathan 1980; Sharma, Kemp, 
Gupta & Bhalla 1982; Kumano, Upsher & Kairallah 1983; Anand- 
Srivastava 1988), renovascular hypertension (Goldblatt, 1K,1C 
and Grollman models) (Woodcock, Funder & Johnston 1978; 
Sharma et al.1982; Anand-Srivastava, Cantin & Genest 1983; 
Kumano et al. 1983; Kumano & Kairallah 1985), DOCA-salt (Amer 
et al. 1974; Woodcock et al.1979), neurogenic (Amer et al. 1974; 
Amer, Doba & Reis 1975) and stress hypertension (Amer et al. 
1973,1974). There is no evidence currently to implicate 
abnormalities of cyclic nucleotides in the causation of hyper­
tension which can with certainty preclude a cyclic nucleotide 
defect due to the presence of hypertension. Several vascular 
tissues have been studied (see table 10) including mesenteric 
arterial vessels (which are representative of resistance 
vessels), aorta and myocardium. Of these the mesenteric 
arteries are most likely to represent the site of greatest 
pathophysiological relevance in the aetiology of hypertension. 
Although the myocardium of hypertensive animals is unlikely to 
initiate hypertension, the hypertrophic changes in the heart 
consequent upon hypertension are well recognised both in human 
and experimental hypertension. Against this background it should 
be remembered that in addition to their possible roles in the
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TABLE 10 ADENYLYL CYCLASE ACTIVITY IN EXPERIMENTAL HYPERTENSION
ARROWS DENOTE A.C ACTIVITY N  HYPERTENSIVE SPECIES (v CONTROL), LETTERS DENOTE REFERENCES
MYOCARDIUM
MODEL BASAL A.C. ACTIVITY ISOPROTERENOL STIM. A.C. ACTIVITY
SHR |  EH ^  B.L ^  B,E,H,I,N,L
RENOVASCULAR* |  1 .L _ ^ G , M ^  G .I.L
NEUROGENIC - ► C 1 c
STRESS B I  B
DOCA-SALT t  B —►  G i  K ^  B.G.K
AORTA
MODEL BASAL A.C. ACTIVITY ISOPROTERENOL STIM. A.C. ACTIVITY
SHR ^ A.B.D.O ^ N 1  A.B.D.N.O
RENOVASCULAR 1 G 1 G
NEUROGENIC —►C I °
STRESS A.B 1  A.B
DOCA-SALT t 8 1 B
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TABLE 10 ADENYLYL CYCLASE ACTIVITY IN EXPERIMENTAL HYPERTENSION
MESENTERIC ARTERY
MODEL BASAL A.C. ACTIVITY ISOPROTERENOL STIM. A.C. ACTIVITY
SHR B *B
RENOVASCULAR
NEUROGENIC
STRESS ^  B
DOCA-SALT t B
KEY TO REFERENCES: A. Amer et al. 1973 J. Blumenthal et al. 1982
B. Amer et al. 1974 K. Schutz et al. 1984
C. Amer et al. 1975 L. Kumano et al. 1983
D. Triner et al. 1975 M. Anand-Srivastava et al.
E. Bhalla et al. 1978 N. Anand-Srivastava 1988
F. Bhalla & Ashley 197 0. Bhalla & Sharma 1982
G. Woodcock et al. 197
H. Bhalla et al. 1980
I. Sharma et al. 1982
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aetiology of and pathological response to hypertension there are 
inherent normal and physiological regional differences in cyclic 
nucleotides within the vascular tree where there is a general 
trend for basal adenylyl cyclase activity to increase towards the 
periphery (for example, enzyme activity in the coronary arteries 
is three times higher than in the upper aorta (Triner et al. 1971).
5.1.2. cAMP (tissue) levels in experimental 
hypertension .
cAMP levels have been quantified in the aorta and myocardium of 
the SHR (Amer 1973; Amer et al. 1974), stress hypertensive rats 
(Amer 1973; Amer et al .1974), DOCA-salt (Amer et al. 1974) 
and neurogenic hypertension (Amer et al. 1975). In all models 
except DOCA-salt hypertension (Amer et al. 1974) cAMP levels 
were generally significantly reduced compared to control 
species; Bhalla, however, using aortas from SHR & WKY reported 
no difference (Bhalla et al. 1978). Although those who reported 
reduction of cAMP ascribed it to increased cAMP phosphodiester­
ase (PDE) activity (Amer 1973;Amer et al.1974) several 
investigators have since demonstrated that cAMP PDE is either 
unchanged (Triner et al. 1985) or lower (Taylor & Shirachi 1977) 
in SHR vascular tissue. In practice an alteration of cAMP may be 
of greater pathological relevance when viewed in the context of 
concurrent cGMP changes which favour further elevation of the 
cGMP : cAMP ratio (Amer et al 1974,1975). Reduction of tissue 
cAMP has also been reported in the hearts of SHR (Amer et al. 
1974) and neurogenic hypertensive species (Amer et al. 1975) 
but was not associated with significant change in the overall
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cGMP:cAMP ratio. No significant cAMP changes were seen in 
hearts taken from the other models of hypertension.
5.1.3. Adenylyl cyclase activity in experimental 
hypertension: studies in vascular tissues.
Table 10 represents a summary of existing evidence. Studies of 
basal ACA have failed to identify consistent abnormalities both 
within a particular model of hypertension and when comparing 
different hypertensive models. The divergent results probably 
result from methodological differences, compounded by 
generally low but otherwise variable basal ACA in the different 
models. Amer et al. (1974 ) have, however, applied similar 
techniques concurrently to different vascular tissues from SHR, 
stress hypertension and DOCA-salt models and have shown 
similar trends in basal activities in relation to control species 
irrespective of the vascular tissue studied (myocardium, aorta 
or mesenteric artery); only in the DOCA salt model did they note 
any change from control, notably an increase of cyclase activity.
In marked contrast to these divergent observations is the 
remarkable constancy of reduced isoproterenol stimulated ACA 
(also expressed as a reduced 'sensitivity' to isoproterenol) which 
is common to all five models of hypertension, and which is 
demonstrable in all three of the vascular tissues studied (myo­
cardium, aorta and mesenteric artery) (table 10).
Using plasma membranes derived from a number of tissues from 
SHR, WKY and Wistar rats several experiments were performed 
to address the following questions:
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1. Does SHR myocardium exhibit reduced stimul­
ation of adenylyl cyclase in response to ligands 
other than isoproterenol?
2. Does non-vascular tissue (renal cortex and
liver) from SHR exhibit the same trend in
adenylyl cyclase responses as myocardium?
3. Do altered G-protein levels contribute to 
changes in adenylyl cyclase activity in SHR?
5.2. Materials & Methods
11 week SHR with WKY and Wistar controls were studied. 
Because of uncertainty regarding the ideal control species in 
such experiments (see discussion section 2.2 ) the study 
includes two control groups (Wistar and WKY species).
Body weight and mean systolic BP were recorded. BP was 
measured in triplicate in warmed, unrestrained conscious rats 
by the tail cuff method (McAreavey et al. 1985) using a W & W 
Electronics recorder (Basle, Switzerland)(see table 11).
Methods:
Following sacrifice by cervical dislocation, the hearts, kidneys 
and livers were rapidly removed. Plasma membranes were 
prepared as described in sections 2.3.3., 2.3.4. and 2.3.2. resp­
ectively. Membrane aliquots were stored at -80°C. Membrane 
protein concentrations were measured by the modified Lowry 
protocol (section 2.6.) and 5' Nucleotidase (5'ND) activities were 
measured (section 2.7.) to verify plasma membrane 'purity' of 
myocardial membranes.
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Adenylyl cyclase studies:
Myocardial, renal cortical and hepatic plasma membrane ACA 
were measured using similar protocols (section 2.8.1). Enzyme 
reactions were performed in the presence or absence of fors­
kolin 10“5 m . A number of ligands were used at concentrations 
previously shown to be saturating with respect to effect on ACA 
(see table 6); these included NaF (10mM), MnCI2 (20mM), PGE1 
(10~5m ), acetyl choline (ACh)(10_4M) used in conjunction with 
the cholinesterase inhibitor physostigmine (10~5M), isoprot­
erenol (10"4 M), glucagon (10_^ M), neuropeptide Y (10“®M) and 
angiotensin II (10'^M) .
The reactions were started by the addition of membrane 
(generally 8pg membrane protein) suspended in 10mM tris pH7.4. 
Tubes were incubated at 30°C for 10 min.- a time shown to be in 
the linear portion of the time course of the reaction.
Imm unoblotting studies:
Immunoblotting studies for G-protein subunits were performed 
under denaturing conditions on10% gels (SDS-PAGE) as described 
in section 2.4.1. The G-protein subunits identified within the 
different plasma membrane fractions are summarised in table 5
The amounts of protein required to give clear reproducible blots 
with the different G-protein subunit antisera were derived from 
'dose-response' curves (section 2.4.). Widely differing quantities 
of protein required to be loaded for the various preparations, 
presumably reflecting differences in purity of the preparations
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Table 11. Comparison of BP, body and organ weights in a
typical group of WKY, SHR & Wistar rats.
mean (sem)
WKY SHR WISTAR
n 9 7 9
W E IG H T (g )(W ) 238.3 (6*4-) 255.3(4-3) 2 8 8 .1 (3 -4 )***
BP (mmHg) 142.2(3-& )*** 212.9(3*5) 155 .3 (3 -3 )***
MYOCARDIAL
W E IG H T (g )(M )
0.88(0-04)* 1.03(0*06) 0.97(0-05)
RENAL
W E IG H T (g )(R )
1.79(006) 1.84(0-08) 2 .0 5 (0 0 4 )* *
M / W 3.71 (o-ia) 4.02 (o-ai) 3 .37(o -!3)**
R / W 7.51(0*1) 7.19(0*^) 7.13(0-13)
Note: Statistical comparisons with SHR data are shown:
*: p = 0.05, **: p = 0.01, ***: p = 0.0001.
derived from different tissues; for example, 80pg and 60pg 
membrane protein were loaded respectively for Gsot and Gia2 
studies in myocardium, while around 200jig protein were 
required for similar studies in the hepatic membrane 
preparations. The antibody-labelled G-protein bands were 
visualised using 12^l-labelled second antibody and were counted 
on a gamma counter.
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5.3. Results
The SHR rats studied were shown by tail cuff blood pressure 
measurements to have significantly higher BP than both WKY 
and Wistar control species (table 11). Body weights were 
different amongst the species; Wistar rats were heavier than 
SHR, which were slightly, but not significantly higher than WKY 
animals. Mean myocardial weight was noted to be heavier in SHR 
than WKY (when expressed as absolute weight (g)) and heavier 
than Wistar myocardium (organ weight expressed as fraction of 
body weight (x 1000)). By contrast SHR kidney mass expressed as 
absolute weight, or corrected for body weight was intermediate 
between control species.
Adenylyl cyclase studies.
Studies of basal AC activity (expressed as pmol cAMP/mg/min) 
in the myocardium revealed a trend (fig.15A); ACA in WKY was 
higher than SHR which in itself was higher than Wistar mem­
branes. Despite the apparent differences, statistical signif­
icance was only achieved in the comparison between control 
species (WKY v Wistar). Similar trends in ACA were seen when 
the enzyme was assayed in the presence of a number of agents 
including NaF, PGE1, isoproterenol, glucagon and forskolin (fig. 
15A). The greatest differences were observed between WKY and 
Wistar rats, while significantly greater stimulation of ACA was 
seen in WKY than SHR in the presence of NaF, PGE1, isoproterenol 
and forskolin (figure 15A); ACAs were higher in SHR than Wistar 
rats only in response to forskolin. By contrast, 20mM Mn2+
(which essentially uncouples AC from G-protein input) 
eliminated the differences amongst the species. When the data
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Fig.16A: Adenylyl cyclase studies in renal cortical
plasma membranes. Comparison of WKY, SHR 
and Wistar species. Data expressed as 
absolute activities, mean ± sem of 6 exp.
were expressed as 'percentage change from 'basal' ('basal' 
measured in the presence of Mn2+' ), the previously observed 
trend persisted (fig.15B); myocardial AC activities from WKY 
were much higher than from SHR and Wistar species. Statistic­
ally significant differences (WKY v SHR/Wistar) were seen only 
when ACA was assayed in the presence of ligands whose 
receptors couple to AC catalytic unit via Gs. However, (despite 
failing to achieve statistical significance) the same trend was 
seen even in receptor independent mechanisms (forskolin and 
NaF)(fig. 15B).
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Minimal inhibition of ACA was achieved despite assaying ACA in 
the presence of several ligands which couple to catalytic unit 
via Gi. No more than 10% inhibition of forskolin stimulated ACA 
was observed in response to ligands including acetyl choline 
(10_4M) (in the presence of physostigmine(10"5M)), angiotensin 
ll(10-6M)(see table 12 and Figure 15A) neuropeptide Y(10~6M) 
(data similar to table 12, but not shown). Furthermore, no
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differences in the extent of inhibition (expressed as 'percentage 
change') were seen when comparing species.
ACA studies in plasma membranes derived from renal cortex (fig. 
16) show no differences in either basal or stimulated ACA when 
comparing WKY v SHR species; ACA were, however, higher in SHR 
than Wistar rats when assayed in the presence of forskolin, 
PGE1, AVP and GppNHp. These differences were completely 
eliminated when expressing the data as 'percentage change from 
'basal' in the presence of Mn2+'(fig. 16B).
ACAs were studied in hepatocytes from SHR and Wistar species 
only (table 14): no differences were seen.
Immunoblotting studies: Gsa, Gia2 and Goa immunoblots of 
myocardial membranes are shown in figs. 17-19; no differences 
were observed. Immunoblotting data from renal cortical 
membranes are presented in table 13, and again show no 
differences in the levels of G-protein subunits.
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2000 -
1000 -
WKY SHR W WKY SHR W MW B
F ig .17. G sa subunit immunoblot data from myocardial plasma membranes from  
WKY, SHR and Wistar rats. Lower— typical blot, showing 2 lanes each 
for sample preps., MW=molecular weight standards, B='standard' 
membrane prep.(brain). Upper-— graph obtained by expressing data as cpm 
obtained by counting 1251-labelled bands from blot.(mean ± sem).
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Table:12 AC studies in myocardial plasma membranes.
Effect of All on forskolin and PGE1 stimulated
eye ase.
WKY SHR W ISTAR
FORSKOLIN 846.6 ± 42.4 804.8 ± 61.7 497.2 ± 47.7
FORSKOLIN /
A l l 778.6 ± 42.3 780.2 ± 57.2 464.2 ± 43.4
PGE1 179.2 ± 20.9 180.2 ± 25.8 114.4 ± 15.5
PGE1/AII 196 ± 20.4 148.2 ± 32.4 98.2 ± 28.8
(data represent mean ± sem of 3 expt., expressed as pmol cAMP/mg/10min.)
Table 13: G-protein levels assessed by Western blot­
ting in renal cortical plasma membranes from 
WKY, SHR & Wistar rats. Data expressed as 
mean ± sem of cpm;n = number of experiments.
G -p ro te in
subunit
WKY SHR W ISTAR n
G s a 4 2 k D a 2243 ± 59 2253 ± 160 2209 ± 147 4
G s a 4 0 k D a 2531 ± 67 2536 ± 136 2491 ± 147 4
G i 1 a 440 ± 14 476 ± 14 536 ± 49 4
G i2 a 2916 ± 540 2618 ± 34 2454 ± 269 4
G o a 1115 ± 101 1169 ± 96 1068 ± 42 4
B 524 ± 20 493 ± 21 524 ± 26 4
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5'ND activities: (assays only performed once): Myocardium: WKY, 
480.8; SHR, 462.6; Wistar 456.4 jig phosphorus/h/mg membrane 
protein.
Table 14. Adenylyl cyclase studies in liver from SHR 
and Wistar rats (data represent mean ± sem 
of results from 5-8 expt., each with 4 
replicates; cyclase data as pmol cAMP/mg /
10mi n) ) .
ASSAY CONDITIONS 
-LIGAND STUDIED
SHR WISTAR
BASAL 102.9 ± 22 91.2 ± 16.7
NaF 441.7 ± 60.3 505.8 ± 72.9
MnCI2 179.1 ± 32 112.7 ± 24.1
FORSKOLIN 785.3 ± 101.5 640.8 ± 96
GLUCAGON 537.4 ± 49.8 691.2 ± 60.1
ISOPROTERENOL 136.2 ± 48.1 104.1 ± 15.8
5.4. Discussion.
The SHR rats had significantly higher BP than both WKY and 
Wistar control species (table 11) and mean myocardial weight 
was noted to be heavier in SHR than WKY (when expressed as 
absolute weight (g)) and heavier than Wistar myocardium (organ 
weight expressed as fraction of body weight (x 1000)) 
suggesting a degree of myocardial hypertrophy in the SHR.
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Studies of basal AC activity (expressed as pmol cAMP/mg/min) 
were significantly higher only when comparing WKY and Wistar 
rats. SHR ACAs differed from WKY (significanlty lower) when 
assayed in the presence of a number of agents including NaF, 
PGE1, isoproterenol, and forskolin (fig. 15A), while comparison 
between SHR and Wistar controls showed essentially no 
differences with the sole exception of higher ACA in SHR in the 
presence of forskolin. 20mM Mn2+ (which essentially uncouples 
AC from G-protein input) eliminated the differences amongst the 
species: this suggests that the amounts of AC catalytic unit are 
unlikely to differ greatly amongst the species. When the data 
were expressed as 'percentage change from 'basal', measured in 
the presence of Mn2+' the previously observed trend persisted; 
myocardial AC activities from WKY were much higher than from 
SHR and Wistar species (fig.15B). Thus although interspecies 
differences exist, the 'abnormal' species appears to be WKY, as 
SHR responses were virtually identical to those seen in the 
Wistar membranes. Statistically significant differences (WKY v 
SHR/Wistar) were seen only when ACA was assayed in the 
presence of ligands whose receptors couple to AC catalytic unit 
via Gs. However, (despite failing to achieve statistical 
significance) the same trend was seen even in receptor 
independent mechanisms (forskolin and NaF)(fig. 15B) adding 
support to the possibility that changes in Gs function and/or 
levels could explain the higher ACA seen in WKY species.
Why no more than about 10% inhibition of forskolin stimulated 
ACA could be achieved despite using a wide range of established 
inhibitory ligands (including acetyl choline, angiotensin II and
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neuropeptide Y remains unclear. However, it may be related to 
the inclusion of Mg2+ in the buffer used to prepare the myo­
cardial plasma membrane homogenate While the results 
obtained with inhibitory ligands tend to exclude a major 
difference in Gi function amongst the species, this may not 
truely reflect the situation in vivo .
Comparison of SHR and WKY myocardial ACAs obtained in the 
current studies under basal conditions shows results similar to 
those of previous workers (Bhalla et al. 1978,1980)(table 10). 
Furthermore, the observed reduction of response of SHR myo­
cardium to isoproterenol stimulation (compared to WKY)(fig. 15 ) 
is entirely consistent with many previous reports (Amer et 
al.1974; Bhalla et al. 1978,1980; Blumenthal, McConnaughey & 
lams 1982; Sharma et al. 1982; Kumano et al. 1983; Anand- 
Srivastava 1988; Matsumori, Ohyanagi, Kawamoto, Shibata & 
Iwasaki 1989).
Reduced receptor-mediated stimulation of cyclase in response 
to adenosine, epinephrine, dopamine and glucagon has previously 
been reported in the SHR(Anand-Srivastava 1988) and to this list 
can be added the reduction of AC stimulation by PGE1. Reduced 
NaF/forskolin induced activation of cyclase (expressed as % 
change from basal) has been reported previously by Anand- 
Srivastava et al. (1988) but not by Kumano et al. (1983)(who 
reported no change).
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Mechanisms of altered AC activity in SHR myocardium
Levels of Gsoc, Gia2 and I3(cpm WKY, SHR, Wistar: 525 ± 15.4, 
517.8± 32.1, 578.1 ± 24.2 (mean ± sem, n=3) the G-proteins 
implicated in regulation of ACA) and Goa did not differ among 
SHR, Wistar and WKY myocardial plasma membrane preparations 
(fig. 17,18,19); thus alterations of the levels of the G-proteins 
which modulate acitivty of AC catalytic unit do not account for 
the differences in ACAs. This is consistent with a previous study 
(Murakami, Katada & Yasuda 1987), which compared SHR and WKY 
myocardium and which showed no difference in the amount of Gs 
as determined by cholera toxin-catalysed ADP ribosylation, nor 
in amounts of Gi by pertussis toxin catalysed ADP ribosylation 
and the amount of By subunit (antibody).
In view of the reduced responsiveness of AC in vascular tissues 
to B adrenergic stimulation reported here and by others (table 
10) in in vitro studies it is not surprising that there are 
functional consequences: the myocardium of hypertensive 
animals is known to exhibit reduced inotropic (Saragoca & Tarazi 
1981) and chronotropic responses to adrenergic stimulation 
(Fujiwara, Kuchii & Shibata 1972; Cohen & Berkowitz 1975). In 
addition aortic muscle strips show less tendency to relax in 
response to isoproterenol (Cohen & Berkowitz 1975). Although 
changes in B-adrenergic receptors have been reported and may 
contribute, it is likely that the altered catecholamine sens­
itivity is multifactorial. B adrenergic receptor characteristics 
have been studied in the SHR. B-receptor numbers have been 
reported to be unchanged (Bhalla et al. 1980; Blumenthal et al.
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1982; Murakami et al. 1987) or decreased (Limas & Limas 1978; 
Robberecht et al. 1981;Kumano et al 1983;Will-Shahab, Kutter & 
Warbanow 1986) in the SHR. One factor contributing to the 
disparity in results may be that there is evidence of altered 
cellular distribution of 8 receptors- both with age (surface 6 
receptors decrease with age) and in SHR compared to WKY 
(Matsumori et al 1989); although total 6 receptors are unchanged 
the surface B receptors may be reduced in SHR. Receptor affinity 
was either not altered (Limas & Limas 1978; Murakami et al.
1987) or reduced ( Bhalla et al. 1980): the reasons for these 
disparate results is unknown and although further clarification 
is required the possibility of the existence in hypertensive 
hearts of altered G-protein function (such as impairment of 
coupling of receptor to G-proteins) is consistent with reduced 
affinity in the context of unchanged receptor numbers as shown 
by Bhalla et al. (1980).
As myocardial hypertrophy is an inevitable consequence of 
experimental (as well as human) hypertension and can occur as 
early as 1-2 weeks after induction of experimental hypertension 
(Kumano & Kairallah 1985), studies of myocardium from 
hypertensive species must acknowledge that hypertrophy per se 
could cause changes independent of any effects due to or 
contributing to the underlying hypertension.
Studies of the evolution of blood pressure changes in the SHR 
show divergence of blood pressure (BP) tracings as recorded by 
the tail cuff method after about 5 weeks of age (the time at 
which tail cuff BP recordings become feasible). Extrapolation of
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such blood pressure curves back to younger ages led to the 
assumption that the BP curves converge and this hypothesis 
engendered the concept of the 'prehypertensive' SHR; such a 
'prehypertensive' state could have potential in allowing 
elucidation of factors relevant to the pathogenesis of hyper­
tension in the absence of the hypertension phenotype. For 
example, 13 adrenergic (isoproterenol) stimulated cyclase 
activity in myocardial membranes from 'prehypertensive' SHR 
has been shown to be increased compared to WKY. Furthermore, 
as the rats age the isoproterenol-stimulated cyclase activity 
declines to lower values-half the original activity at100 days 
and in absolute terms a level of activity below that in WKY of 
similar age (Blumenthal et al. 1982). Increased ACA was 
proposed to be a possible factor in the pathogensis of 
hypertension. However, the concept of the ’prehypertensive1 
animal may be flawed as recent evidence based on intraarterial 
blood pressure measurements in these young animals suggests 
that even at 3 weeks of age significant differences in BP 
recordings already exist (Morton, J.J., Personal communication).
Does myocardial hypertrophy per se cause specific 
changes in adenylyl cyclase activity?
The studies herein(table 11) suggest that SHRs do exhibit a 
degree of myocardial hypertrophy, at least compared to WKY. 
Correction of myocardial mass for differences in total body 
weight tends to reduce (but not eliminate) the difference 
between SHR and WKY. As SHR and Wistar membranes behaved 
similarly in assays of ACA it seems unlikely that hypertrophy is 
the sole explanation for the observed differences. However, the
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similarity in mean myocardial weights between the SHR and 
Wistar rats does not exclude a contribution to altered ACA 
associated with myocardial mass per se (possbly associated 
with altered amount or composition of plasma membranes).
Our studies of 5'ND activity(a plasma membrane marker) tend to 
exclude major differences in plasma membrane concentration 
within the plasma membrane preparations which might cause 
artifactual differences in our immunoblotting and ACA studies.
It is impossible to dissociate myocardial hypertrophy 
completely from hypertension. However, myocardial hypertrophy 
in the context of systemic hypertension(SHR) has been compared 
to hypertrophy due to an aortic coarctation (proximal ligature); 
in the absence of genetic risk of developing hypertension, 
identical changes in cyclase activities were reported. Both 
exhibited reduced epinephrine stimulated adenylyl cyclae 
activity (Will-Shahab et al.1986) which was ascribed to the 
reduction of cardiac B receptors (30-35% reduction). However, 
other studies have suggested that myocardial hypertrophy 
resulting from different models of hypertension may be 
associated with different alterations in the B-adrenergic- 
receptor-G-protein-cyclase system (Kumano & Khairallah 1984). 
Further evidence of this was provided by study of the effects of 
angiotensin II (which mediates renovascular hypertension) and 
epinephrine (used because there is some evidence implicating 
catecholamines in hypertension of SHR-Williams et al. 1976) 
infusions (subcutaneously) in rats (Kumano & Khairallah 1984); 
both groups exhibited hypertension and myocardial hypertrophy.
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However, although the myocardial plasma membrane from the 
epinephrine treated group had lower basal and ligand (isoprot- 
erenol/glucagon/forskolin /GppNHp) stimulated cyclase 
activities the membranes from the All treated group showed no 
differences in cyclase activity (neither basally nor in response 
to ligands) (Kumano & Khairallah 1984). The overall pattern of 
results in our experiments is similar to that observed by Kumano 
& Khairallah in response to infused epinephrine, possibly 
suggesting an explanation for our findings.
Changes in other vascular tissues of the SHR.
Changes in basal and ligand stimulated cyclase which are 
identical to those in myocardium have been reported in the aorta 
of the SHR (Bhalla & Sharma 1982; Anand-Srivastava et al.1988). 
In studies which have assessed vascular physiology and its 
vascular correlates noradrenaline (B) mediated relaxation of 
precontracted femoral vascular smooth muscle strips has been 
reported to be reduced in SHR (Asano, Masuzawa & Matsuda 
1988a; Asano, Masuzawa, Matsuda & Asano 1988b): elegant 
elucidation of of the site of biochemical abnormality by Asano & 
colleagues suggests that reduced Gs function may be the prime 
determinant of these changes (vide infra ) (Asano et al. 1988b).
Studies in non-vascular tissues: adenylyl cyclase 
activity in non vascular tissues of the SHR.
Changes in ACA may be more widely distributed than the 
vasculature allowing dissociation of the effects of hypertension 
or of its underlying determinants. The kidney contributes 
fundamentally to the mechansims of hypertension in genetically
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hypertensive rats and is a major determinant of blood pressure 
as shown in renal transplant studies of these models (Bianchi et 
al. 1974). Liver has been studied as it represents a tissue 
without a direct role in BP regulation and which is not subject 
to the hypertrophic response to hypertension.
Plasma membranes derived from renal cortex (fig. 16) and liver 
(table 14) show no differences overall in basal, NaF, MnCI2, 
forskolin, glucagon and isoproterenol stimulated AC activity 
when expressed as absolute levels of activity. A number of non- 
vascular tissues from SHR have been studied by others; these 
include platelets, adipocytes (Chiappe de Cingolani 1988) and 
kidney (Umemura, Smyth & Pettinger 1985 ). Reduced PGE1 and 
PGE2 stimulation of ACA was found in renal cortical plasma 
membranes from SHR (v WKY) and although the responses to PTH, 
AVP, isoproterenol, forskolin, GppNHp and MnCI2 were unaltered, 
NaF stimulation of ACA was also reduced (in contrast to the 
current observations). In the single study of adipocyte function 
from SHR, reduced lipolysis in response to noradrenaline was 
reported (Chiappe de Cingolani et al. 1988).
Hypertension of different aetiologies-genetic and reno­
vascular hypertension:
Study of acquired hypertension, for example the 2K,1C Goldblatt
■-v.
model of renal hypertension (analogous to renal artery stenosis) 
allows dissociation of the effects of hypertension from possible 
underlying genetically determined membrane defects which 
might predispose to hypertension. In contrast to the SHR, and in
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common with the human condition, the Goldblatt hypertension 
model is essentially hyperreninaemic hypertension (at least in 
its early stages). In common with the SHR, the RHR exhibits 
reduced myocardial adenylyl cyclase response to 13 agonists 
(Sharma et al.1982; Anand-Srivastava et al. 1983; Kumano et al 
1983) and although basal or forskolin stimulated cyclase 
activities may be unaltered (Anand-Srivastava et al. 1983; 
Kumano et al 1983 ) or reduced (Sharma et al.1982; Kumano et al 
1983; Anand-Srivastava et al. 1983) stimulation of cyclase via 
receptors (dopamine and adenosine) and activation of 
Gs/catalytic unit (NaF) appears to be reduced (Sharma et 
al.1982; Anand-Srivastava et al. 1983; Kumano et al 1983). 
Receptor changes have been reported. As in the SHR, divergent 
results have been reported; B receptors may be increased 
(Kumano et al 1983) or reduced (Sharma et al.1982), and in 
addition, glucagon receptors may be reduced (Kumano et al.
1985).
Reduced G-protein activity may accompany both types of 
hypertension (Kumano et al 1983;Kumano et al. 1985; Asano et al
1988), suggesting an association with blood pressure change per 
se. Of interest is the observation in RHR that several changes 
may contribute to reduced ACA. The earliest change, occurring as 
early as 1-2 weeks after induction of hypertension (Kumano & 
Khairallah 1985), is reduction in G-protein activity (associated 
with unaltered catalytic unit activity (Kumano et al 1983)), 
followed subsequently by a decline in catalytic unit activity 
(Kumano & Khairallah 1985)(a change established at around 10 
weeks) as a consequence presumably of sustained hypertension.
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Downregulation of B receptors may occur in both SHR and RHR 
(vide infra ) possibly in association with uncoupling of G-protein 
from receptor in experimental hypertension but it remains 
unclear whether these changes are a consequence of excessive 
local or systemic catecholamines or whether the alterations in 
receptor characteristics are implicated in the pathogenesis of 
hypertension (Stiles, Caron & Lefkowitz 1984). Woodcock and 
Johnston (1980) have however demonstrated in the Goldblatt RHR 
model that receptor changes are tissue specific (reduced alpha 
and beta receptor concentrations occur only in myocardial 
membranes and not in renal or pulmonary membranes)
(supporting current findings of differences in AC between SHR 
myocardium and liver) suggesting that a specific effect of 
enhanced sympathetic drive is more probable than a systemic 
increase in circulating catecholamines.
5.5. C onc lus ion
It has been demonstrated in this chapter that functional changes 
in ACA occur in SHR myocardium compared to WKY, but not 
Wistar control species. These changes are characterised 
essentially by relatively reduced stimulation of AC by agents 
that act on Gs or ligands whose receptors couple to AC via Gs. 
However, identical changes are seen in Wistar membranes. 
Alterations in the receptors per se cannot be excluded but 
concurrent reductions of responses to NaF and forskolin suggest 
that catalytic unit and/ or Gs or their mutual coupling may be 
abnormal. Murakami et al. (1987) previously showed altered Gs 
function in SHR myocardium (Gs function is significantly lower)
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using a reconstitution assay based on G-protein cholate extracts 
from SHR. Neither Murakami using ADP ribosylation studies nor 
ourselves using specific antibodies could demonstrate any 
differences in amounts of Gi or Gs which could account for the 
functional differences. Similar changes have been reported in 
vascular smooth muscle plasma membranes from aorta (Anand- 
Srivastava 1988) and other vessels. No changes in ACA were 
seen in the current studies of non-vascular tissues (liver and 
renal cortical plasma membranes) from the three species. Thus a 
ubiquitous, perhaps genetically determined, abnormality of 
membrane function in SHR cannot be implicated. There is 
however, a surprising degree of similarity between the AC 
activities in rat myocardium in response to epinephrine infusion 
and those seen in SHR myocardium raising the possibility that 
the process of heterologous desensitisation which accounts for 
the former may also explain the latter.
Desensitisation has been catagorised into 'homologous' and 
'heterologous' (Su et al. 1980). The former is agonist specific 
and is characterised by reduced responsiveness to a ligand due to 
reduction in its binding sites (Mukherjee et al. 1975) and/or 
receptor-catalytic unit coupling (Mukherjee & Lefkowitz 1976). 
The latter is a complex process characterised by reduced 
response to a number of hormones and other activators of AC 
after chronic exposure to an agent. Several mechanisms may 
contribute to heterologous desensitisation as demonstrated by 
Tanif & Harbon (1987), who characterised the heterologous 
desensitisation observed in the rat uterine AC during gestation
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(presumably in response to steroid hormones): heterologous 
desensitisation was mediated by altered function and altered 
levels of G-proteins as well as altered receptor function. Thus if 
heterologous desensitisation is invoked to explain the observed 
changes in AC in SHR myocardium compared to WKY which are 
consistent with altered G-protein function, this begs the 
question as to its cause. The SHR is characterised by a number of 
physiological and biochemical abnormalities (Yamori 1983 ); it 
is possible that increased activity of the sympathetic nervous 
system which has a key role in inititiating hypertension and 
which is reflected in increased plasma noradrenaline (Nakamura 
& Nakamura 1979) and increased sypathetic neuronal discharges 
(Judy, Watanabe, Murphy, Aprison & Yu 1979) could play a role in 
much the same way as adrenaline infusion has been shown to 
induce a state of heterologous desensitisation (Kumano & 
Khairallah 1984). However, if this mechanism were operating 
then greater differences in ACA might be expected between SHR 
and Wistar controls. The reasons for the differences between 
WKY and Wistar rats is not clear. The current studies, however, 
do emphasise the problems inherent in studies of the SHR. The 
absence of an isogenetic control species raises the distinct 
possibility that the differences observed in our studies may 
relate to the inherent genetic heterogeneity among the species 
studied: this problem cannot be circumvented. The inclusion in 
our study of the second control species (Wistar) highlights the 
dangers of the customary comparison between SHR and WKY 
species. Further studies are planned in the Milan rat-another 
model of genetic hypertension for which an isogenetic control
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exists, to ascertain whether our observed changes in ACA are 
seen in this model also.
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Chapter 6
Glucocorticoid hypertension: 
effect of dexamethasone treatment of 
rats on G-protein levels and/or function 
in brain, renal cortex, myocardium and 
vascular tissue.
6.1.General Introduction to Chapters 6 & 7.
6.1.1. Glucocorticoids and essential hypertension:
Human essential hypertension precludes, by definition, a major 
underlying role for steroid abnormalities in its pathogenesis. 
Early studies which sought to link EH to steroid abnormalities 
through the identification of abnormal accumulation of unusual 
steroids or steroid metabolites have proved equivocal: 18- 
hydroxysteroids and 19nordeoxycorticosterone have previously 
been reported to be elevated in EH although subsequent studies 
have failed to confirm this (Griffing, Dale, Holbrook & Melby 
1985; Gomez-Sanchez, Holland & Upcavage1985). Enhanced 
aldosterone secretion in response to All (Kisch, Dluhy &
Williams 1976) occurs in a minority of EH (Dluhy, Bavli, Leung et 
al.1979) and probably reflects an abnormality of the renin, 
angiotensin system rather than a primary adrenal phenomenon 
(Wisgerhof & Brown 1979). The most promising support to date 
for a role for glucocorticoids in the pathogenesis of EH was 
provided by Watt and colleagues (Watt, Harrap, Foy et al. 1990) 
who reported that adolescent offspring of parents whose blood 
pressure is at the upper end of the range had significantly higher 
plasma cortisol than in the adolescent offspring of children 
whose parents have lower blood pressure (without necessarily
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being abnormal when the disorder is fully established). However, 
this finding contrasts with previous work showing that hyper­
tensives and their first degree relatives exhibit reduced mid­
afternoon plasma cortisol concentrations and reduced cortisol 
binding capacity (unchanged free cortisol) (Nowaczynski, 
Murakami, Wilkins & Levin 1986). There is thus some evidence to 
support a role for glucocorticoids in the pathogenesis of 
essential hypertension but at present the case remains ’not 
proven'.
6.1.2. Steroids and hypertension
Four classes of steroid hormones have been shown to produce 
hypertension (see review Coghlan, Butkus, Denton et al. 1980): 
androgens, oestrogens, mineralocorticoids and glucocorticoids. 
Androgens (in high doses) inhibit 11 hydroxylation which 
permits an ACTH driven excess of deoxycoricosterone which 
causes hypertension through its mineralocorticoid actions. 
Oestrogens primarily cause elevation of blood pressure through 
increased levels of angiotensin II consequent upon elevation of 
renin substrate. Mineralocorticoids cause hypertension through 
salt and water retention.
6.1.3. Glucocorticoid hypertension
Glucocorticoid hypertension, although the commonest cause of 
steroid hypertension in clinical practice, is the least under­
stood. The association of glucocorticoids with hypertension is 
however well established; more than 70% patients with 
Cushing’s syndrome have hypertension (Plotz, Knowlton & Ragan 
1952; Raker, Cope & Ackerman 1964; Orth & Liddle 1971) The
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hypertension is independent of ACTH, and is rather less frequent 
in recipients of steroid therapy (prevalence 5-25%) where there 
is less likely to be contribution to blood pressure elevation from 
adrenal mineralocorticoids: its incidence is however dependent 
upon type and dosage of the steroid used and is higher in 
association with impaired renal function (David, Grieco & 
Cushman 1970).
6.1.4. Features of glucocorticoid hypertension
Certain features of glucocorticoid hypertension are well 
established: the onset of glucocorticoid hypertension is of 
rapid-onset (blood pressure elevation demonstrable at 24h) and 
is induced by receptor dependent mechanisms (as administration 
of steroids with antiglucocorticoid properties can prevent or 
reverse the early phase of glucocorticoid hypertension 
(Grunfeld, Eloy, Movra et al. 1985)).
6.1.5. The pathogenesis of glucocorticoid hypertension
It is doubtful whether any single mechanism explains the patho­
genesis of glucocorticoid hypertension. However, a number of 
glucocorticoid induced changes have been observed in vivo and 
may contribute; these include alterations in plasma volume, the 
renin-angiotensin system, prostaglandin synthesis and in 
vascular reactivity.
6.1.6. Glucocorticoids and plasma volume
Glucocorticoid-mediated plasma volume change has been 
implicated in the pathogenesis of glucocorticoid hypertension;
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glucocorticoids effect an increase in plasma volume by causing 
shift of water from intracellular to extracellular compart­
ments. However, while this change undoubtedly occurs it is 
unlikely to cause the hypertension as blood pressure elevation 
precedes plasma volume change (Haack, Mohring, Petri & 
Hackenthal 1977): whereas blood pressure elevation is demon­
strable at 24h, plasma volume elevation is a late (possibly 
beyond day 5) event. In fact plasma volume actually falls early 
(Grunfeld et al. 1985) at a stage when hypertension is already 
established. Although said to be independent of Na+ status 
(Knowlton et al. 1952; Haack et al. 1977), uncertainty regarding 
the role of sodium status has been increased by species 
d ifferences.
6.1.7. Glucocorticoids and the renin-angiotensin system
Glucocorticoid excess may stimulate the renin-angiotensin 
system by increasing plasma renin substrate (Krakoff, Nicolis & 
Amsel 1975); angiotensinogen synthesis by liver is increased by 
glucocorticoids and reduced by adrenalectomy (Hasegawa, 
Nasjletti, Rice & Masson 1973).
6.1.8. Glucocorticoids and prostaglandin synthesis
Glucocorticoids cause major changes in prostaglandin synthesis; 
however, contrasting effects are seen in vitro and in vivo . 
Glucocorticoids can prevent prostaglandin synthesis in a number 
of in vitro systems including cultured cells (Cloix, Colard, 
Rothhut & Russo-Marie 1983) and whole tissue preparations (for 
example rat renal papillary slices & aorta (Jeremy & Dandorra
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1986). Inhibition of prostaglandin synthesis is mediated by 
glucocorticoid-induced synthesis of lipocortin (Wallner, 
Mattaliano, Hession et al. 1986) a protein which inhibits 
phospholipase A2 (phospholipase A2 catalyses the hydrolysis of 
phosphatidylcholine to lysophosphatidylcholine and arachidonic 
acid); inhibition of phospholipase A2 interferes with prosta­
glandin generation by reducing the availability of fatty acid 
substrates (from phospholipids) (Flower & Blackwell 1979, 
Hirata, Schiffman, Venkatasubranian, Salomon & Axelrod 1980).
Exposure to glucocorticoids in vivo may however, involve more 
complex mechanisms than the induction of lipocortin synthesis 
as increased urinary excretion of prostaglandins (for example 
PGE2) have generally (but not invariably (Handa, Kondo, Suzuki & 
Saruta 1983) been reported in animal and human studies; 
although lipocortin may be induced in vivo other factors may be 
more important in determining the net effect on prostaglandin 
synthesis, for example, increased free fatty acid availability, 
increased prostaglandin synthesis or reduced 15HO prosta­
glandin generation, where the net effect is enhanced production 
of prostaglandins.
Glucocorticoid induced alterations of prostaglandin synthesis 
could contribute to changes in vascular physiology: gluco­
corticoids may reduce prostacyclin synthesis in vessel walls in 
ex vivo studies of abdominal aorta; such a mechanism could at 
least partly explain (by attenuating the effects of vasocon­
strictors) increases vascular response to noradrenaline or 
angiotensin II seen experimentally and clinically.
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6.1.9. Glucocorticoids and vascular reactivity
The regulation of blood pressure by direct action of cortico­
steroids on blood vessel walls was first hypothesised by Tobian 
& Binion (1952). The recent demonstration of glucocorticoid 
receptors in arterial vessels from rats (Meyer & Nichols 1981), 
rabbits (Kornel, Kanamarlapudi, Travers et al. 1982) and humans 
(Scott, Lawrence, Nguyen & Meyer 1987) is consistent with this 
concept, but begs the question as to the mechanism of action. 
There is, however, substantial evidence to implicate gluco­
corticoids in the regulation of pressor responsiveness which 
raises the possibility at least of a pathological role for gluco­
corticoids in the aetiology of hypertension. The evidence linking 
glucocorticoids to pressor responsiveness will be reviewed 
b rie fly .
Increased vascular reactivity to infused pressor substances has 
been observed in patients with Cushing's syndrome (Mendlowitz, 
Gitlow & Naftchi 1958). Furthermore similar effects can be 
demonstrated in humans and in a number of animal species under 
experimental conditions in response to several pressor agents 
including adrenaline, noradrenaline, isoproterenol, phenyl­
ephrine, vasopressin (AVP), angiotensin II (All) and KCI.
Pressor responsiveness to adrenaline and noradrenaline is 
increased within a few minutes of glucocorticoid administration 
to humans (Reis 1960), dogs (Besse & Bass 1966) and rats 
(Kalsner 1969) using conjunctival vascular bed (in wVo)(Reis 
1960), and aortic strip (Fowler & Chou 1961; Kalsner 1969) 
preparations.
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Longer term exposure of rats (Russo, Fraser & Kenyon 1990; 
Schomig, Luth, Dietz & Gross 1976; Krakoff, Selvadurai & Sutter 
1975; lijima & Malik 1985; Handa, Kondo, Suzuki & Saruta 1984), 
dogs (Lefer, Manwarring & Verrier 1966) and humans 
(Whitworth, Connell, Lever & Fraser 1986; Sudhir, Jennings,
Esler et al. 1989) to DEX (Russo et al.1990; lijima & Malik 1985; 
Handa et al. 1984), corticosterone (Schomig et al. 1976), 
methylpredinsolone (Krakoff et al. 1975) and hydrocortisone 
(Whitworth et al. 1986; Sudhir et al. 1989) for between two 
(Handa et al. 1984) and 14d (Russo et al. 1990; Krakoff et al. 
1975; lijima & Malik 1985) induces enhanced pressor respons­
iveness to noradrenaline (Russo et al. 1990; Schomig et al. 1976; 
Handa et al. 1984), All (Krakoff et al. 1975), AVP (lijima & Malik 
1985) and phenylephrine (Whitworth et al.1986). It is note­
worthy, however, that responses to all pressor agents were not 
necessarily enhanced concurrently (for example, Russo et al. 
1990; Schomig et al. 1976; Krakoff et al. 1975; lijima & Malik 
1985).
It is thus clear that the effect is not restricted to any 
particular glucocorticoid (although may not necessarily occur 
with all glucocorticoids (Krakoff et al. 1975; Elijowitch & 
Krakoff 1980; Kohlman, Ribeiro, Marson, Sarogoca & Ramos
1981) and is common to several species including humans. The 
alteration in pressor responsiveness occurs rapidly and in 
response to several pressor agents (but not necessarily con­
currently). However, most studies (but not all-Russo et al.1990) 
have studied the effects of high 'suprapharmacological' 
concentrations. As will be discussed further later, gluco­
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corticoids may exhibit mineralocorticoid effects when used in 
high doses; as mineralocorticoids can independently alter 
vascular reactivity, difficulty may arise in differentiating the 
mineralocorticoid from the glucocortiocid contribution to the 
altered vascular reactivty. However, Russo et al. (1990) have 
shown changes in vascular responsiveness in a rat model 
pretreated with DEX 2pg/d for 14d: this is similar to the model 
used in our in vivo studies and represents a more physiological 
dosage of glucocorticoid at which mineralocorticoid actions are 
less likely.
The possible relevance of altered vascular reactivty to the 
pathogenesis of glucocorticoid hypertension has been raised by 
the observation that the enhanced pressor response to nor­
adrenaline precedes the development of hypertension in DEX 
treated rats (Handa et al.1984). However, it is unclear whether 
the degree to which glucocorticoids can enhance pressor 
responsiveness in human studies could be relevant to the 
pathogenesis of hypertension (Whitworth et al. 1986) Pressor 
response in steroid induced hypertension in man).
Several mechanisms have been proposed to account for the 
glucocorticoid mediated changes in vascular reactivity. Handa 
and colleagues (1984) showed that indomethacin administration 
could block the glucocorticoid associated change in pressor 
responsiveness raising the possibility that altered prosta­
glandin synthesis could be relevant. Supported by the previous 
observation that alteration of prostaglandins (specifically, 
noradrenaline-mediated stimulation of PGE2) reduces vascular
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reactivity (Malik, Ryan & McGiff 1976; Armstrong, Thirsk, Biol & 
Salmon 1979; Lippton, Chapnick, Hyman, Kadowitz 1979; Jackson 
& Campbell 1980) the action of glucocorticoids to inhibit 
prostaglandin synthesis (vide supra) has been implicated in the 
mechanism by which glucocorticoids alter vascular reactivity. 
Despite the observation that PGI2 administration abolishes the 
increase in hind limb vascular reactivity to noradrenaline 
produced by corticosterone in the rat (Rascher, Dietz, Schomig, 
Burkart & Gross 1980) the studies of lijima & Malik (1985) cast 
doubt on a significant contribution of altered prostaglandin 
levels to the enhancement of the vasoconstrictor response to 
AVP; lijima & Malik (1985) demonstrated that dexamethasone 
attenuated the rises of prostaglandins (6ketoPGF1 alpha & PGE2) 
in response to noradrenaline, AVP and All but were able to show 
altered vascular reactivity only to AVP.
Kalsner (1969) proposed alternatively the glucocorticoid effect 
was mediated by inhibtion of catecholamine hydrolysis (by 
COMT). Other possble mechanisms could account for the 
glucocorticoid-mediated change in vascular reactivity including 
structural change in vessel wall (although this seems unlikely 
given that changes occur as early as 15min. after exposure to 
glucocorticoid (Kalsner 1969)), electrolyte changes, alteration 
of the Na/K pump and altered membrane permeability. In 
chapters 6 & 7 the possible role for glucocorticoid mediated 
changes in G-proteins in altered vascular responsiveness and in 
glucocorticoid hypertension will be studied in detail.
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6.2. Introduction to chapter 6 
Glucocorticoids and experimental hypertension:
The elucidation of the possible physiological role of gluco­
corticoids in regulating G-protein function or levels has been 
hampered by the lack of a de fin itive  model in which gluco­
corticoid effects can be exclusively and specifically studied in  
vivo. However, two approaches have been adopted to address this 
problem. The effects of glucocorticoids have been inferred from 
studies of adrenalectomy (vide infra), followed by glucocort­
icoid replacement. In addition, a number of glucocorticoids have 
been administered to otherwise normal rats with successful 
induction of hypertension; these include cortisone (Knowlton & 
Loeb 1957), corticosterone (Haack et al.1977), methylpred- 
nisolone (Krakoff, Selvadurai & Sutter 1975) and dexamethasone 
(Suzuki et al.1982). Irrespective of the glucocorticoid used 
however, there is a risk that the resulting elevation of blood 
pressure could result, not from the direct action of the gluco­
corticoid but from ancillary mineralocorticoid properties 
(sodium and fluid retention with expansion of ECV and body 
weight gain); the potency of these non-glucocorticoid effects 
varies among the glucocorticoids and with the dosage used but 
may be prominent given the common practice to administer very 
high, 'supra-pharmacologicaP doses of these glucocorticoids.
The preferred model depends on glucocorticoid administration to 
animals with intact adrenal glands. Only one previous study has 
examined the effects of in vivo glucocorticoid on G-protein 
levels in a particular tissue; Saito et al. (1989) showed that 
100mg corticosterone (the predominant glucocorticoid in rats)
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administered subcutaneously over 7d (to Sprague Dawley rats) 
resulted in 40% elevation of Gsa and 15% reduction of Gia (with 
similar changes in the corresponding mRNAs) in brain which 
raises the possibility of a role for glucocorticoids in G-protein 
regulation. Corticosterone, however, is not the ideal glucocort­
icoid for elucidating mechanisms of glucocorticoid hypertension 
as it exhibits weak sodium retaining properties; this mineralo- 
corticoid action probably accounts for the plasma and extra­
cellular fluid volume expansion (with renin suppression) and fall 
in plasma potassium which accompanies high dose cortico­
sterone administration (for example, 10mg/ rat /day) (Haack et 
al. 1977).
Full details of the model used for the following in vivo studies 
of glucocorticoid hypertension have been previously described 
(Tonolo et al. 1988). This model allows assessment of the in  
vivo effects of relatively low doses of exogenous gluco­
corticoids (likely to be high physiological/ low pharmacological 
doses) administered to animals with intact adrenal glands; 
briefly, it is based on the administration (by mini-osmotic 
pump-see methods) to rats of dexamethasone, a gluco-corticoid 
with minimal mineralocorticoid receptor activty (Bia et al.
1982). Dexamethasone causes a dose related rise in blood 
pressure with failure of weight gain (the change in body weight 
correlates inversely with dexamethasone dosage). At the dosage 
of dexamethasone used in this study (5pg/day), a 20mmHg 
increment in SBP and body weight gain of around 40% (v 100% 
control) would be anticipated, without significant mineralo­
corticoid effects as reflected in plasma renin, aldosterone,
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sodium and potassium (none of which is altered) (Tonolo et al. 
1988). 5pg/day dexamethasone represents a substantially lower 
dose of glucocorticoid than previously used (doses of up to 375x 
greater have been given (reviewed by Tonolo et al. 1988)) and 
yet results in hypertension with minimal effective weight loss 
(actually failure to gain weight to the extent of untreated rats). 
A theoretical concern is that the substantial weight loss and the 
underlying catabolic state which accompany higher doses could 
potentia lly  have adverse effects on plasma membrane function 
and composition and thus could possibly cause artifactual 
changes in G-protein expression and/or function.
The purpose of this study was to assess whether 
induction of glucocorticoid hypertension (using nearer 
physiological concentrations of the glucocorticoid, 
dexamethasone, in vivo) was associated with evidence 
of either altered G-protein function or levels in a 
number of organs implicated in the control of blood 
pressure.
6.3. Materials and Methods
Three groups of adult male 180g Sprague Dawley rats were 
studied (each group consisted of 6 treated & 6 control rats). 
Dexamethasone (Decadron, Merck, Sharp and Dohme, Hoddesden, 
Hertfordshire, UK) was administered in 0.154 mol/l NaCI through 
mini-osmotic pumps (Alzet Model 2002, Palo Alto, California, 
USA) which were implanted subcutaneously. The pumps released 
5pg/d DEX over 14d (verified by previous studies (Tonolo et al. 
1988) Control rats received vehicle alone.
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Body weight and mean systolic BP were recorded. BP was 
measured in triplicate in warmed, unrestrained conscious rats 
by the tail cuff method (McAreavey et al. 1985) using a W & W 
Electronics recorder (Basle, Switzerland)(see table 15).
Table 15. Details of one (of three) group of Sprague- 
Dawley rats studied-showing effects of 
dexamethasone 5jig/d for 14d.
CON DEX
n 6 6
INITIAL WT. (g) 186 ± 4 186 ± 4
WT. GAIN (g) 6.5 ± 0.2 3.1 ± 0 .3 * *
FINAL BP (mmHg) 147 + 4 175 ± 5 * *
GLUCOSE (mmol/l) 3.4 ± 0.2 3.1 ± 0.2
total organ mass
HEART (g) 5 . 5 3 5 . 1 6
KIDNEY (g) 5 . 9 8 5 . 2 9
BRAIN (g) 9 . 6 5 1 0 . 5 6
(mean ± sem) **p < o o o o i
After 14d DEX the animals were sacrificed by cervical 
dislocation-heparinised blood was collected for glucose 
estimation (2.9.)(table 15). Brains, hearts, kidneys and 
mesenteric vascular beds were recovered on ice and plasma 
membrane homogenates were prepared as described (sections 
2.3.4., 2.3.3., 2.3.5. & 2.3.6.). G-protein function was assessed
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indirectly by studies of ACA (section 2.8., mix A).
G-protein levels by Western blotting (2.4.1.) using the antibodies 
listed in table 4 (with exception of antiserum against Gi3, as 
exploratory blots had failed to identify this G-protein in any of 
the membrane preparations studied).
Protein concentrations within the plasma membrane homo- 
genates were measured by the modified Lowry protocol (section
2.6.) and 5' nucleotidase activity was assessed within the 
various membrane fractions as a limited marker of altered 
membrane composition (section 2.7.)(see table 16).
T ab le :16 . 5' Nucleotidase activities of tissues
obtained from SD rats treated in vivo with 
DEX 5pg/d for 14d.
MEMBRANE PREP. CON DEX
BRAIN 4 5 . 6 3 9 . 8
LIVER 1 6 4 . 4 199. 1
MYOCARDIUM 5 6 6 . 8 4 7 3 . 9
RENAL CORTEX 4 6 2 . 1 4 6 5 . 5
6.4. Results:
Immunoblotting data (with typical blots) for the various G- 
protein subunits identified in the plasma membrane preparations 
studied are shown if figs. 20 (brain), 21 (myocardium), 22 (renal
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cortex) and 23 (liver). No significant differences in G-protein 
levels were seen in any of these blots of membranes derived 
from 4 organs; DEX treated B subunits were studied only in 
myocardial plasma membranes and were shown to be slightly 
reduced (CPM: 722 ± 35 v 940 ± 40 (control) n=4 exp.). Western 
blot data for mesenteric vasculature are shown in table 17.
Table 17: Levels of G-protein subunits (determined
from cpm, expressed as mean ± sem of data) 
in mesenteric vasculature from DEX-treated 
and control rats.
G-PROTEIN
S U B U N IT
CON DEX NO. EXP.
Gs 42 kDa 1652 ± 23 1573 ± 33 6
Gs 40 kDa 834 ± 68 816 ± 54 6
G i2 565 ± 35 671 ± 44 4
Adenylyl cyclase data are available from renal cortical plasma 
membranes (fig. 24) and from myocardial and mesenteric plasma 
membranes (table 18).
6.5. Discussion
The experimental model of glucocorticoid hypertension respond­
ed to 5pg/d DEX infusion (s.c.) in a predictable, reproducible 
manner (Tonolo et al. 1988): tail-cuff BP increased by 30mmHg- 
representing an increase of around 25% with minimal 
compromise of weight gain (table 15). Blood glucose conc­
entration was unaffected by DEX exposure.
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F ig .24. Adenylyl cyclase activities in plasma mem­
branes derived from renal cortex of DEX (5jig/d 
for 14d) treated rats (STIPPLED BARS) and 
control (SOLID BARS). Data expressed as 
absolute cyclase activities, mean ± sem of 3 
experiments each wih 4 replicates. Assay 
conditions and ligands studied are indicated 
along abscissa.
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Table 18: Adenylyl cyclase activities in plasma
membranes derived from myocardium and 
from mesenteric vasculature. ACA 
represented as pmoi cAMP/mg/10 min., mean 
+ sem of 3 exp. (each with 4 replicates).
MYOCARDIUM
LIGAND CON DEX
BASAL 412.5 ± 67.2 367.4 ± 16.3
MnCI2 433.6 ± 54.8 394.7 ± 36.4
NaF 1317.3 ± 172.8 1121.4 ± 126.1
FORSKOLIN 6177.6 ± 387.5 5879.5 ± 276.4
ISOPROTERENOL 1158.1 ± 136.4 987 ± 136.3
MESENTERY
LIGAND CON DEX
BASAL 610.4 ± 61.8 604.7 ± 65.4
FORSKOLIN 3158.4 ± 97.5 2986.5 ± 110.6
ISOPROTERENOL 1107.8 ± 78.8 985.6 ± 80.7
Myocardial weight was reduced v CON suggesting that myo­
cardial hypertrophy had not developed during the period of study.
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Immunoblotting studies for G-protein subunits failed to identify 
any relevant changes in brain, myocardium, renal cortex, liver 
and mesenteric vasculature (figs. 20-23, table 17). These organs 
were studied as they represent the organs with roles in BP 
regulation; liver was included because of its central role in 
metabolism. None of the membrane preparations is a highly 
purified preparation; the myocardial, renal cortical and hepatic 
preps, were partially purified by differential centrifugation, 
while the preparations derived from brain and mesentery are 
likely to be even less purified. It is possible that the relative 
impurity of the membranes studied, perhaps by including either 
relativley small amounts of plasma membrane or by including 
plasma membrane fragments derived from other (contaminating) 
cell types could have reduced the specificity of the assays. Only 
slight differences were seen in 5'ND activities (measured only 
once per membrane prep.) and there was no overall trend in 
activities amongst the four tissues in which this was measured 
(table 16) excluding an artifactual contribution to our results 
from glucocorticoid mediated changes in plasma membrane 
content of our study samples.
ACA studies in renal cortical, myocardial and mesenteric plasma 
membranes showed that DEX did not affect enzyme activity.
The current results show important differences from those of 
previous workers. Only one previous study has examined the 
effects of in vivo glucocorticoid on G-protein levels in a 
particular tissue, in animals which have not been adrenal- 
ectomised; Saito et al. (1989) showed that 100mg cortico-
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sterone (the predominant glucocorticoid in rats) administered 
subcutaneously over 7d (to Sprague Dawley rats) resulted in 40% 
elevation of Gsa and 15% reduction of Gia (this latter change 
was not apparently statistically significant)(with sim ilar 
changes in the corresponding mRNAs) in brain which raises the 
possibility of a role for glucocorticoids in G-protein regulation. 
Corticosterone, how-ever, is not the ideal glucocorticoid for 
elucidating mechanisms of glucocorticoid hypertension as it 
exhibits weak sodium retaining properties; this mineralo- 
corticoid action probably accounts for the plasma and extra­
cellular fluid volume expansion (with renin suppression) and fall 
in plasma potassium which accompanies high dose cortico­
sterone administration (for example, 10mg/ rat /day) (Haack et 
al. 1977).
The bulk of studies assessing the effect of glucocorticoids have 
been in animals previously subjected to adrenalectomy. The 
reported effects of adrenalectom y on G-proteins are 
summarised in table 19.
Clearly adrenalectomy effects changes in G-protein subunits 
which vary depending on the particular subunit and on the tissue 
studied.
Glucocorticoid administration to adrenalectomised rats 
generally restores G-protein levels to those of the intact 
animal (Saito, Guitart, Hayward et al. 1989; Haigh, Jones & 
Milligan 1990). However, it does appear that DEX exerts 
differential effects on G-protein subunit expression and may
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control other processes which modulate G-protein levels. Ros 
and colleagues (1989) showed that 4d DEX at a dose of 0.4mg/d 
restored levels
Table 19: Effect of adrenalectomy on levels of G-
protein subunits in vivo.
TISSUE G s a G i a G o a B REFERENCE
ADIPOSE 4r' V De Mazancourt 
et al. '89
ADIPOSE Ros et al. '89
BRAIN t 4 Salto et al. '89
LIVER f r Garcla-Salnz et 
al. '89
AORTA ^ 3 4 ^ - > 3 - * 3 Haigh et al. '90
Note:
Method of assessment of G-proteins
1. Pertussis toxin-ADP ribosylation of 40-41 kDa substrate= Gi + 
Go.
2. Western Blots with specific antisera
3. Cholera toxin-ADP ribosylation
4. Based on mRNA studies
of Gs in adipose tissue from . adrenalectomised rats to those of 
the intact animal without apparent change in Gsa mRNA, while B 
subunit levels were increased to final levels some 30% higher 
than in the intact animal in parallel with alterations of mRNA. 
Haigh et al. (1990) showed that DEX administration to adrenal­
ectomised animals in vivo essentially restored Gsa (which had
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been increased 210% by adrenalectomy) and Gia (53% reduction 
with adrenalectomy) to control levels: B subunit was reported to 
be increased by DEX (levels unaltered by adrenalectomy). How­
ever, in Haigh's study doses of DEX 20x those used here were 
administered to the animals. Haigh reported that although 
adrenalectomy did not alter B subunit levels in aorta, DEX 
increased the amount of this subunit by 90%. Their assessment 
was made on the basis of densitometric assessment of blots 
rather than direct counting of radiolabelled second antibody; 
furthermore in our hands antibody raised against B subunit 
invariably produced the poorest blots of all those prepared- 
probably due to low concentrations of this subunit in all preps, 
(despite generally using 4-5x more protein per blot) that 
confirmation of this finding by other groups is required. B 
subunit was only assessed in myocardium from our hypertensive 
rats and was shown to be lower, if anything (CPM: DEX-722 ± 35 
v CON-940 ± 40) in the DEX treated group.
Adrenalectomy is, however, associated with multiple endocrine 
and metabolic effects; these include glucocorticoid, mineralo- 
corticoid and catecholamine deficiencies. Although death from 
mineralocorticoid insufficiency can be prevented by main­
tenance on exogenous saline, experimental adrenalectomy is 
nonetheless associated with numerous metabolic derangements 
which could at least in theory contribute to changes in G- 
proteins. The potential influence of such confounding factors 
(which may stem not from glucocorticoid deficiency but from 
loss of catecholamines or of the mutual interaction between 
catechol-amines and glucocorticoids) are highlighted by a brief
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review of the effects of adrenalectomy on the adrenergic- 
adenylyl cyclase system. Adrenalectomy is associated with 
pleotropic effects on the B receptors (depending on the tissue 
studied; B receptor number may be increased in liver (Guellaen, 
Yates-Aggerbeck, Vauquelin, Strosberg & Hanoune 1978), 
decreased in lungs (Mano, Akbarzadeh & Townley 1979) and fat 
or unaltered in myocardium (Davies, DeLean & Lefkowitz 1981). 
cAMP accumulation or ACA associated with catecholamines may 
be reduced (myocardium (Davies et al. 1981; Phorchirasilp & 
Melangkasombut 1982) adipose tissue (Allen & Beck 1972; Exton, 
Friedman, Hee-Aik et al.1972; Lamberts, Timmenmans, 
Krammer-Blankestijn & Birkenhager 1975) or increased (liver 
(Chan, Blackmore, Steiner & Exton 1979; Exton et al.1972; 
Bitensky et al. 1970; Leray, Chambaut, Perrenoud & Hanoune 
1973) and brain (Mobley & Suler1980; Roberts & Bloom 1981). 
The physiological relevance of the subsequent administration of 
'suprapharmacologicaP doses of glucocorticoids to such a 
system is debatable as major catabolic effects including 
negative sodium balance and weight loss (due to muscle and fat 
catabolism)(Haack et al. 1977; Handa et al. 1984) are inevitable 
at these high doses. The obvious clinical correlate of this model 
(which in practice bears little similarity) is the patient with 
Addison's disease in whom adrenal medullary function is 
preserved and for whom glucocorticoid replacement doses are 
restricted to 'near physiological' levels.
On the basis of adrenalectomy studies it is possible to conclude 
that glucocorticoids may have a role in regulating G-proten 
levels- but given the limitations of the model it would be
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difficult to conclude that this amounts to anything more than a 
permissive role.
The current studies of ACA failed to reveal any differences in 
ACA responses in renal cortical (fig. 24), myocardial and 
mesenteric plasma membranes (table 19). This contrasts with 
the in vitro work which will be reviewed in chapter 7, and 
suggests that neither changes in G-protein function nor AC 
catalytic unit are implicated in the pathogenesis of 
glucocorticoid hypertension.
In conclusion, induction of hypertension in the rat, with 
dexamethasone concentrations which are nearer physiological 
glucocorticoid levels than used generally, is not associated with 
alterations in G-protein subunit levels (those which can 
currently be identified) nor G-protein function. Furthermore, no 
evidence of altered ACA in renal cortical, myocardial, nor 
mesenteric plasma membranes was found.
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Chapter 7
Glucocorticoid hypertension: 
effect of dexamethasone on G-protein 
levels and function in VSMC.
7.1. Introduction
Glucocorticoids and adenylyl cyclase activity:
Dexamethasone (DEX) administration in vitro has been shown to 
increase adenylyl cyclase activity in vascular smooth muscle 
cells (VSMC)(from renal arteries)(Yasunari, Kohno, Balmforth et 
al.1989) and non-vascular cell lines including 132N1 astracyt- 
oma cells (Foster & Perkins 1977), cultured NRK fibroblasts 
(Johnson & Jaworski 1983), osteoblast cell line ROS 17/2.8 
(Rizzoli, von-Tscharner & Fleisch1986, Rodan & Rodan 1986) and 
GH3 pituitary tumour cells (Chang & Bourne 1987). As will be 
discussed later, glucocorticoids can potentially modulate the 
adenylyl cyclase-second messenger pathway at several levels: 
there is increasing evidence that glucocorticoids can alter G- 
protein levels in vitro , in GH3 (rat pituitary cell line)(Chang & 
Bourne 1987) and the ROS 17/2.8 cells (Rodan & Rodan 1986). In 
both systems glucocorticoids (DEX 150nM for 3d or 30 nM for 4d) 
caused similar changes in Gs; cholera toxin substrate (Gs) was 
increased (40-70%). Contrasting effects of DEX on pertussis 
toxin substrate were reported (no change (Chang & Bourne 1987) 
and 20-50% increase (Rodan & Rodan 1986). In the former 
system corresponding changes were seen in G-protein mRNA 
species. Furthermore concurrent enhancement of ACA was 
observed (vide infra) although as discussed later altered G- 
proteins may not be the sole explanation for these changes. The
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ability of cycloheximide to prevent changes in G-protein mRNA 
species (Chang & Bourne 1987) suggests that the glucocorticoid 
effect on G-proteins is mediated through altered protein 
synthesis.
The purpose of this study is to reassess the effects of 
glucocorticoids on cultured VSMC in vitro (these cells 
are representative of those from arteriolar resistance 
vessels) and to ascertain whether AC changes are 
associated with alterations in G-protein levels.
7.2. Materials and Methods
VSMC were isolated from the mesenteric vascular bed of 300- 
350g Spargue Dawley rats and cultured as described in section
2.4. Cells were subcultured as required up to 7th passage and 
were used for experiemnts when confluent. After exposure of 
cells to 10nM DEX or vehicle for 24-48h, plasma membrane 
homogenates were prepared as described (section 2.3.6.). A 
similar experiment was conducted after 48h pretreatment with 
anticortisol antibody (kindly donated by SAPU, Law Hosptial, 
Carluke) to ascertain whether the ambient glucocorticoid 
concentration within the culture medium (foetal calf serum) 
might tend to reduce the apparent effect of exogenous gluco- 
cortiocid exposure.
G-protein function was assessed indirectly by studies of ACA 
(section 2.8.1, mix A). ACA was studied under basal conditions 
and in the presence of MnCI2 (20mM), NaF (10mM), PGE1 (10-5M), 
Isoproterenol (10-4M), forskolin (10-5 M) and forskolin/GppNHp
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(0.1 nM). Experiments were conducted both in the presence of, and 
without IBMX (10mM).
G-protein levels were measured by Western blotting (2.4.1.) 
using the antibodies listed in table 4 (with exception of antisera 
against Gi1 and Go), as exploratory blots had failed to identify 
these G-proteins in the membrane preparations studied).
Protein concentrations within the plasma membrane homo- 
genates were measured by the modified Lowry protocol (section
2.6.) and 5' nucleotidase activity was assessed (section 2.7.) 
within the various membrane fractions as a limited marker of 
altered membrane composition.
7.3. Results
Adenylyl cyclase activitites are shown in fig. 25. Exposure of 
VSMC to 10nM DEX for 24h was associated with significantly 
greater ACA, under basal conditions and in the presence of PGE1, 
isoproterenol and forskolin; the trend for DEX treated cells to 
exhibit higher ACA was also seen in the presence of MnCI2 and 
NaF, although the differences did not achieve statistical 
significance. Similar cyclase results were obtained after DEX 
exposure for 48h. Inclusion of anticortisol antibody for 48h 
prior to DEX exposure made little difference to the differential 
in cyclase activities between DEX and control membranes. In 
addition, although AC activities were slightly increased in both 
control and DEX treated cells, no difference was observed in the 
net effect of DEX (i.e. DEX exposure was still associated with
195
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higher enzyme activities ) on ACA when the cAMP phospho­
diesterase inhibitor, IBMX,was included.
Data obtained from the Western blot studies are shown in figs. 
26-28.
5' nucleotidase activitites were identical (0.84 Shinowara 
Units) in DEX treated and control cells.
7.4. Discussion
10nM DEX for 24h (and 48h) caused an increase in ACA (fig. 25) 
under basal conditions and irrespective of ligand added to the 
assay mix. Basal ACA was increased about 50%. The inclusion of 
20mM MnCI2 did not eliminate the difference in cyclase 
activities between treated and control cells (although the 
difference was not statistically significant, it is likely to be 
relevant) suggesting that the major difference between DEX 
treated and control cells may relate to activity or levels of AC 
catalytic unit. The differences persist and are independent of 
ligand mediated stimulation of catalytic unit via Gs (by iso­
proterenol and PGE1) and of direct, Gi mediated inhibition of 
catalytic unit by GppNHp (0.1 nM), lending support to the 
suggestion that catalytic unit is altered rather than the G- 
proteins which modulate the activity of catalytic unit.
These results are consistent with those previously reported in 
DEX treated vascular smooth muscle cells (VSMC)(from renal 
arteries) (Yasunari et al. 1989) and non-vascular cell lines 
including 132N1 astracytoma cells (Foster & Perkins 1977),
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cultured NRK fibroblasts (Johnson & Jaworski 1983), osteoblast 
cell line ROS 17/2.8 (Rizzoli et al. 1986, Rodan & Rodan 1986) 
and GH3 pituitary tumour cells (Chang & Bourne 1987). These 
previous studies have shown distinct changes over a wide range 
of concentrations of DEX (from 1nM to 1 pM), with exposure for 
between 48h and 6d. However, the time course of the effect of 
DEX on ACA has previously been studied in detail; changes have 
been reported as early as 6h, reaching a maximum at 24h 
without further increase up to 72h in VSMC (Yasunari et al.
1989). In the current studies, little change in ACA was noted 
when comparing ACA at 48h v 24h, and the longer period of 
exposure to DEX did not alter the net effect attributable to DEX 
its e lf .
DEX increased basal ACA by about 50% in cultured VSMC.
Previous studies have shown DEX to enhance cyclase activity to 
a widely differing extent in different in vitro systems; basal 
ACA has been enhanced between 17% (Rizzoli et al. 1986) and 
200% (Yasunari et al. 1989). In addition, consistent with our 
results, DEX has been observed to enhance ACA responses to a 
number of stimulatory agents including guanine nucleotides, 
forskolin, NaF, isoproterenol, dopamine and PTH; increases of 
between 50% (Rizzoli et al. 1986) and 600% (Foster and Perkins 
1977) have been seen. Virtually all studies have shown a 
uniform stimulation of ACA by DEX virtually irrespective of the 
ligand studied but exceptions have been reported: Foster & 
Perkins (1977) observed that DEX enhanced PGE1 stimulation of 
ACA without enhancement of isoproterenol action and Johnson &
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Jaworski (1983) showed that DEX reduced NaF stimulated ACA 
without alteration of baal activity.
Enhancement of ACA by DEX has been reported irrespective of 
whether ACA was assayed in membrane homogenates (Chang & 
Bourne 1987; Rodan & Rodan 1986; Rizzoli et al. 1986) or in 
whole cells (Yasunari et al. 1989; Foster & Perkins 1977; Rodan 
& Rodan 1986) and whether assessment was based on measure­
ment of ACA (Chang & Bourne 1987; Rodan & Rodan 1986; Rizzoli 
et al. 1986; Yasunari et al 1989; Foster & Perkins 1977) or cAMP 
content (Johnson & Jaworski 1983; Rizzoli et al. 1986).
The inclusion of a phosphodiesterase inhibitor in the assay mix 
was not a prerequisite for demonstrating the effect of DEX; 
inclusion of IBMX made no difference to the net effect of DEX on 
ACA. However, previous workers have shown that the changes 
were abolished by administration of inhibitors of protein 
synthesis such as cycloheximide (Yasunari et al. 1989; Foster & 
Perkins 1977).
Other factors which may influence the increment of ACA 
observed following DEX exposure in vitro include the time of 
study after passage of the cells; Foster & Perkins (1977) 
demonstrated that PGE1 stimulated ACA was 2 fold greater on 
day 1, 6 fold greater on day 3 and 2 fold greater on day 8. All 
cells used in our studies were studied at either 7th or 8th 
passage, and DEX and control cells were grown concurrently. 
Membrane preparations from DEX treated and control cells were 
also prepared concurrently.
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Dexamethasone is the glucocorticoid which has been studied 
most widely: the bulk of studies report use of dexamethasone in 
'juprapharmacological doses' of around 10_7M (Foster &
Perkins 1977; Johnson & Jaworski 1983; Rizzoli et al. 1986; 
Chang & Bourne 1987). Yasunari (Yasunari et al. 1989) used 
concentrations of dexamethasone up to 10"6m  while Rodan & 
Rodan (1986) used 30nM dexamethasone in their culture medium 
to attain 'physiological levels' of steroid. 10nM DEX was used in 
the current studies. Inclusion of anticortisol antibody for 48h 
prior to DEX exposure made no difference to the obtained ACA 
suggesting that the glucocorticoid present within the FCS did 
not tend to have a major action in reducing the apparent effect 
of exogenous glucocorticoid.
The interpretation of these data is complex. The results are 
compatible with possible alteration of AC catalytic unit and 
this conclusion is in agreement with two previous groups of 
workers (Rizzoli et al. 1986, Chang & Bourne 1987). However, 
this explanation is not universally accepted (Johnson & Jaworski 
1983). The changes may be independent of Gs (at least in osteo­
blast cell line ROS 17/2.8- as suggested by a reconstitution 
assay) (Rizzoli et al. 1986) but two groups have implicated 
glucocorticoid mediated increased in Gs to the enhanced ACA 
(Rodan & Rodan 1986; Chang & Bourne 1987).
The studies identified Gsa, Gi2a, Gi3a and 13 subunits in 
membranes derived from VSMC (figs 26-28). Western blotting 
for these subunits excluded a role for DEX mediated alteration of 
the levels of G-protein subunits in the cyclase changes (fig. 25).
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In addition to the data shown, no differences were seen in the 
amount of (3 subunit present.
In addition to the multiple possible sites in the AC system at 
which DEX might exert its effects, glucocorticoids are known to 
exhibit a number of other influences on cAMP and its subsequent 
actions. Although it is clear that the effects of DEX discussed 
previously are not a consequence of enhanced cAMP phospho­
diesterase (PDE) activity, previous workers have shown that 
high concentrations of glucocorticoids (specifically cortisol at 
concentrations of > 2 pM) can inhibit (testicular and beef heart) 
cAMP PDE (Schmidtke, Wienker, Flugel & Engel 1976)
(Manganiello & Vaughan 1973; Chen & Feldman 1978). Gluco­
corticoids have also been shown to induce cAMP dependent 
kinase activity (Lamberts, Timmermans, Krammer-Blankestijn 
1975). Whatever the ultimate fate of cAMP generated in DEX 
treated cells these studies support an effect of DEX on 
increasing levels and/or activity of AC cataytic unit. Other 
factors may have contributed to the observed changes in ACA; 
gluco-corticoids have previously been shown to increase 6 
receptor numbers in human neutrophils (Davies & Lefkowitz 
1980), in rat lung (Mano et al. 1979) and in cultured human lung 
cells (Fraser & Venter 1980). In addition, glucocorticoid 
mediated alteration of G-protein coupling to receptors (without 
necessarily affecting levels of G-protein subunits)(Davies & 
Lefkowitz 1984; Haigh & Jones 1990) has previously been 
reported but the current AC studies suggest that neither of 
these mechansims is particularly prominent in our experimental 
system. As cAMP mediates vasodilatation, it is unlikely that the
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current observation in vitro is of relevance to the pathogenesis 
of glucocorticoid hypertension.
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Chapter 8
Conclusions
G-proteins are transmembrane signal transducers which couple 
receptors to effector mechansims. They are ubiquitous in human 
and animal tissues, and are located in the plasma membranes of 
cells. The current studies, based on Western (immuno-)blotting 
have identified a number of G-protein subunits (table 5) within 
plasma membranes derived from human platelets, and from a 
number of animal tissues including myocardium, renal cortex, 
liver, brain and mesenteric arterioles.
Table 5: G-proteins expressed in membrane preparations
MEMBRANE PREP. G s a G i a 1 G i a 2 G i a 3 G o a B
PLATELET * • • •
MYOCARDIUM •  • •
RENAL CORTEX • •  •  • •
LIVER
BRAIN •  •
VSMC/MESENTERY • •  • •
All membrane preparations studied were derived from rat species except 
platelet*-from humans.
In addition to immunoblotting studies to identify the presence 
of specific G-protein subunits, the function of G\2a and Gsa 
subunits which mediate inhibition and stimulation of adenylyl 
cyclase was assessed.
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G-protein abnormalities have previously been demonstrated both 
in human disease (pseudohypoparathyroidism and in some GH 
secreting adenomas causing acromegaly) and in experimental 
animal models of disease, for example STZ-IDDM and obesity. 
Houslay's group have shown that chemically induced IDDM in the 
rat is associated with altered G-protein expression and function 
(table 3) (Gawler et al. 1987; Bushfield et al. 1990a; Bushfield 
et al.1990b; Srassheim et al.1990). The alterations are tissue 
specific, do not invariably reflect altered expression and are 
selective for particular G-protein a subunits. Hepatocytes from 
STZ-IDDM manifest insulin resistance and enhanced ability of 
glucagon to stimulate AC (Gawler et al. 1987; Bushfield et al.
1990) and have been shown to exhibit loss of tonic inhibition of 
AC by Gi and attenuation of receptor mediated inhibition (via 
Gi)(GawIer et al.1987; Bushfield et al. 1990); Gi levels are also 
reduced (Gawler et al.1987). These alterations of G-protein 
levels and function are reversible with insulin administration. 
Similar changes of Gi function may be seen in hepatocytes from 
the Zucker rat, a model of obesity which also features insulin 
resistance raising the possibility that abnormalities of G- 
proteins may be implicated in diseases characterised by insulin 
resistance. Insulin resistance and hyperinsulinaemia are 
features of some human diseases including obesity (Olefsky, 
Kolterman & Scarlett 1982), NIDDM (DeFronzo & Ferrannini 
1982) and essential hypertension (Ferrannini et al.1987) and 
studies were performed in platelets from human NIDDM and 
essential hypertensives to ascertain whether G-protein 
abnormalities might be present and lend support to the concept 
of a common pathophysiology (by virtue of insulin availability
determining G-protein function). Platelets represent a homo­
geneous tissue from which purified plasma membranes can be 
readily prepared and exhibit abnormalities of function both in 
NIDDM and EH.
In the study of platelets from NIDDM, significant reductions in 
the levels of Gsa and Gj2a were observed in NIDDM compared to 
controls. This result was similar to previous findings in 
hepatocyte membranes from the STZ-IDDM (Gawler et al. 1987; 
Bushfieldet al. 1990) although contrast with those in adipocytes 
where Gi3 has previously been shown to be increased (Strass- 
heim et al.1990) and with a number of other vascular and non- 
vascular tissues where no changes in G-protein transcripts have 
been identified (see section 3.3.1). The observed reduction of G- 
protein levels in human platelets from NIDDM and hepatocytes 
from STZ-DM are consistent with the possibility that insulin 
may have a role in the regulation of G-proteins: despite elevated 
plasma levels of insulin in NIDDM, there will be a net intra­
cellular deficiency of insulin, while STZ-DM is characterised by 
insulopenia due to pancreatic destruction. This hypothesis is 
supported indirectly by several correlations (table 8). Levels of 
Gia2, Gia3 and Gsa have all been shown to correlate inversely 
with fasting blood glucose concentration.
No evidence of altered function of Gia2 was seen in our diabetic 
platelets on the basis of studies with GppNHp which effect AC 
inhibition directly via Gi and with adrenaline (in conjunction 
with propranolol) which binds to the a2 receptors which are 
coupled to AC catalytic unit via Gi. The study of GppNHp was
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limited by the small numbers studied (n=6 CON, n=6 NIDDM).
When forskolin and PGE1 responses were expressed as 'fold 
stimulation' over 'basal' cyclase, the NIDDM platelets exhibited 
significantly lower cyclase activities which may reflect altered 
amounts of AC catalytic unit and/or reduction in net Gsa effect. 
Reduced Gsa effect could be due to reduction in Gsa levels or 
possib ly alteration in Gia2: Gs ratio. Either possibility is 
consistent with the immunoblotting studies.
The possibility exists that reduced intracellular insulin 
concentrations consequent upon insulin resistance which is 
common to hepatocytes from STZ-DM (Bushfield et al. 1990b) 
and to human NIDDM may contribute to the altered levels of G- 
proteins seen in this study. It would be useful to extend the 
current study to include a group of newly presenting IDDM to 
assess the effects of insulin deficiency in human subjects on G- 
protein levels and function.
The study in human EH is based on the strong epidemiological 
and clinical links between NIDDM and EH, and the increasing 
evidence of at least some overlap in pathophysiology on the 
basis of insulin resistance (Ferrannini et al. 1987). Given the 
abnormalities of G-proteins demonstrated in NIDDM, platelets 
from EH (which also exhibit functional abnormalities) were 
subjected to similar assessment of G-protein levels and 
function. However, no changes in levels of G-proteins were seen 
and in contrast to the observations in NIDDM, the studies of AC 
function identified greater PGE1 stimulated AC activites in 
hyper-tensive platelet membranes than controls (p=0.018). This
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is consistent with the findings of previous workers and may 
have its physiological basis in protection of cells against Ca2+ 
overload (Resink et al. 1986).
Overall, no major changes were found in G-protein levels in 
essential hypertension, in contrast to the results obtained in our 
group of NIDDM The data argue against alteration of G-proteins 
in hypertension by virtue of hyperinsulinaemia, but further study 
would be desirable in metabolically active tissues such as fat or 
live r.
However, an interesting, if weak correlation was noted between 
plasma cholesterol concentration and relative amounts of Gia2 
(z=-2.084, n=29, p=0.04) when considering all EH and control 
subjects together; this observation will be investigated further 
in a formal study of G-protein levels in hyperlipidaemic 
conditions.
In chapter 5, one of the most widely used models of genetic 
hypertension- the spontaneously hypertensive rat (SHR) was 
studied. This model is particularly useful as it has many 
features in common with human EH including glucose intoler­
ance/ insulin resistance. This experimental model of hyper­
tension was used in order to study G-protein changes in 
myocardium (tissue which is not available from human subjects) 
as there is substantial evidence of abnormalities of AC 
activation (reduced B adrenergic activation of adenylyl cyclase 
has been widely reported). Differences in ACA were seen in SHR
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myocardium compared to WKY, but not Wistar control species. 
These changes are characterised essentially by relatively 
reduced stimulation of AC by agents that act on Gs or ligands 
whose receptors couple to AC via Gs. However, identical changes 
are seen in Wistar membranes. Alterations in the receptors per 
se cannot be excluded but concurrent reductions of responses to 
NaF and forskolin suggest that catalytic unit and/ or Gs or their 
mutual coupling may be abnormal. No differences in amounts of 
Gi or Gs were identified which could account for the functional 
differences. Furthermore, no changes in ACA were seen in the 
studies of non-vascular tissues (liver and renal cortical plasma 
membranes) from the three species. Thus, a ubiquitous, perhaps 
genetically determined, abnormality of membrane function in 
SHR cannot be implicated. There is however, a surprising degree 
of similarity between the AC activities in rat myocardium 
reported by others in response to epinephrine infusion and those 
seen in the studies of SHR myocardium raising the possibility 
that the process of heterologous desensitisation which accounts 
for the former may also explain the latter.
These studies, however, emphasise the problems inherent in 
studies of the SHR. The absence of an isogenetic control species 
raises the distinct possibility that the observed differences 
may relate to the inherent genetic heterogeneity among the 
species studied: this problem cannot be circumvented. The 
inclusion in the studies of the second control species (Wistar) 
highlights the dangers of the customary comparison between 
SHR and WKY species. Further studies are planned in the Milan
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rat-another model of genetic hypertension for which an 
isogenetic control exists, to ascertain whether the observed 
changes in ACA are seen in this model also.
The studies of G-proteins in hypertension were extended using 
the poorly understood entity of glucocorticoid hypertension. As 
humoral regulation of G-protein expression and function (section
1.5.) by glucocorticoids (see chapters 6 & 7)(Rodan & Rodan 
1986; Chang & Bourne 1987; Ros et al.1989; Saito et al.1989) 
has apparently been demonstrated in experimental animals and 
cell culture it seemed possble that G-protein changes could be 
implicated in this pathological state. Previous studies of gluco­
corticoid effect on the differential regulation of G-protein sub­
units have generally been based on administration of massive 
doses of glucocorticoid to adrenalectomised animals: however, 
in contrast, in the current studies a model of glucocorticoid 
hypertension based on rather more physiological concentrations 
(likely to still be in the 'pharmacological range') of the gluco­
corticoid, dexamethasone was used (Tonolo et al. 1988). With 
administration of 5jig/d DEX infusion (s.c.) elevation of tail- 
cuff BP by 30mmHg-representing an increase of around 25% with 
minimal compromise of weight gain (table 15) was achieved. 
Immunoblotting studies for G-protein subunits failed to identify 
any relevant changes in brain, myocardium, renal cortex, liver 
and mesenteric vasculature. Studies of ACA failed to reveal any 
differences in ACA responses in renal cortical (fig. 24), myo­
cardial and mesenteric plasma membranes (table 18). This 
contrasts with the in vitro work reviewed in chapter 7, and 
suggests that neither changes in G-protein function nor AC
catalytic unit are implicated in the pathogenesis of gluco­
corticoid hypertension
The results show important differences from those of previous 
workers and on the basis of previous adrenalectomy studies it is 
possible to conclude that glucocorticoids may have a role in 
regulating G-proten levels- but given the limitations of the 
adrenalectomy model it would be difficult to conclude that this 
amounts to anything more than a permissive role. It seems clear 
however, that glucocorticoids are not implicated in the 
pathogenesis of glucocorticoid hypertension.
As dexamethasone administration in vitro has been previously 
shown to increase adenylyl cyclase activity in vascular smooth 
muscle cells (from renal arteries)(Yasunari et al.1989) and non- 
vascular cell lines plasma membranes from VSMC treated 
similarly with DEX were studied in vitro to assess whether G- 
protein changes could be implicated in the observed changes. The 
findings were in agreement with those of Yasunari et al. (1989) 
viz., 10nM DEX for 24h (and 48h) effected an increase in ACA(fig. 
25) under basal conditions and irrespective of ligand added to 
the assay mix. Basal ACA was increased about 50%. The 
differences persist and are independent of ligand mediated 
stimulation of catalytic unit via Gs (by isoproterenol and PGE1) 
and of direct, Gi mediated inhibition of catalytic unit by GppNHp 
(0.1 nM), lending support to the suggestion that catalytic unit is 
altered rather than the G-proteins which modulate the activity 
of catalytic unit.
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The results are compatible with possible alteration of AC 
catalytic unit and this conclusion is in agreement with two 
previous groups of workers (Rizzoli et al. 1986, Chang & Bourne 
1987). However, this explanation is not universally accepted 
(Johnson & Jaworski 1983). The changes may be independent of 
Gs (at least in osteoblast cell line ROS 17/2.8- as suggested by 
a reconstitution assay) (Rizzoli et al. 1986) but two groups have 
implicated glucocorticoid mediated increased in Gs to the 
enhanced ACA (Rodan & Rodan 1986; Chang & Bourne 1987).
The current studies identified Gsa, Gi2a, Gi3a and 8 subunits in 
membranes derived from VSMC (figs 26-28). Western blotting 
for these subunits excluded a role for DEX mediated alteration of 
the levels of G-protein subunits in the cyclase changes (fig. 25). 
In addition to the data shown, no differences in the amount of B 
subunit was seen.
In addition to the multiple possible sites in the AC system at 
which DEX might exert its effects, glucocorticoids are known to 
exhibit a number of other influences on cAMP and its subsequent 
effectors including cAMP dependent kinase activity (Lamberts, 
Timmermans, Krammer-Blankestijn 1975). Whatever the 
ultimate fate of cAMP generated in DEX treated cells the current 
studies support an effect of DEX on increasing levels and/or 
activity of AC cataytic unit although other factors may have 
contributed to the observed changes in ACA including altered 
receptor numbers. However, as cAMP mediates vasodilatation, it 
is unlikely that this observation in vitro is of relevance to the 
pathogenesis of glucocorticoid hypertension.
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The major findings of this thesis can be summarised:
• The studies of platelet membranes from NIDDM and EH exclude 
common pathophysiology based on alterations of G-proteins, 
although both conditions do feature abnormalities of ACA which 
may contribute to the altered platelet function observed seen in 
these diseases. Platelets from NIDDM (but not EH) do exhibit 
reduced levels of G-protein subunits which may contribute to 
the altered ACA, but these changes may be related to altered 
plasma membrane composition in diabetes mellitus.
• Species differences exist in ACA in myocardial plasma mem­
brane preparations (comparing SHR, WKY and Wistar species).
The validity of the customary comparison between SHR and WKY 
is challenged. Differences in ACA are not explained through 
altered G-protein levels, but may be due to differences in AC 
catalytic unit.
• Despite evidence implicating glucocorticoids in G-protein 
regulation, no changes in G-protein levels were seen in myo­
cardium, brain, kidney and mesenteric artery in a validated 
model of glucocorticoid hypertension. Glucocortiocoid exposure 
did enhance ACA in cultured VSMC but probably by altering AC 
catalytic unit, and not through changes in the levels of G-protein 
subunits.
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